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ABSTRACT 
 
 Malaria and visceral leishmaniasis are major killer parasitic diseases. These diseases 
though occur primarily in tropical countries; economic burden and overall health impacts of 
malaria and leishmaniasis are global. The emergence of drug-resistant and more-virulent strains 
of the pathogens has further amplified the problems.  New drug discovery approaches primarily 
rely on in vitro and in vivo models of the disease. The pathogens causing leishmaniasis and malaria 
are intracellular. Leishmania parasite grows as amastigotes in macrophages cells, and malaria 
parasite grows within the hepatocytes or erythrocytes. The intracellular forms of the pathogens are 
responsible for the pathophysiology of the diseases. New phenotypic cell-based models have been 
developed for leishmaniasis and malaria, those have been employed for in vitro/in vivo screening 
for new drug discovery.  
A parasite-rescue and transformation assay was developed for macrophage-internalized 
Leishmania donovani amastigotes. The assay has been applied for high-throughput screening of a 
library of plants’ fractions. Two fluorescent transgenic cell lines of L. donovani were developed 
with mCherry and Citrine reporter genes by stable transfection approach. The transgenic cell lines 
have shown stable and constitutive expression of the fluorescent reporter proteins. The in vitro 
screening methods were developed with the transgenic leishmania cells employing flow-
cytometric and fluorescent microscopy analyses.   
Analysis of parasitemia and intra-erythrocytic growth of the parasite are hallmarks of 
iii 
 
malaria research.  A flow-cytometric assay, based on staining of the malaria parasites with LDS-
751, a fluorescent cell-permeant nucleic acid stain, was developed for parasitemia analysis. 
Staining of malaria-infected RBCs may be performed directly without additional processing. 
Selective staining of malaria-infected erythrocytes by LDS-751 was confirmed with fluorescent 
microscopy. The method has been applied for flow-cytometric analysis of parasitemia in mice 
blood infected with Plasmodium berghei and human blood infected with P. falciparum. The utility 
of this developed method was established for both in vitro and in vivo antimalarial drug screenings. 
Establishment of the new phenotypic assay will expedite the process of new drug discovery 
against the tropical parasitic diseases. These assays would also have utility for understanding 
biology, virulence, and pathogenesis of malaria and leishmania pathogens.  
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CHAPTER I 
CURRENT DRUG DISCOVERY MODELS FOR VISCERAL LEISHMANIASIS AND 
MALARIA 
 
1.1. INTRODUCTION 
Tropical diseases refer to the diseases, which are more prevalent in tropical regions of the 
world. These include mostly infectious diseases such as leishmaniasis, malaria, Chagas disease, 
African trypanosomiasis, schistosomiasis, onchocerciasis, filariasis, and dengue, that epidemic in 
the hot and humid environment of tropical areas  
Malaria, leishmaniasis, Chagas disease and African trypanosomiasis are caused due to the 
infections with protozoan parasitic pathogens.  These protozoan parasitic diseases are responsible 
for high mortality and morbidity, globally affecting more than 500 million people (WHO, 2016). 
Protozoan parasites namely, Plasmodium spp., Leishmania spp. and Trypanosoma spp., are more 
prevalent in tropical and subtropical countries, causing heavy loss of lives and reduced working 
abilities (Dupouy-Camet, 2004). Despite heavy burden to humanity due to the diseases caused by 
the parasitic protozoa, very few antiparasitic drugs have been developed in the last few years 
(Simon, 2016). The Recent involvement of some nonprofit and public-private partnership 
organizations for the development of strategies to treat and control malaria and other neglected 
diseases, namely leishmaniasis, sleeping sickness and Chagas’ disease, has generated the 
unprecedented interest of several laboratories and pharmaceutical companies in new, antiparasitic 
drug discovery programs (Tekwani and Walker, 2006). Neglected tropical diseases (NTDs), are a 
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group of 17 diseases including leishmaniasis, sleeping sickness and Chagas’ disease that are found 
primarily among the poorest people in 149 countries and territories. According to recent World 
Health Organization (WHO) estimates, more than 2 billion people are at risk of contracting an 
NTD, of whom more than 1 billion people are afflicted with one or more. Roughly 534,000 people 
are believed to be killed by an NTD annually. If we include the annual deaths because of malaria 
(438,000), that makes the total deaths 1 million because of NTD and malaria (WHO, 2016). 
Vaccines are still not available for malaria and other neglected diseases, namely leishmaniasis, 
sleeping sickness and Chagas’ disease. So cure of these diseases mainly depends on drug 
treatments.  
Visceral leishmaniasis (VL) and malaria are the primary focus of the work reported in this 
dissertation. There are only a few drugs available for the treatment of malaria and leishmaniasis. 
Most of them are toxic and going out of the market because of resistance development. Toxicity 
and emerging resistance against current antileishmanial and antimalarial drugs necessitate the 
discovery of new drugs and drug leads. Drug discovery approaches for both the diseases are based 
on the availability of in vitro and in vivo screening models that help in selections of novel 
pharmacophores from natural products and synthetic compounds libraries. As both leishmania and 
malaria parasite exist in the intracellular forms in the human host, it is significantly challenging to 
analyze the growth of the intracellular parasites (Fidock et al., 2004; Sereno et al., 2007). 
Maintaining in vitro cultures for intracellular forms of these parasites are complex. The host and 
parasite cells have to be maintained together, and growth of parasite inside the host cells may be 
analyzed by different techniques. Currently available technologies have severe limitations and are 
labor intensive. Simpler technologies, which yield reproducible results, are desperately needed. 
Current status of available in vitro and in vivo screening models for visceral leishmaniasis and 
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malaria is presented here. 
 
1.2. VISCERAL LEISHMANIASIS 
Leishmania donovani, a protozoan parasite, is the causative agent of visceral leishmaniasis 
(VL). VL is fatal if left untreated. It is highly endemic in the Indian subcontinent and East Africa. 
An estimated 200,000 to 400,000 new cases of VL occur worldwide each year. Over 90% of new 
cases occur in 6 countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan (WHO 
Expert Committee on the Control of the Leishmaniases. Meeting (2010 : Geneva) and World 
Health Organization., 2010).  
 
1.2.1. TREATMENT OF VISCERAL LEISHMANIASES: LIMITATIONS AND 
PROBLEMS WITH CURRENT THERAPEUTIC OPTIONS  
The choice of drugs available to treat leishmaniasis is already limited, and even these suffer 
from limited efficacy and significantly high toxicities at therapeutic doses (Table 1.1).  A few of 
the first line treatment drugs, namely Sodium stibogluconate, have already lost their utility due to 
increasing multiple drug resistance (Croft et al., 2006b). Use of the pentavalent antimony 
compounds sodium stibogluconate (SSG), and meglumine antimonite has remained the mainstay 
of treatment of VL (Tiuman et al., 2011). However, in several areas where leishmaniasis has 
developed refractoriness against antimonials, the treatment option has been shifted mainly to the 
use of amphotericin B (Croft et al., 1991). Both antimonials and amphotericin B have to be 
administered parenterally, are highly toxic, and require a long duration of treatment (Croft et al., 
2006b). Lipid formulations of amphotericin B, however, have greatly reduced the toxicity of the 
drug, allowing administration of large doses and shortening the treatment period (Croft and 
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Olliaro, 2011). However, the high cost of treatment and the requirement for administration of the 
drug under supervised hospitalization have limited its use in endemic areas and for routine 
treatments (Croft and Olliaro, 2011). Recently, miltefosine, an alkyl phospholipid derivative, 
which was originally developed as an anticancer agent, has been approved as the first orally active 
drug for the treatment of visceral leishmaniasis in India. At a dose of approximately 2.5 mg/kg/day 
for 28 days, miltefosine is > 90% curative for visceral disease in India and cutaneous disease in 
Colombia (Dorlo et al., 2012). Miltefosine causes reversible gastrointestinal disturbances and renal 
toxicity. The teratogenic nature of this drug prevents its use in pregnant women and other young 
females not following contraceptive measures (Dorlo et al., 2012). The antileishmanial potential 
of paromomycin, an antibacterial/antiprotozoal aminoglycoside, was discovered as early as the 
1960’s. The drug remained neglected due to unavailability of suitable formulations and 
discontinuation of its production.  Injectable paromomycin was equally effective to amphotericin 
B for the treatment of visceral leishmaniasis in India in phase III clinical trials (Sundar et al., 2007). 
The antifungal azole compounds are promising antileishmanial agents. However, the results of the 
treatment of VL with antifungal azole drugs have been highly variable. Pentamidine isethionate, 
an aromatic diamidine was previously used as a second line treatment for leishmaniasis as a 
parenteral drug, but in later trials, pentamidine failed to produce a satisfactory cure (Croft and 
Olliaro, 2011). Use of pentamidine for treatment of visceral leishmaniasis has been discontinued, 
due to limited efficacy and other toxicity concerns with this drug (Tiuman et al., 2011). Thus the 
armamentarium of drugs for the treatment of VL is severely limited and underscores the need for 
discovery of new antileishmanial drugs with proven clinical efficacy and broader utility for oral 
treatment of VL. The major clinical drugs with their mode of action, their primary source, available 
toxicity and the important remarks are given in Table 1.1. The structures are given in Figure 1.1. 
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Table 1.1: The drugs presently used for treatment of visceral leishmaniasis. *Adapted from 
(Croft and Olliaro, 2011).  
 
Drug Name Mode of Action Primary  
Therapeut
ic Use 
Toxicity Remarks 
Sodium 
Stibogluconate 
Multiple 
Pathways 
Leishmania
sis 
Pancreatitis, 
Cardiac toxicity 
Drug resistance 
Amphotericin 
B 
Ergosterol 
pathway 
Antifungal Severe Kidney 
damage 
Severe Toxicity, 
Liposomal 
Formulations 
Pentamidine Multiple 
Pathways 
Pneumonia 
(PCP) 
Insulin- Dependent 
diabetes mellitus. 
Drug resistance 
Miltefosine Lipid 
metabolism, 
Apoptotic effect 
Anticancer Teratogenicity Drug resistance 
High Cost 
Paromomycin  Antibiotic  Drug resistance 
Azole Ergosterol 
pathway 
Antifungal Cardiac problems Suboptimal 
efficacy 
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Figure 1.1: The chemical structures of clinical available antileishmanial drugs. 
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1.2.2. ANTILEISHMANIAL DRUGS CURRENTLY UNDER CLINICAL 
DEVELOPMENT FOR VISCERAL LEISHMANIASIS. 
 
1.2.2.1. NITROIMIDAZOLES 
1.2.2.1.a.  FEXINIDAZOLE 
 Fexinidazole is believed to act as a prodrug that requires enzyme-mediated reduction by 
nitroreductases to generate cytotoxic species that cause DNA, lipid and protein damage (Raether 
and Hanel, 2003). As the genomes of leishmania parasites contain a homologous nitroreductase 
gene, a study to assess the leishmanicidal activity and preclinical profile of fexinidazole was done. 
In vivo sensitivity of L. donovani to the drug was excellent with five single daily doses of 200 mg/ 
kg in BALB/c mice suppressing infection by 98.4%.Lower doses of the drug were also effective 
in treating the murine model of infection, with the ED50 and ED90 estimated at 12 and 57 mg/ kg, 
respectively (Wyllie et al., 2012). Overexpression of the leishmanial homolog of this 
nitroreductase in L. donovani increased sensitivity to fexinidazole sulfone by 19-fold indicating 
that nitroreductase played a crucial role in activation of fexinidazole and its metabolites in L. 
donovani (Wyllie et al., 2012). Phase 1study of fexinidazole in healthy male volunteers has been 
completed (ClinicalTrial, 2012, 2014). A phase II proof of concept trial to determine the efficacy 
of fexinidazole at the daily dose of 1800 mg (3 tablets) once a day for four days continued by 
1200mg (2 tablets) once a day for six days in VL patients in Sudan is recruiting patients 
(ClinicalTrial, 2013).  
 
1.2.2.1.b.  Pretomanid (PA-824)  
 Pretomanid (PA-824) is a bicyclic nitroimidazole-like molecule. (S)-PA- 824 showed 
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antileishmanial activity against both developmental stages of the parasite, with EC50 of 0.9± 0.1 
and 4.9± 0.3μM against promastigotes and intracellular amastigotes, respectively (Patterson et al., 
2013). The efficacy of both (R)- and (S)-PA-824 was assessed in a mouse model of VL. Dosing 
with (R)-PA-824 (99.9% suppression) at this concentration proved to be superior to treatment with 
sodium stibogluconate (41.9% suppression) and miltefosine (68.7% suppression) (Patterson et al., 
2013). A phase 1 study was done in 58 healthy male volunteers using single oral doses (50, 250, 
500, 750, 1,000, 1,250, or 1,500 mg) or multiple doses of 200, 600 and 1,000 mg of (S)- PA-824 
each day for 7 days (Ginsberg et al., 2009). PA-824 was well tolerated following oral doses once 
daily for up to 7 days, and pharmacokinetic parameters were consistent with a once-a-day regimen. 
 
1.2.2.2. QUINOLINE DERIVATIVES 
1.2.2.2.a. 8-AMINOQUINOLINES 
 Sitamaquine (WR- 6026) is an 8-aminoquinoline analog discovered by the Walter Reed 
Army Institute of Research (WRAIR, USA) being developed as an oral treatment for VL. 
Sitamaquine was shown to be 708 times more active than meglumine antimoniate (Glucantime®) 
against L. donovani in hamsters (Kinnamon et al., 1978). The first phase 2 study was done in 
Kenya in 16 patients at a dose of 0.75-1.00mg/kg for 2-4 weeks with 50% cure rate for 28-day 
treatment with 1mg/kg (Sherwood et al., 1994). Final cure in Brazilian patients (primary efficacy 
outcome) was achieved in 92 of 106 (87%) overall and 25 of 31 (81%), 24 of 27 (89%), 23 of 23 
(100%), and 20 of 25 (80%) patients at doses of 1.5, 1.75, 2.0, or 2.5 mg/ kg/day sitamaquine, 
respectively (Jha et al., 2005). Recent data suggest that sitamaquine accumulate in Leishmania 
parasites (Lopez-Martin et al., 2008). However, its molecular targets remain unknown yet. The 
short elimination half-life of sitamaquine is preventing a rapid resistance emergence(Loiseau et 
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al., 2011). The selection of a sitamaquine-resistant clone of L. donovani in the laboratory and the 
phase II clinical trials pointing out some adverse effects such as methemoglobinemia and 
nephrotoxicity are considered for a further development decision (Jha et al., 2005). 
 
1.3. IN VITRO PHENOTYPIC MODELS FOR ANTILEISHMANIAL SCREENING  
Phenotypic parasite culture-based in vitro screening and in vivo preclinical evaluation are 
the hallmarks of new antileishmanial drug discovery (Gupta and Nishi, 2011; Reguera et al., 2014; 
Sereno et al., 2007). Different methods have been reported for phenotypic cell-based screening 
assays for leishmania. These assays differ regarding the type of parasite forms employed, the 
complexity of the experimental protocol and the methods used for evaluation of growth and 
proliferation of the parasite cells in culture. L. donovani cycles between phagolysosomes of 
mammalian macrophages and alimentary tract of sand flies (Herwaldt, 1999). During its life-cycle, 
the parasite exists in two forms. ‘Amastigotes’ found in the mammalian host and ‘Promastigotes,' 
which grow in the sandfly host, which is also the vector for transmission of leishmaniasis. 
Amastigotes are ovoid, non-motile, intracellular stages; promastigotes are elongated, motile, 
extracellular stages. Promastigotes are injected into the skin of the mammalian host by the bite of 
the infected female sandfly.  Promastigotes selectively invade macrophage cells and transform into 
the intracellular amastigotes. The parasite remains in amastigote form for the duration of the 
mammalian phase of the life cycle. Sandflies feed on an infected mammal host and ingest 
amastigotes during blood feeding. The amastigotes transform into promastigotes for the vector 
phase of the life cycle (Figure 1.2). The phenotypic screening assays employing promastigotes as 
well as amastigotes forms of the parasite have been described.            
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Figure 1.2:  Life cycle of Leishmania donovani parasite. (Leishmania donovani life cycle by 
Center for Disease Control and Prevention). 1- The sandflies inject the promastigotes during blood 
meals. 2- Promastigotes are phagocytized by macrophages cells. 3,4-Progmastigotes transform in 
these cells into the amastigotes., which multiply by simple division and proceed to infect other 
mononuclear phagocytic cells. 5,6- Sandflies become infected by ingesting infected cells during 
blood meals. 7,8- In sandflies, amastigotes transform into promastigotes, develop in the gut, and 
migrate to the proboscis. 
Figure adapted from https://www.cdc.gov/parasites/leishmaniasis/biology.html  
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1.3.1. PROMASTIGOTES-BASED PHENOTYPIC SCREENING ASSAYS  
 The leishmania promastigotes grown in simple media have been used as the test parasite 
to screen potential antileishmanial agents.  Simplicity and potential for automation of the 
promastigotes-based assay account for its wide popularity. The promastigotes are a culture in vitro 
in the medium at 21 to 27oC. The promastigotes are treated in vitro with the test drugs and 
compounds for 48 to 72 h. The growth of prokaryotes is analyzed by different cell viability 
indicators, e.g., AlamarBlue, MTT (Dutta et al., 2005; Kulshrestha et al., 2013; Manda et al., 
2014). The technique is simple and easily applicable for high-throughput screening (Gupta and 
Nishi, 2011). However, the metabolism and physiological conditions for culture and growth of 
promastigote differ from those of amastigote (host stage of the parasite). Because of these 
metabolic and physiological differences, screening data obtained from in vitro promastigote 
screening may not  reflect  activity against intracellular amastigotes (Sereno et al., 2007). 
Promastigotes grow at a lower temperature (21-27°C), while amastigotes in human host grow at 
37oC. Intracellular amastigotes grow within the macrophage phagolysosomes, the amastigotes face 
the acidic environment of phagolysosomal vacuoles, while promastigotes growth at neutral pH 
(Vermeersch et al., 2009). Due to these problems, use of promastigotes culture for in vitro 
antileishmanial screening has lesser value than the screening against intracellular amastigotes.  
 
1.3.2. AXENIC AMASTIGOTES-BASED PHENOTYPIC SCREENING ASSAYS  
Axenic amastigotes are the leishmania cells in amastigote forms adapted to grow in the 
medium in vitro  by providing the optimum temperature of  30oC and acidic 5.5 pH (Zakai et al., 
1999). The in vitro screening with axenic amastigotes culture has several advantages. The test is 
directed against the amastigotes (host stage of the parasite). The axenic  amastigotes are easy to 
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manipulate in in vitro culture.  The growth analysis (Rahman et al., 2011) is of axenic amastigote 
can be performed with simple cellular growth indicators. Axenic amastigotes-based screening is 
simple and inexpensive. Axenic amastigotes system for drug screening has been used earlier 
(Callahan et al., 1997; Doyle et al., 1991). Several investigators used different methods for 
evaluating activity of compound against axenic amastigotes such as viability of cell population 
with a 3-(4-5 dimethyl-thiazol–2–yl)–2, diphenyl tetrazolium bromide, thiazole blue (MTT) based 
method (Ganguly et al., 2006; Sereno and Lemesre, 1997), determining ornithine decarboxylase 
activity or using a fluorescent dye like propidium iodide (PI) and fluorescence-activated-cell-sorter 
(FACS)(Sereno et al., 2005; Vergnes et al., 2005). Several Leishmania parasites expressing 
reporter genes have been selected, and the capacity of some of them to be used in axenic amastigote 
drug screening protocol has been assessed. Axenic L. infant amastigotes with Luciferase 
expressing DNA transformed and showed its utility in high throughput screening for new 
antileishmanial drugs (Sereno et al., 2001). A rapid fluorescent assay using AlamarBlue for 
screening drugs on axenic amastigotes of L. donovani and L. tropica was done recently (Shimony 
and Jaffe, 2008). However, the assay is semi – predictive, it neither test for penetration of the 
compound into the host cell nor for activity in the peculiar environment of the macrophage 
phagolysosome(Gupta and Nishi, 2011). Axenic amastigotes may have different metabolic 
processes than intracellular amastigotes. As this parasite grows in medium with 5.5 pH, there are 
chances that compounds may get precipitated at acidic pH. These assays do not have same 
pathophysiological environmental as in human host.  So any compounds active here may not be 
active in human macrophage cells internalized amastigote form.  
 
1.3.3. INTRACELLULAR AMASTIGOTES-BASED PHENOTYPIC SCREENING 
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ASSAYS  
 Amastigotes growing inside the phagolysosomal vacuoles of macrophage cells represent 
the pathophysiology of leishmaniasis disease (Handman, 1999). These intracellular amastigotes 
are the real target for the antileishmanial drug candidate. For the discovery of new antileishmanial 
drug candidate, there is a need for screening compounds libraries against intracellular growth and 
proliferation of the amastigotes in the host cells. The intracellular amastigotes-macrophage 
phenotypic assays also have application for evaluation of infectivity of clinical and laboratory 
isolates of leishmania cells.  These assays offer significant challenges compared to the simple 
promastigotes/axenic amastigotes assays (a) regarding selection of appropriate host cells (b) 
individual variations in host cell populations (c) variable infectivity of pathogen-cells and 
susceptibility of the host-cells, (d) long-term maintenance of the host-parasite cell cultures and (e) 
quantitative/qualitative monitoring of intracellular growth of the parasites. Recent advancements 
in vitro cell culture methods, availability of a variety of primary and culture-derived host cells, 
high-throughput sensitive/quantitative cell-imaging technologies and development of transgenic 
parasite cells with stable constitutive expression of reporter genes have addressed these challenges.     
 
1.3.3.1. THE HOST CELLS 
Macrophages are the primary host target cells during the leishmaniasis disease condition 
in mammalian hosts. Assay for intracellular amastigotes requires host macrophages cells, which 
can be infected with the leishmania cells and development growth and proliferation of intracellular 
amastigotes (Handman, 1999). Primary macrophages cells can be obtained from various sources 
like peritoneal exudate cells (PEC), peripheral blood monocyte cells (PBMC), and bone marrow-
derived macrophages (BMM)(Alexander et al., 1999; Maia et al., 2007). Mice are injected with 
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3.0 ml of 3% thioglycollate medium intraperitoneally to obtain PECs. After three days of injecting 
thioglycollate medium, the peritoneal exudates cells were harvested with 5ml of ice-cold 
phosphate buffer saline (PBS). PBMC are obtained by Ficoll-Hypaque fractionation of the 
heparinized blood, washed with Hank’s balanced salt solution (HBSS-Sigma H6136) and re-
suspended in warm RPMI-1640 medium. BMM is harvested from both femur and tibia of the 
individual mouse by washing with RPMI (Maia et al., 2007). These differentiated primary 
macrophages collected from various sources such as mice and rats are non-dividing in nature, but 
these cell preparations may not have homogeneous cell populations (Croft et al., 2006a). There are 
several human macrophage cells lines are available namely, THP1 (human monocytic leukemia 
cell line) (Sodji et al., 2014), U937 (pro-monocytic, human myeloid leukemia cell line)(Abdullah 
et al., 1999) and HL-60 (acute promyelocytic leukemia cell line)(Chen et al., 2009). There are 
several mice macrophage cell lines are available namely, J774 (Alexander et al., 1999) and RAW 
264.7 cells (Kolodziej and Kiderlen, 2005). The cultured cells lines have a homogenous population 
of macrophages cells.  However, the assays, which use dividing host cells, must ensure that the 
confounding effects of drug activity on both parasite and host cells number are considered. Out of 
different monocyte cell lines, differentiated THP1 cells forms a non-dividing monolayer, like 
primary cells and have complete characteristics of macrophage cells and offer an attractive 
alternative to primary isolated macrophages (Croft et al., 2006a; Jain et al., 2012).  
 
1.3.3.2. THE PARASITE CELLS FOR INFECTION OF THE HOST CELLS 
  There are more than 30 species for the genus leishmania. However, for screening purpose 
L. donovani or L. infant used for visceral leishmaniasis and L. major, L. tropica, L. mexicana, L. 
brazilensis are used for cutaneous leishmaniasis (CL) drug screening (Gupta and Nishi, 2011).  
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Particularly for visceral leishmaniasis, L. infantum parasite has been used for promastigote 
screening as well as intracellular amastigote screening using macrophage cell line and other 
primary macrophages cells (Abamor, 2017; Maia et al., 2007). Several in vivo studies have been 
done using L. infantum in mice (Cajueiro et al., 2017), golden hamster host (de Almeida et al., 
2017; Rouault et al., 2017) and dogs (Albuquerque et al., 2017). Similarly, L. donovani parasite 
has been used for promastigote screening as well as intracellular amastigote screening using 
macrophage cell lines and other primary macrophages cells (Abdullah et al., 1999; Manda et al., 
2014). Several in vivo studies have been done using L. donovani in mice (Amit et al., 2017), golden 
hamster host (Rouault et al., 2017) and dogs (Jambulingam et al., 2017). 
 Metacyclic promastigotes (Figure 1.3) are the infective stage of the parasite. Parasite 
acquires the metacyclic stage at the stationary phase of in vitro culture. Metacyclic promastigotes 
are highly mobile, cylindrical and are highly infective to macrophages cells (Jain et al., 2012).  
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Figure 1.3: Procyclic and metacyclic forms of Leishmania donovani promastigotes. Image 
collected in phase contrast microscopy. (A) Procyclic promastigotes are short and ellipsoid with 
short flagellum and are only weakly motile (B) Metacyclic promastigotes are long cylindrical 
forms with a long flagellum, which are highly motile.  
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1.4. METHODS FOR INTRACELLULAR AMASTIGOTES GROWTH ANALYSIS 
 Intracellular amastigotes assays are complex assays that require both host cells 
(macrophages cells) and leishmania parasites cells. Several kinds of macrophages can be selected 
as host cells for screening purposes (Section 1.2.3.1.). Macrophages cells seeded in plates and 
incubated overnight at 37oC 5%CO2 incubator. Some monocytic cell lines (THP1cells) require 
Phorbol Myristate Acetate (PMA) treatment to differentiate them into full macrophages cells (Jain 
et al., 2016a; Jain et al., 2012). Once the macrophages cells adhere to the plate surface, metacyclic 
leishmania promastigotes parasites are allowed to infect these macrophages cells. Different 
macrophages cells have specific infectivity for different leishmania parasites. There is a need for 
rigorous standardization of ratio of macrophage to parasite ratio (multiplicity of infection) to get 
an optimum infectivity(Jain et al., 2012). The infected macrophages cells are treated with test 
compounds for 48 h to 96 h. After test compounds treatment the growth of intracellular amastigotes 
is measured with one of the following methods. 
 
1.4.1. MICROSCOPIC METHOD 
 This approach involves infection of the host macrophage cells with leishmania 
promastigotes or amastigotes. The infected macrophage cells are stained with nucleic acid stains 
(e.g., Giemsa, SYBR Green I). The infected macrophages are treated with the standard drugs and 
the test compounds. The anti-leishmanial activity of the test drugs/compounds is measured either 
by comparing the ratio of some amastigote nuclei to macrophages cell nuclei or by comparing 
percentages of infected cells (Figure 1.4). Classical microscopic evaluation based on manual 
direct cell and parasite counting is labor intensive. The absence of automation limits the utility of 
this assay. The classical microscopic methods have been modified to digital image-analysis 
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methods. In these methods, the images of nucleic acid stained infected macrophage cells are 
captured with a microscope and the counting of amastigote nuclei and macrophages cell nuclei 
done with the help of ImageJ software (Gupta and Nishi, 2011; Neal and Croft, 1984). 
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Figure 1.4:  Infection of macrophage cells with L. donovani and their analysis with fluorescent 
microscopy. A- Uninfected differentiated THP1 cell; B- L. donovani amastigote infected THP1 
cell; C-digital differential counting of amastigotes and THP1 cells with the help of ImageJ 
software; D to F- L. donovani amastigotes infected THP1 cells (big green nuclei with gray cell 
membrane). Images A to C are stained with SYBR Green I and image collected in Fluorescein 
isothiocyanate (FITC) filter of a fluorescent microscope. Image D is stained with SYBR Green I 
and image collected in differential interference contrast (DIC) with FITC filter of a fluorescent 
microscope. Image E (Imani et al., 2014) and F (https://www.cdc.gov/leishmaniasis/index.html) 
are stained with Giemsa and image collected in the light microscope. (mN- Macrophage nucleus; 
kDNA-Kinetoplast DNA; pN-Parasite nucleus).  
 
 
D 
A B C 
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1.4.2. IMAGE-BASED MICROSCOPIC HIGH CONTENT SCREENING 
Microscopic imaging-based technologies represent powerful tools for the primary and 
secondary screening of drug compounds, as these methodologies have high throughput screening 
capability and also offer important information related to the infectious pathogen and the target 
host cell and organ. Therefore, the imaging-based high content screening methodologies have great 
potential for elaborating a more biology-driven environment for compound discovery in vitro as 
well as in vivo studies. A high content analysis for wild-type of L. donovani has been developed 
using Draq5 nuclear staining. This method involves rigorous analysis using Image Mining (IM) 
software and computing the Voronoi diagram (Siqueira-Neto et al., 2012). Another high content 
method was developed for L. donovani using Hoechst staining using intravital microscopy imaging 
(IVM) technique through confocal microscopy (Forestier et al., 2015). 
 
1.4.3. FLOW CYTOMETRIC ASSAYS 
The fluorescent dyes and monoclonal antibodies have also been employed for analysis of 
the leishmania infected macrophages by flow cytometry. BCECF-Am (29,79bis-(2-carboxyethyl)-
5-(and-6)carboxyfluorescein, acetoxymethyl ester), SYTO 17, PKH2-GL (PKH2 Green 
Fluorescent General cell linker), propidium iodide, and acridine orange have tested for their 
capacity to monitor leishmania infection in a U-937 host cell model (Abdullah et al., 1999). This 
method could not be used to monitor infection for longer periods. The incubation of the infected 
macrophage cells with the test compounds/drugs ranges from two to four days, which makes this 
technique imperfect for the intracellular screening purposes (Sereno et al., 2007). Several 
Leishmania-specific monoclonal antibodies have been used with analysis of infected-macrophages 
by flow-cytometry. Specific monoclonal antibody against the leishmania lipophosphoglycan 
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(LPG) has been used for flow-cytometry based analysis (Di Giorgio et al., 2000; Guinet et al., 
2000). These antibody-based assays allowed the accurate assessment of the activity of standard 
and test compounds against intracellular amastigote. However, the antibody-based 
immunostaining methods are time-consuming and are not cost effective for large screening. The 
antibody-immunostaining-based methods may have limited use for large-scale high-throughput 
screening programs. This approach may not differentiate between live and dead intracellular 
amastigotes (Di Giorgio et al., 2000; Sereno et al., 2007). The compounds with cytostatic actions 
against leishmania amastigotes may not show activity in these assays.  
 
1.4.4. TRANSGENIC LEISHMANIA CELLS WITH REPORTER GENES 
The externally inserted genes, which are expressed into the readily measurable phenotypic 
proteins that can be differentiated easily from the background of endogenous proteins are termed 
as reporter-genes. Introduction of such exogenous genes facilitate the measuring of the growth of 
the transgenic cells or microbes population and may be applied for the screening of antimicrobial 
agents. The transgenic cells carrying a reporter gene can be developed by either an episomal 
transfection of recombinant plasmids with the copy of reporter gene or after integration of reporter 
gene on a defined locus of the genome, generally the rDNA locus, of the target cells. There are 
several leishmania transgenic parasites were developed with different reporter genes including 
fluorescent protein reporter genes (green fluorescent protein (GFP), mCherry protein, Infra-red 
fluorescent) and catalytically enzymes reporter genes (β–galactosidase, β–lactamase, 
Luciferase)(Gupta and Nishi, 2011; Sereno et al., 2007). Fluorescent protein reporter genes have 
an advantage over catalytic reporter genes, as transgenic cells with fluorescent reporter gene do 
not require cofactors or substrates since the protein is intrinsically fluorescent. 
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1.4.4.1. GREEN FLUORESCENT PROTEIN (GFP) 
GFP is a fluorescent protein, which originates from the Aequorea victoria (jellyfish). GFP 
based assays offer simplicity, time-dependent growth monitoring with low cost compared to 
classical non-reporter gene assays and enhanced biosafety in vivo animal models. Transgenic 
Leishmania spp cells with GFP have been developed by both episomal transfection or by stable 
transfection and applied for drug screening studies (Dube et al., 2009; Singh et al., 2009). The 
transgenic GFP leishmania cells do not express GFP fluorescence protein, which may not be 
sufficient for measurement with a spectrofluorometric reader. The GFP transgenic leishmania cells 
may not be suitable for application for the assays with fluorescence measurements.   A multimeric 
form of GFP was engineered and expressed in Leishmania promastigotes to increase the intensity 
of the fluorescence in transgenic parasites (Chan et al., 2003).  Stably transfected leishmania 
parasite was developed in which the GFP reporter gene was integrated downstream of the 18 S 
rRNA gene promoters within the genome of the parasite (Singh et al., 2009). 
 
1.4.4.2. RED FLUORESCENT PROTEIN (RFP) 
The GFP produces significant fluorescence and is extremely stable, but the excitation 
wavelength of the light required for GFP is close to the ultraviolet range. Exposure of leishmania 
cells to this light may damage the cells and affect their viability. In contrast, Red-fluorescence 
labeled parasites have excitation maxima in the safe region. Transgenic L. major Red Fluorescent 
Protein 1 (RFP)-expressing strain found helpful in identification of the site of sandfly bites has 
been identified in vivo in a mouse model (Peters et al., 2008; Ribeiro-Gomes et al., 2012). 
Transgenic L. infantum cells with expression of  RFP have been employed to report the recruitment 
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of neutrophils and their role in non-ulcerative forms of leishmaniasis (Thalhofer et al., 2011). 
Recently, a transgenic leishmania parasite with an expression of mCherry (A modified form of 
RFP) has been developed and implemented for in vitro and in vivo screening (Calvo-Alvarez et 
al., 2012). A transgenic cell line of L. amazonensis was generated by chromosomal integration of 
the fluorescent DSRED2 molecule. A High Content Analysis assay was developed based on the 
use of homogeneous populations of primary mouse macrophages hosting transgenic fluorescent 
DSRED2 L. amazonensis amastigotes. This multi-parametric assay helped in monitors the 
parasitic load of fluorescent DSRED2 amastigotes-hosting macrophage cultures (Aulner et al., 
2013).  
 
1.4.4.3. INFRARED FLUORESCENT PROTEIN 
The fluorescence with an emission spectrum in the visible region has low tissue penetration 
(Shcherbo et al., 2007). A new fluorescent protein with the emission spectrum of near infrared 
region has been discovered from the bacteriophytochrome of Deinococcus radiodurans (Chernov 
et al., 2017; Shcherbakova et al., 2015). The infrared fluorescent proteins (iRFPs) have advantages 
over the fluorescent reporter proteins with better tissue penetration capacity of the light emitted 
from the iRFPs. The emission spectrum of this protein is in the near infrared region, and the emitted 
fluorescence is free of any background interference derived from organs or tissues (Shu et al., 
2009). The fluorescent iRFPs have been successfully applied to image the in vivo infection of the 
adenovirus serotype 5 in mouse liver (Calvo-Alvarez et al., 2015). More recently, a new infrared 
fluorescent protein (iRFP) from the photosynthetic bacterium Rhodopseudomonas palustris has 
been engineered with more penetration capacity (Ref). Recently, (Calvo-Alvarez et al., 2015) Have 
reported generation of two strains of L. infantum strains, which stably overexpress the IFP 1.4 and 
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iRFP reporter genes. The bio-photonic properties of the transgenic L. infantum cells were 
compared for promastigote and amastigote stages. The constructs for transfection were engineered 
with the regulatory sequences of genes (A2, AMASTIN, and HSP70 II), which are differentially 
expressed in the leishmania amastigotes, to improve the fluorescence emission of the selected 
reporter in intracellular amastigotes. The transgenic leishmania strain, which carries the iRFP gene 
under the control of the L. infantum HSP70 II downstream region (DSR), showed selective and 
high expression of  iRFP in leishmania amastigotes. Application of this strain for phenotypic 
screening using ex vivo splenocytes from infrared-infected BALB/c mice was also reported 
(Calvo-Alvarez et al., 2015).   
 
1.4.4.4. β-GALACTOSIDASE 
The β-galactosidase is an enzyme that hydrolyzes the colorless substrate o-nitrophenyl-β-
D-galactopyranoside (ONPG) to o-nitrophenol (ONP), which is yellow. Transgenic Leishmania 
promastigote expressing β-galactosidase were developed and utilized in drug screening procedures 
(Okuno et al., 2003). Β-Galactosidase presents the advantage of colorimetric detection. However, 
some common drawbacks including its large size (the monomer is 116 kDa), expensive substrate 
and the endogenous expression of β-galactosidase by some mammalian cell types including 
macrophages, hinder the use of these transgenic parasites for general drug screening purpose, 
particularly for intracellular amastigote screening and in vivo screening(Buckner and Wilson, 
2005; Campbell, 2004). 
 
1.4.4.5. β–LACTAMASE 
The β–lactamase is an enzyme that hydrolyzes the colorless substrate nitrocefin to a 
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chromogenic cephalosporin, a colored product. This product can be colorimetrically measured at 
490 nm. The β–lactamase is a smaller sized protein than β–galactosidase. Two transgenic 
leishmania parasites cells lines, L.  major and L. amazonensis, with the β-lactamase reporter gene, 
were developed (Campbell, 2004). The transgenic leishmania cells were developed through stable 
transfection, in which β-lactamase gene was integrated into ribosomal RNA (rRNA) region of the 
genome, thereby allowing for high-level of stable expression of the enzyme. The activity of some 
standard antileishmanial drugs was evaluated on the transgenic intracellular amastigotes, which 
demonstrate that this method could be used for phenotypic drug screening procedures (Zlokarnik 
et al., 1998).  
 
1.4.4.6. LUCIFERASE 
Luciferase is an enzyme found in fireflies that catalyze the conversion of luciferin to 
oxyluciferin, which produces luminescence. The luminescence is produced because the reaction 
product oxyluciferin remains in an electronically excited state. The reaction releases a photon of 
light as oxyluciferin goes back to the ground state. Various transgenic leishmania parasites (L. 
donovani, L. infantum, L. major) cell lines expressing luciferase have been developed (Ashutosh 
et al., 2005; Roy et al., 2000). The high sensitivity of the assay and the absence of background 
activity in the host cell are important advantages of the luciferase assays. Recently, a transgenic 
cell line of L. amazonensis expressing firefly luciferase has been used to monitor leishmania 
infection in real time, through imaging analysis. The advantage of this methodology relies on the 
capacity to perform experiments on live cells, making the analysis faster and more accurate since 
the viability of both the parasites within the host cells is monitored (Sereno et al., 2007). 
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1.4.4.7. TRANSGENIC LEISHMANIA CELL MODELS: ADVANTAGES AND 
DISADVANTAGES FOR PHENOTYPIC SCREENING 
The transgenic leishmania cells lines with stable and constitutive expression of reporter 
proteins have provided valuable tools for phenotypic screening and new antileishmania drug 
discovery.  These models have been extensively applied for large-scale high-throughput, and high- 
content screenings (Aulner et al., 2013; De Rycker et al., 2013) The intracellular transgenic 
parasite cells can be monitored by digital image analysis, by flow-cytometry or 
chemiluminescence reader, based on the nature of the reporter gene.      
The construction of transgenic leishmania models requires the application of drug-
resistance markers for selection of transgenic cells. The transgenic cells were grown with a contact 
pressure of the selection drug for maintenance of episomal expression of the reporter genes. If the 
reporter gene is expressed, episomally the relative expression of the reporter protein may depend 
on the number of copies of the transfected plasmid, rather than on the activity of the drug (Buckner 
and Wilson, 2005). In case of stable transfections and genetic integration, the use of selection-drug 
may not be necessary once the integration of reporter gene into the leishmania genome and stable 
expression of the reporter protein are confirmed.  The assays based on transgenic parasites with 
luciferase reporter gene required substrate and cell lysis buffer, which makes the assays expensive 
for large-scale screening (Calvo-Alvarez et al., 2015; Roy et al., 2000).  Growth analysis methods 
of intracellular amastigotes with their advantages and disadvantages are summarized in Table 1.2. 
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Table 1.2. Macrophage internalized leishmania amastigotes models for phenotypic screening: 
the approaches for evaluation of intracellular growth and proliferation of leishmania amastigotes   
Type of 
Assay 
Method Advantages Disadvantages 
Classical 
microscopic 
evaluation 
Nuclear staining of 
infected macrophage 
cells 
Gold Standard 
Reliable 
Labor intensive 
Time consuming 
Low Throughput 
Human Bias 
Advanced 
Digital-Image 
analysis based 
assays 
Analysis of digital 
images of the 
intracellular leishmania 
amastigotes 
[fluorescent probe 
staining/Immuno-
staining/Transgenic 
leishmania cells] 
Can be automated 
Multi-parametric 
High throughput 
Screening 
High-content 
analysis 
Costly instrumentation 
Limited facility 
Flow 
cytometric 
assays 
Antibodies-based 
analysis 
Specific, Less 
background signal 
Sensitivity  issues 
Transgenic 
leishmania- 
Reporter gene 
assays 
Transfections of reporter 
gene 
Live imaging 
Live growth 
analysis 
Require drug selection 
for episomal 
expression. 
Relative expression of 
the reporter gene may 
depend on the copy 
number of the 
transfected plasmid. 
Altered physiological 
properties of the 
parasite 
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1.5. IN VIVO ASSAYS FOR ANTILEISHMANIAL SCREENING 
Animals with the similar pathological responses as observed in humans after infection of 
leishmania parasite could be selected for in vivo anti-leishmanial studies. In visceral leishmania 
parasites reside in deep organs like spleen or liver. So in animal models for visceral leishmaniasis, 
parasites must be able to invade in macrophages cells, transform there to amastigotes and must be 
able to reside in deep organs like spleen and liver. There are several animal models available for 
visceral leishmaniasis to research various aspects including host-parasite interactions, 
pathogenesis, biochemical changes, prophylaxis, and maintenance of parasites and evaluation of 
antileishmanial activity of drug leads. These in vivo experiments include the intravenous parasite 
inoculation, compounds dosing, preparation of impression smears of weighed livers, staining of 
slides and analyzing the parasitemia and other host-parasite interactions  (Garg and Dube, 2006; 
Gupta and Nishi, 2011).  
Although none of the animal models accurately reproduce what happens in humans during 
visceral leishmaniasis, there are several animal models developed with their advantages and 
disadvantages. Several animals like BALB/c mice, Syrian golden hamster, dogs, and monkeys 
(squirrel, vervet, and Indian languor) were developed as an experimental host for VL. Besides 
evaluating drug activity, a suitable animal host for leishmania parasite is very important for other 
studies including host-parasite interactions, immunological changes, pathogenesis, biochemical 
changes, and prophylaxis. Animal models help to evaluate the antileishmanial activity with other 
significant information like bioavailability, absorption, distribution, metabolism, excretion, and 
maximum tolerated dose that help in determining the route, treatment dose, duration of dosing, 
therapeutic window and the toxicity of new leishmanicidal lead. Ideally, a drug should have an 
invasive route of administration (administered orally), should be effective in a small dose with a 
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shorter course of action (around a week) and should not have any toxicity, even at higher doses.   
 
1.5.1. RODENT MODELS 
Rodents are the preferred choice for primary in vivo experiments, and several rodent 
models were adopted for antileishmanial drug screening. Rodents are comparatively smaller in 
size. So they are cheaper, require less maintenance and area, require less quantity of testing 
compound and are easy to handle during experiments. Common rodent models for visceral 
leishmaniasis include BALB/c mice and Syrian golden hamsters (Oliveira, 2004). These rodent 
models of leishmaniasis have been extensively used to evaluate the pharmacological effects of 
anti-leishmanial efficacy, toxicity profiling, host-pathogen interaction and pathogenesis of the 
disease. These are available as inbred strains that in help in generation reproducible results with 
less variation. 
Mice are susceptible to different species of Leishmania parasite. Inbred strains of mice 
have been used widely for both L. donovani susceptible, resistant and intermediate strains (Barbosa 
Junior et al., 1987). The infection of Leishmania parasite in different mouse strain needs to be 
characterized to ensure that the test compounds are tested for their effect appropriately. Athymic 
(with Foxn1nu mutation) and SCID (with Prkdcscid mutation) mice provide a model for treatment 
of VL in immunosuppressed cases (Croft et al., 2006a).  
 
1.5.1.1. MICE MODEL 
The BALB/c mouse is a most common strain with reproducible levels of infection 
(Parasitemia) when the amastigote or metacyclic promastigote inoculum is administered 
intravenously.  Initially, all BALB/c mice divided into groups with five mice in each group and 
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infected intravenously with L. donovani parasite. The test compounds are prepared in different 
doses and dosed to mice orally, intraperitoneally, or intravenously at day 7 of post-infection for 
five consecutive days (day 7 to day 11). All infected mice are sacrificed at day 14 of post-infection. 
Spleen and liver were collected from all mice and weighed. During the whole experiment, mice of 
all group are observed for change in weight and behavior.  Impression smears are collected on 
slides from spleen and liver of each mice. Slides with smears are fixed with methanol and stained 
with Giemsa. The total number of leishmania amastigotes are counted in per 500 liver cells with 
the help of a microscope.  The parasitemia of each treated mice liver smears is compared with liver 
smears of untreated mice (Gupta and Nishi, 2011).  
 
1.5.1.2. RAT MODEL 
Mastomys albicandatus (the African white-tailed rat) also investigated for in vivo 
maintenance (Mikhail and Mansour, 1973)and long-term experiments with L. donovani and L. 
Brazilians. Sigmodon hispidus (The cotton rat) is also a good susceptible animal host for L. 
donovani (De Lima et al., 2002). The Leishmania infection sustained in this host for 3-4 months 
after the appearance of initial clinical symptoms. Mastomys natalensis (Natal multi-mammate Rat) 
was also used to develop the experimental model for visceral leishmaniasis using L. donovani as 
a parasite (Nolan and Farrell, 1987). The experimental procedures for rat animal models are similar 
to mice models. Here the rat is able to sustain the parasite for longer duration then mice and is a 
better model for long-term studies (Gupta and Nishi, 2011). 
 
1.5.1.3. HAMSTER MODEL 
Mesocricetus auratus (The Syrian golden hamster) established a good model for VL and 
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which provides a synchronous infection in the liver and spleen that can develop into a chronic non-
curable disease that is similar to human VL (Farrell, 1976; Gifawesen and Farrell, 1989). It 
reproduces the clinical and pathological features of human disease such as a progressive increase 
in visceral parasite burden, cachexia, massive splenomegaly, hyper-gammaglobulinemia, and 
ultimately death (Gifawesen and Farrell, 1989).  
Most VL studies involve intravenous, intracardiac or intraperitoneal inoculations of 
rodents (Melby et al., 1998) with 106 to 108 parasites; however, VL has also been induced via 
intradermal inoculation, a route considered much closer to natural infection (Osorio et al., 2012). 
More recently, a new hamster model of progressive leishmaniasis was developed by natural 
transmission of the parasites via bites by vector sand flies (Aslan et al., 2013). Parasitemia is 
reported in tissues by monitoring parasites in spleen, liver and bone marrow by limiting dilution 
cultures or by imprinting smears with splenic biopsy (Melby et al., 2001). 
Several methods have been developed using hamster as a model for VL. Classically, the 
pre-treatment parasitic burden was assessed by a splenic biopsy that helps to carry the similar 
parasitic load by the same experimental animal. This method comes with the disadvantages of its 
inability to assess the delayed action of drugs. Later this technique was modified for repeated 
spleen biopsies on the same animal at different intervals of day 7, 14, and 28, thus making it 
suitable for studying the long-acting and delayed action drug in the model(Gupta and Nishi, 2011). 
The advantage is that biopsy is possible to monitor pre- and post-treatment infection status and all 
antileishmanials are active against liver as well as spleen parasites. Golden hamster is the best 
experimental model to study VL, because it reproduces the clinical and pathogenesis of the disease, 
as seen in humans and dogs (Oliveira, 2004).  
Recently level of infection was accessed by real-time imaging of golden hamster model 
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with the help of virulent transgenic L. donovani that stably express a reporter luciferase and 
compared with the real-time RT-PCR to quantify both Leishmania and host transcripts(Rouault et 
al., 2017). 
 
1.5.1.4. REAL-TIME IMAGING OF A MURINE LEISHMANIASIS MODEL 
Episomally transfected Leishmania parasite with enhanced green fluorescent protein, and 
stably transfected infrared fluorescent Leishmania parasite strains are enabling in vivo real-time 
fluorescence imaging to analyze the time-dependent progression of Leishmania infection in 
parasitized tissues. Level of fluorescence correlated with the number of Leishmania parasites in 
the tissue and that demonstrated the real-time efficacy of a test compound or vaccine. There are 
several advantages of this approach over the classical microscopic based approach. Here the 
change in the level of infection could be analyzed in real time manner without scarifying the 
animal. These include improvements in sensitivity and the ability to acquire real-time data on 
progression and spread of the infection. 
 
1.5.2. DOG MODEL 
Wild canines and dogs are the main reservoirs of zoonotic visceral leishmaniasis caused 
by L. infantum in the Mediterranean area, Middle-East, Asian countries and Latin America. The 
role of dogs as the main reservoir of visceral leishmaniasis has led to an increased interest in 
developing dogs and canine as an animal model for VL(Alvar et al., 2004). Canine visceral 
leishmaniasis is a multi-systemic disease with variable clinical signs.   Dogs have been developed 
as an experimental model for Leishmania infections in the 1990s using L. donovani, L. infantum 
or L. chagasi. Dogs are important laboratories models because they reproduce the natural infection 
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similar to human infection(Ciaramella et al., 1997). German shepherd dogs are reported to give 
better results than beagles, but some workers claim highly successful infection rate with mixed 
breeds. The level of infection is accessed by spleen or liver biopsies (Baneth et al., 2008). 
 
1.5.3. NON-HUMAN PRIMATE (NHP) MODEL  
There are several observations in rodent models those are not relevant to human hosts due 
to several physiological and anatomical differences. However, non-human primates have 
similarities to humans in anatomy, immunology, and physiology. So they are valuable primate 
models for biomedical research. They are expensive laboratory animals that are difficult to obtain 
and to handle. Furthermore, the institutional animal committee also hinder the use of primates 
because of ethical reasons in biomedical research. So, only a few laboratories worldwide are 
working on primate model, especially for a neglected disease like visceral leishmaniasis. 
Availability of a non-human primate model for visceral leishmaniasis would facilitate the study of 
different aspects of this disease and would accelerate the development of vaccines and testing of 
new drug candidates. 
 Monkeys are normally used for the final preclinical studies for safety and efficacy of any 
new drug candidate or newly developed vaccines (Gupta and Nishi, 2011; Loria-Cervera and 
Andrade-Narvaez, 2014). Anti-leishmanial screening has been performed in owl and squirrel 
monkeys. Initially, the effort has been made to develop an infection in New and Old World 
monkeys and demonstrated that Aotus trivirgatus (owl monkeys) and Saimiri sciureus (squirrel 
monkey) developed an acute and fulminated, but short-lived, infection (Chapman and Hanson, 
1981; Chapman et al., 1983). Attempts were also made to establish VL in Presbytis entellus (Gray 
langur) showed that this species was highly susceptible to single intravenous inoculation of 
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hamster-spleen-derived L. donovani amastigotes, which invariably produced consistent and 
progressive acute fatal infection, leading to death between 110 to 150 days post-infection. The 
infected animals presented all the immunopathological clinic features as observed in human VL. 
The Indian languor has also been used for preclinical evaluation of potential antileishmanial drugs 
and vaccine (Gupta and Nishi, 2011; Loria-Cervera and Andrade-Narvaez, 2014). 
 
1.6. MALARIA 
Malaria is another deadly parasitic disease and major global health challenge. An estimated 
3.4 billion people continue to be at risk of malaria. According to a recent estimate by the World 
Health Organization (WHO), there had been 212 million cases of malaria globally in 2016, which 
caused 429 000 deaths (WHO, 2016). Malaria is caused by the protozoan parasites of  Plasmodium 
genus. P. falciparum is a fatal species of malaria. Another species, P. vivax has a broad geographic 
distribution as it can grow at low temperature in female Anopheles mosquito vector, can persist at 
higher altitudes and in colder climates (Beck-Johnson et al., 2013). Additionally, P. vivax forms a 
dormant liver stage called hypnozoites, increases its survival, acts as a potential inventory of 
infection, activates months after primary infection when the conditions are optimum and cause 
relapse (Judith Recht, 2014). The first synthetic drug chloroquine (CQ) was discovered in the 
1940s (Goldsmith, 1946). CQ helped in malaria treatment and eradicated throughout the world 
(Hoekenga, 1952). However, the therapeutic efficacy of CQ for malaria parasite was diminished 
due to the occurrence of CQ resistance (Da Silva and Lopes, 1964; Montgomery, 1964; 
Sandosham, 1963).  Due to the lack of potent alternative drug for treatment of CQ-resistant malaria 
parasite, the number of deaths increased to 2–3-fold in the 1980s (Trape, 2001).  Since then, several 
amino quinolones derivatives were developed, but the parasites developed the similar resistance 
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against most of the amino quinolones derivative. Several alternative drugs like sulfadoxine, 
pyrimethamine (SP) (Simpson et al., 1972) and artemisinin (Bruce-Chwatt, 1982) emerged later 
as the first-line of treatment for malaria. However, several cases of parasite resistance were 
reported for these new drugs also (Hurwitz et al., 1981; Meshnick, 1998). These conditions of 
emerging resistance alarm the further possibility of an increase in malaria fatalities (Table 1.3). 
There is an urgent need for better alternative treatment for malaria and necessitate the discovery 
of new drugs and drug leads.  
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Table 1.3. Available treatments for malaria. Adopted from (Antony and Parija, 2016) 
 
 
 
 
 
 
 
 
 
 
 
Chemical class Name of drug Mode of Action Primary  
Therapeutic Use 
Status of 
resistance 
4-
Aminoquinolines 
Chloroquine, 
Amodiaquine, 
Accumulation in 
digestive vacuole 
of parasite 
Treatment of Non 
severe 
falciparum 
Yes 
Amino alcohols Mefloquine, 
Halofantrine, 
Lumefantrine 
Accumulation in 
digestive vacuole 
of parasite 
Multidrug 
resistance 
falciparum 
Yes 
8-
Aminoquinolines 
Primaquine Not precisely 
known 
Infection of vivax 
and ovale. 
Prevent relapse. 
Gametocytocidal 
agent 
Yes 
Naphthoquinone Atovaquone Target 
cytochrome bc1 
complex 
 
Yes 
Artemisinin and 
derivative 
Artesunate 
Artemether 
Artemisinin 
 
Chloroquine 
resistance 
falciparum 
Yes 
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1.6.1. LIFE CYCLE OF MALARIA PARASITE 
When the female Anopheles mosquito bites a human host, it injects sporozoites into the 
bloodstream. These sporozoites travel through the bloodstream to the liver.  In all plasmodium 
species these sporozoites are rapidly taken up by the liver cells, and there they get converted to 
schizont and eventually to merozoites. Merozoites attack to healthy red blood cells where the 
asexual reproduction occurs. In red blood cells (RBCs), merozoites reproduce and eventually 
rupture the cells and produce more merozoites which in turn going to infect other RBCs leading 
to massive destruction of RBCs. A small percentage of merozoites differentiate into gametocytes, 
which are taken up by the mosquito during another subsequent blood feeding. In mosquito, these 
gametocytes convert to sporozoites (Figure 1.5). 
 
 
 
 
 
38 
 
Figure 1.5: The life cycle of the malaria parasite. When the female Anopheles mosquito bites a 
human host, it injects sporozoites into the bloodstream. These sporozoites travel in the bloodstream 
to the liver.  In all plasmodium species these sporozoites are rapidly taken up by the liver cells, 
and there they get converted to schizont and eventually to merozoites. Merozoites attack to healthy 
red blood cells where the asexual reproduction occurs. In RBCs, merozoites reproduce and 
eventually rupture the cells and producing more merozoites which in turn going to infect other 
RBCs leading to massive destruction of RBCs. A small percentage of merozoites differentiate into 
gametocytes, which are taken up by the mosquito during another subsequent blood feeding. In 
mosquito, these gametocytes convert to sporozoites. Figure collected from Medicine for Malaria 
Venture (MMV) (Delves et al., 2012). 
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There are many challenges in malaria control, particularly diagnosis and treatment of 
malaria. The majority of malaria cases worldwide rely on clinical diagnosis to define the type of 
treatment (Landier et al., 2016). Diagnosis of malaria is based on the confirmation of malaria 
parasites in RBCs of patients. New antimalarial drug discovery approaches rely on in vitro 
screening of compound libraries against malaria parasite culture and further activity assessment of 
lead compounds in vivo animal models. In vitro and in vivo antimalarial screening methods are 
based on malaria parasitemia analysis which is the ratio of infected RBCs to total RBCs. 
 
1.6.2. METHODS FOR INTRAERYTHROCYTIC MALARIA PARASITE GROWTH 
ANALYSIS 
 
1.6.2.1. MICROSCOPIC PARASITEMIA ANALYSIS 
The microscopic parasitemia method with the help of Giemsa stain was developed in 1904 
(Shute and Maryon, 1963). Since that time it remains as the official gold standard for malaria 
diagnosis (Makler et al., 1998). Although microscopy is the time consuming and laborious method, 
most of the clinical laboratories depend on microscopy for confirmation of malaria and species 
identification. Microscopy is the major method for malaria diagnosis in the clinical laboratories as 
well as malaria parasitemia analysis in antimalarial screenings (Makler et al., 1998). An infected 
mice blood smear slide stained with Geimsa is given in Figure 1.6. However, the microscopic 
analysis has some potentials problem in all clinical diagnosis as well as laboratory parasitemia 
analysis. Significant misdiagnosis of false positives (7–36%), false negatives (5–18%), and wrong 
identification (13–15%) have been reported in shortcomings in the diagnosis of malaria in the 
United Kingdom (Milne et al., 1994) and Thailand (Beadle et al., 1994; Fix et al., 1988).  A high 
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frequency of technical errors (e.g., wrong pH in staining solution or a poor quality film) was also 
reported. Therefore, microscopy is an imperfect ‘Gold Standard’ diagnostic methodology (Collier 
and Longmore, 1983; Makler et al., 1998). 
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Figure 1.6: Blood smear slides prepared from P. berghei infected swiss webster albino mice. The 
slide is fixed with methanol and stained with Giemsa. The image has been collected by Nikon 90i 
eclipse light microscope. RBCs identified here as pink cells. The parasite nuclei as well as white 
blood cells (WBCs) nuclei identified as purple colored. 
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1.6.2.2. RADIOACTIVE SUBSTRATE INCORPORATION ASSAY 
The malaria parasitemia analysis method based on incorporation of radioactive substrates, 
such as [3H] isoleucine, [3H] hypoxanthine, and [3H] ethanolamine to measure parasitic growth 
was developed as an alternative to laborious and time-consuming microscopic assays (Desjardins 
et al., 1979).  
These assays are widely used, accurate, and reliable, and this method could be used for 
high throughput screening purposes. However, these assays are very expensive, involve multiple 
processing steps and require special handling and waste disposal procedures. Thus, these 
radioactive assays are functional in only a few labs with radioactive research facilities and not in 
the field of diagnosis. These assays are also not convenient for detection of parasite stage-specific 
effects. Here incorporation of H3 purine from radioactive hypoxanthine could be possible in other 
blood cells like WBC and lymphocyte,  which leads to a higher background. Also,  hypoxanthine 
uptake does not measure parasitemia directly, as its incorporation is dependent on DNA synthesis 
which only occurs in the later stages of the parasite life cycle (Yayon et al., 1983). So radioactive 
incorporation is directly proportional to further growth of the malaria parasite. Also, the DNA 
synthesis, in turn, is dependent on the growth rate of the parasite strain being observed. 
 
1.6.2.3. P. FALCIPARUM LACTATE DEHYDROGENASE (Pf LDH) 
There are some more methods developed for monitoring malaria growth based on the 
enzymatic activity of parasite’s lactate dehydrogenase (pLDH) (Beadle et al., 1994). The lactate 
dehydrogenase enzyme of several Plasmodium species can use 3-acetylpyridine NAD (APAD) as 
a coenzyme in the reaction leading to the formation of pyruvate from lactate (Sherman 1961; 
Kaushal et al. 1993) and the measurement of this parasite lactate dehydrogenase (pLDH) has been 
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presented as an easy and rapid method for the diagnosis of malaria in humans (Makler & Hinrichs 
1993; Makler et al. 1993). Here the malaria parasite interacts with Malstat reagent (0.21% v/v 
Triton -100, 222mM L-(+)-Lactic acid, 54.5mM Tris, 0.166mM 3-acetylpyridine adenine 
dinucleotide (APAD) The spectrophotometric assessment of LDH activity is facilitated by adding 
nitroblue tetrazolium (NBT), phenazine ethosulfate PES to the Malstat reagent. As APADH is 
formed, the NBT is reduced and forms a formazan product that is blue and can be detected visually 
and measured at 650 nm. This metabolic changes can be detected by a plate reader. So assays can 
be applied for high throughput screening. However, there is a low degree of concordance between 
LDH-based assay and standard microscopy-based determinations of parasitemia (Jelinek et al., 
1996; Knobloch and Henk, 1995).  
 
1.6.2.4.  P. FALCIPARUM HISTIDINE-RICH PROTEIN-II (Pf HRP-II) 
The enzyme-linked immunosorbent assay (ELISA)-based methods that use monoclonal 
antibodies to Plasmodium falciparum histidine-rich protein-II (pf HRP-II) have begun to be widely 
used in recent years due to their ease of use. PfHRP-II is found in the parasitophorous vacuole or 
the parasite cytoplasm, and the protein actively facilitates the polymerization of toxic heme, 
resulting from the degradation of host hemoglobin to form a non-toxic hemozoin (Sullivan et al., 
1996). PfHRP-II has multiple repeats of AHHAAD, with AHH and AHHAA and the presence of 
repetitive B-cell epitopes; this enables the detection of the protein by multiple antibodies, 
increasing the sensitivity of methods detecting the protein (Wellems & Howard, 1986; Panton et 
al.,1989). PfHRP2-based rapid diagnostic tests (RDTs) are the most widely used of the RDTs and 
have been utilized in low- and high-density malaria zones in both pregnant women and non-
pregnant individuals for the diagnosis of mild and paediatric severe malaria (Mueller et al., 2007; 
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Hopkins et al., 2007, 2008; Houze´ et al., 2009; Laurent et al., 2010; Abba et al., 2011; Hendriksen 
et al., 2011; Kattenberg et al., 2011, 2012b; Kyabayinze et al., 2011; Aguilar et al., 2012). 
This assay has sensitive and specificity. However, PfHRP-II based assay is expensive. The 
PfHRP-II based rapid diagnostic tests are not useful for the prediction of parasite responses to 
treatments because of the persistence of the PfHRP-II antigen in the peripheral blood circulation 
after parasite clearance (Tjitra et al., 2001; Houze´ et al., 2009). 
 
1.6.2.5. SYBR GREEN 1 ASSAY 
SYBR Green I is a nucleic acid stain and has been used to monitor the presence of DNA 
in biochemical matrices. As the RBCs do not have DNA and intraerythrocytic stage of parasite 
development is the primary target of antimalarial drugs, assays based on SYBR green I am helpful 
for high-throughput screening for new antimalarial therapies. In the assay, SYBR green with RBC 
lysis buffer is used to expose the parasite DNA and bind with SYBR green I to generate the 
fluorescence. Here, the fluorescence correlated with the growth of intraerythrocytic malaria 
parasites. These assays could be applied for automation to develop high throughput screening 
systems. However, there assay come with high fluorescent background signals. 
 
1.6.2.6. FLOW CYTOMETRIC ASSAYS 
Several new methods of malaria diagnosis and parasitemia analysis have been developed 
based on flow cytometry. These methods can be applied to automation and high throughput 
parasitemia analysis, but no technique can yet be used for routine clinical diagnosis or automated 
screening. Most of the flow cytometric methods have taken advantage of the absence of DNA in 
uninfected RBCs and presence of parasite DNA in malaria-infected RBCs. This intraerythrocytic 
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malaria parasite could be detected by flow cytometry by staining with nucleic acid-binding 
fluorescent dyes. Different fluorescent dyes, such as Hoechst 33258(van Vianen et al., 1990), 
SYTO-9(Izumiyama et al., 2009), SYTO-61(Fu et al., 2010), Ethidium bromide(Staalsoe et al., 
1999), Propidium iodide(Pattanapanyasat et al., 1997), Acridine orange(Hare, 1986),  4,6-
diamidino-2-phenylindole (Baniecki et al., 2007), YOYO-1 (Campo et al., 2011; Xie et al., 2007), 
SYBR Green I (Izumiyama et al., 2009) recently have been considered for the determination of 
parasitemia in vitro cultures of Plasmodium falciparum by FCM. Some dyes such as YOYO-1(Xie 
et al., 2007), SYTO-16 (Jimenez-Diaz et al., 2009) and SYBR Green I (Somsak et al., 2012)have 
been recently employed for the determination of parasitemia in in vivo blood samples from 
Plasmodium berghei infected mice. The parasitemia analysis directly from human or mice blood 
samples is particularly difficult because blood samples have a mixed population of erythrocytes, 
neutrophils, leukocytes, monocytes, and reticulocytes. Because of this mixed population, all 
fluorescence detection methods for parasitemia have high backgrounds. Mixed cell populations of 
blood samples could be separated in Forwarding Scatter (FSC)/Side Scatter (SSC) dot plot. 
However, still, it is not possible to separate reticulocyte and erythrocyte populations in FSC/SSC 
dot plot(Terstappen and Levin, 1992; Wiczling and Krzyzanski, 2008). Reticulocytes remain a big 
problem in malaria parasitemia analysis in blood samples that come with high background and 
sometimes give a false signal of parasitemia. Reticulocytes have RNA. Thus the effect of 
reticulocytes could be neutralized by treatment of blood samples with RNase. If the fluorescent 
nucleic acid dye is not cell permeant, then permeabilization is required. So most of the methods 
based on flow cytometric analysis of parasitemia in blood samples have steps of cells fixation, 
permeabilization, RNase treatments, nucleic acid dye staining and complex flow cytometric 
analysis (Jimenez-Diaz et al., 2009; Xie et al., 2007). Each step added the chances of error and 
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loss of samples, which in also increases the duration of parasitemia analysis and required a higher 
volume of blood sample. 
 
1.6.2.7. REPORTER GENE ASSAYS 
1.6.2.7.a. GREEN FLUORESCENCE PROTEIN 
Green fluorescent protein (GFP)-expressing P. berghei (NK65 stain and ANKA stain) have 
been produced and detected in the red blood cells, cultured liver cells, and midgut and salivary 
glands of the mosquito(Franke-Fayard et al., 2004; Frischknecht et al., 2004; Sanchez et al., 2004).  
Initially, P. berghei lines were constructed that expresses GFP under control of the regulatory 
sequences of the P. berghei dihydrofolate reductase-thymidylate synthase (pbdhfr-ts) gene (de 
Koning-Ward et al., 2000). However, these P. berghei lines have several disadvantages including 
the relatively low level of expression of GFP and the lack of expression in certain stages or the 
episomal nature of the introduced GFP (de Koning-Ward et al., 1998). The GFP gene is integrated 
into the genome in the c-ribosomal-RNA gene unit (c-rRNA), which is not essential for parasite 
development (van Spaendonk et al., 2001). This stably P. berghei GFP parasite showed similar 
growth characteristics as wild-type P. berghei and the use of this parasite is demonstrated as a 
reference line for visualization, investigation of parasite-host interactions and confirming 
phenotypes of mutant parasites in co-infection studies(Franke-Fayard et al., 2004; Sanchez et al., 
2004). Previous studies using GFP-expressing malaria parasites revealed how malaria parasites 
moved in the skin and invaded blood vessels during their migration to the liver(Amino et al., 2006; 
Jin et al., 2007). However, the fluorescence emitted by GFP was not strong enough to observe 
these parasites from outside of the animal. 
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1.6.2.7.b.  LUCIFERASE  
To overcome the drawback of GFP parasite, researchers have developed transgenic 
parasites that express luciferase; transgenic P. berghei expressing luciferase was initially 
developed(Franke-Fayard et al., 2006; Ploemen et al., 2009), followed by transgenic P. yoelii 
expressing luciferase(Miller et al., 2013; Mwakingwe et al., 2009). Not only the blood stage, but 
also the liver stage in the development of malaria parasites could be observed these transgenic 
malaria parasites, and the liver was confirmed as the first organ that malaria parasites reached, 
entered, and increased in in vivo imaging of animal models.  
Transgenic luciferase P. berghei parasite has been successfully used to study sequestration 
during blood-stage infection in mice. However, the transgenic luciferase P. yoelii is commonly 
used to study the efficacy of agents against liver stages, because its sporozoites infect the 
hepatocytes efficiently and develop large numbers of liver-stage parasites (Tarun et al., 2006). P. 
yoelii has also been used extensively for immunology and vaccine studies because it is thought to 
better mimic in experimental animals the immune response to human malaria (Khan and 
Vanderberg, 1991). After inoculation, P. yoelii sporozoites result in the release of a high number 
of merozoites into the blood. Because of that, the partial therapeutic effects of drugs could not 
accurately measure by analysis of the infected state (Mwakingwe et al., 2009). 
8-week-old mice were inoculated intravenously with 2 X 105 red blood cells infected with 
transgenic luciferase P. yoelii to infect the naive mice. Five mice are included in each infection 
group. Luciferase activity is measured using an intensified charged coupled device video camera 
of the In Vivo Imaging System (IVIS). WT- and luciferase P. yoelii infected animals were 
intravenously injected through the tail with 200µl of D-1uciferin sodium salt (100 mg/kg of body 
weight) dissolved in PBS. Luciferin is allowed to distribute systemically for 3 min. The infected 
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animals are anesthetized with the use of isofluorane. Anesthetized animals were placed in the 
camera chamber of IVIS 100 system, and a bioluminescence signal is acquired for 5 min. 
Bioluminescence measurements produced by the IVIS 100 system are expressed as a pseudocolor 
on a gray background, with red denoting the highest intensity and blue the lowest. A region of 
interest is outlined and analyzed by use of Living Image (with the help of Igor Pro (version 4.02A; 
WaveMetrics) software to quantify luminescence. Images of mice infected by mosquito bites are 
displayed with the minimal signal set at 4000 photons (Franke-Fayard et al., 2006; Ploemen et al., 
2009). 
 
1.7. IN VITRO MODELS FOR MALARIA  
In vitro antimalarial screens for compound activity, which constitute a key component of 
a critical path for an antimalarial drug discovery program, are based on the ability to culture P. 
falciparum in vitro in human erythrocytes. Typically, the parasite was grown erythrocytes with 2 
to 6% hematocrit in RPMI 1640 medium supplemented with 0.23% sodium bicarbonate, 0.006% 
Amikacin, 10% A+ human serum, A+ human erythrocytes (6% hematocrit), and 0.027% 
hypoxanthine in 25-mm2 culture flasks. Culture flasks are kept in an environment of 5% O2, 5% 
CO2, and 90% N2 and at 37°C. The medium is changed after every 48 h. For adaptation of the P. 
falciparum culture growing in the medium with human serum.The medium is changed every 48 h, 
and the parasite was subcultured with fresh RBCs after every 6 to 7 days (Singh et al., 2007).  
Multiple drug-resistant (W2, Indochina, stain) and drug-sensitive (D6, Sierra Leone, stain) 
of P. falciparum isolate from around the world have now been culture-adapted and can be obtained 
from the Malaria Research and Reference Reagent Resource Center. The appropriate dilutions of 
the drugs are prepared in DMSO or RPMI-1640 medium and added to the cultures of P. falciparum 
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(2% hematocrit, 2% parasitemia) set up in clear, flat-bottomed, 96-well plates. The plates are 
placed in the humidified incubator with  90% N2, 5% CO2 and 5% O2 gas mixture and 37oC. The 
cultures plates are incubated at 37°C for 48–120 h (Sahu et al., 2014). Parasitemia of the treated 
infected RBCs can be analyzed by several methods and then compared with untreated infected 
RBCs as a positive control and uninfected RBCs as a negative control. In vitro screening of malaria 
comes with several advantages. These screenings are  precise and efficient for big compounds 
libraries. Thousands of compounds can be screened rapidly in few months. It is easier to studies 
drug combinations effects like synergism or antagonism. In vitro screening come with a better 
assessment of the intrinsic activity of a drug. Intro screenings also with several limitations. Drugs 
acting through active metabolite cannot be studied in in vitro settings.  Pharmacokinetic effects 
cannot be studied in vitro studies. There is also a possibility that the toxic compounds also come 
out as false positives in in vitro screening. Active compounds in in intro screening lack the clinical 
correlation (Kalra, 2006). 
 
1.8. IN VIVO MODELS FOR MALARIA 
Animal models of malaria are important tools for antimalarial drug discovery (Fidock et 
al. 2004). Animal models are integrated systems in which the antimalarial efficacy of drugs is 
assessed in pathophysiological conditions of real disease. There are several factors contributed to 
the efficacy, e.g., absorption, distribution, metabolism and excretion, toxicity and antimalarial 
activity. Both pharmacokinetic and pharmacodynamics of antimalarial drugs may be different in 
animal models and humans because of dissimilarity in anatomy, physiology, and susceptibility to 
the different malaria parasite. However, many pharmacological interactions between drugs and 
parasites are independent of the host involved. So, animal models allow an investigation into the 
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in vivo pharmacological properties of drugs and their combinations. 
 
1.8.1. RODENT MODEL 
The mouse model is the most often used malaria drug discovery model because of its 
versatility, accessibility, and requirement of low amounts of compound. There are four 
Plasmodium species adapted to grow in mice that includes P.  berghei, P. yoelii, P. chabaudi and 
P. vinckei (Bhattacharjee et al., 2007; Chong et al., 2006; Cosledan et al., 2008; Jain et al., 2004; 
Jimenez-Diaz et al., 2014; Kelly et al., 2009). Out of these four, the P. berghei is the most widely 
used species in antimalarial drug discovery program. The progression of the disease in mice ranges 
between lethal infections to a self-limited disease that depends on the strain of Plasmodium species 
and also on the murine genetic background. The choice of Plasmodium species is based on their 
susceptibility to test the drug in rodent hosts(Jimenez-Diaz et al., 2014). The Plasmodium spp. of 
rodents have biological cycles of about 24 h, which is a major difference from the classical human 
pathogens(Sanni et al., 2002). However, the rodent-adapted parasites species can reproduce the 
full cycle of malaria in mammals (Scheller et al., 1994). Even though, the evaluation of new drugs 
leads is performed with parasites that show significant evolutionary divergence from P. falciparum 
and P. vivax in these models (Prugnolle et al., 2008). The choice of Plasmodium species also 
depends on the genetic similarity at the level of the molecular target. For example, P. yoelii was 
chosen to test 4-pyridones because of the high sequence homology with P. falciparum for the target 
cytochrome bc1, which is a key protein in the mitochondrial respiratory chain (Yeates et al., 2008). 
On the other hand, diamidines have been tested in the P. vinckei model because P. berghei is 
almost insensitive to these drugs (Angulo-Barturen et al., 2008). P.chabaudi and P. vinckei 
generate a high level of parasitemia and produce synchronous infections enabling studies on 
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parasite stage specificity. Also, P.chabaudi and P. vinckei are more sensitive than P. berghei to 
iron chelators and lipid biosynthesis inhibitors (Wengelnik et al., 2002). 
 
1.8.1.1. ANTIMALARIAL EFFICACY TEST 
Two different assays are typically employed to access the efficacy of any test drug. One is 
the Thompson test, and another is Peters’ suppressive 4-day test (Peters and Robinson, 1999). In 
the Thompson test, P. berghei pre-infected mice are treated with a drug for three days and the 
survival time of a group of treated mice is compared to a group of vehicle-treated controls. In the 
Peters’ 4-day test, the administration of test drug starts from day one, just after one to three hours 
after infection with P. berghei infected erythrocytes and the resulting parasitemia is measured on 
the fifth day that is 24 h after the last dose administration and compared to vehicle-treated controls. 
This is the most widely used preliminary test, in which the efficacy of a compound is assessed by 
comparison of blood parasitemia and mouse survival time in treated and untreated mice. On day 
0, mice are injected with the Plasmodium parasite-infected erythrocytes intravenously or 
intraperitoneally into an experimental group (five each). The group of vehicle-treated mice is 
compared with the test drug-treated group. For a positive control of reference antimalarial drug, a 
group of chloroquine also compared with the group of test drug treatment. The drugs are prepared 
at required concentration, as a solution or suspension and administered 2-4 h post infection by 
appropriate routes (Orally, intraperitoneally, and intravenously). On day 1 to 3, the experimental 
groups are treated again (with the same dose and same route) as on day 0. On day 4, 24 h after the 
last dose (i.e., 96 h post-infection), blood smears from all animals are prepared with Giemsa stain. 
Parasitemia is determined microscopically by counting four fields of approximately 100 
erythrocytes per field. For low parasitemia (<1%), up to 4000 erythrocytes have to be counted. 
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The difference between the mean value of the control group (taken as 100%) and those of the 
experimental groups is calculated and expressed as percent reduction or suppression. For slow 
acting drugs, additional smears should be taken on days 5 and 6, to determine parasitemia from 
which the activity is calculated accordingly. Untreated control mice typically die within two weeks 
after infection. For treated mice, the survival-time is recorded and the mean survival time for 
treated group compared with untreated and reference antimalarial drug-treated groups. If no 
parasitemia appears in mice until day 28 of post-infection, they are considered cured.  
 
1.8.1.2. ONSET/RECRUDESCENCE TEST 
In the ‘onset/recrudescence test,' mice are administered with single dose of the test 
compound on day 3 of postinfection, subcutaneously. Control mice receive the suspension vehicle 
alone. Blood smears are prepared at intervals of 12 h, 24h and then daily until day 33, Giemsa 
stained and assessed for parasitemia. Results are expressed regarding the rapidity of onset of 
action, time to onset of recrudescence, increase of parasitemia and duration of survival (in days). 
Compounds are also tested for prophylactic activity by administrating them before infection, 
followed by a daily examination of smears (Kalra, 2006). 
 
1.8.1.3. CAUSAL PROPHYLAXIS AND RESIDUAL ACTIVITY TEST (HILL’S TEST) 
In this model, mice are inoculated with P. yoelii (N67 strain) sporozoites from Anopheles 
stephensi mosquitos. Sporozoites are harvested from mosquitos at 8-11 days after the infected 
blood meal. Whole mosquitoes are grounded with Tyrode’s Ringer solution and centrifuged to 
remove the debris. Each mouse receives approximately 104-105 sporozoites intravenously in a total 
volume of 0.2ml. For a compound to be considered as prophylactic, it must pass through four 
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different phases.(Ager, 1984; Kalra, 2006) 
Phase 1 (Protective effect): This is the basic procedure that involves evaluation of causal 
prophylactic activity of the test drug in mice. Test drug is administered in infected mice 3h after 
the sporozoites inoculation. During the 14 day period, blood smears are taken until 2% parasitemia 
is achieved. If no parasitemia appeared until 14 days, the test drug is considered protective (Kalra, 
2006). 
Phase 2 (Residual activity): Test drug is then tested for residual activity against blood stage 
parasites by administrating a single dose of the test drug 48 h before inoculation of 104 trophozoites 
intravenously. If the time interval to reach 2% parasitemia is similar to that of the control group 
(untreated group), then it is considered that no residual activity has occurred (Kalra, 2006). 
Phase 3 (Reconfirmation of Residual activity): Test drug with the possibility of prolonged 
residual activity is tested by inoculation of sporozoites followed by the administration of drug after 
3 h. After an additional 48 h, 0.2 ml blood is removed from each mouse and injected 
intraperitoneally into a clean (new) mouse. Blood smears from recipient mice are examined for a 
14 day period or until parasite appears. If less than 50% of the recipient mice develop parasitemia, 
then test drugs considered with residual activity. A compound has no residual activity of 75% or 
more recipient mice develop an infection (Kalra, 2006). 
Phase 4: Mice are injected intravenously with 104 trophozoites 48 h after the compound 
administration to determine if the intra-erythrocytic plasmodium parasites are still viable. After an 
additional 3-4 h, 0.2ml of blood collected and injected to clean (new) recipient mice. Blood smears 
are taken and the time interval to reach 2% parasitemia is compared with control mice. If the time 
interval is similar, it reflects that no permanent damage has been done to the parasites and thus no 
residual activity is present (Kalra, 2006). 
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1.8.1.4. SPORONOICIDAL ACTIVITY TESTING 
Here, albino mice are inoculated with P. yoelii nigeriensis N 67 parasite (107 infected red 
blood cells)) on day 0. Female Anopheles stephensi mosquitoes are placed in containers (about 25 
mosquitos per container) and fed with 4% sucrose for the first five days after hatching. They are 
kept at a constant temperature of 24oC and 75% humidity. After five days, mosquitos are starved 
for 24 h. On third-day post infection in mice, mosquitoes which were starved for 24 h are allowed 
to feed on mice. Before mosquitoes are allowed to feed, the presence of mature gametocytes is 
confirmed on blood smear of mice. The mice are then anesthetized with a single dose of 60 mg/kg 
of sodium pentobarbitone i.p. and laid on top of mosquito containers, so that the mosquitos can 
feed on them through the membrane covering of mosquito container for about 30 min. On the 
seventh day after the blood feed, a sample of each batch of mosquitos is removed and dissected. 
Midguts are examined for plasmodium parasites oocysts. The mean count for each batch is 
calculated. It is dissolved in 4% sucrose and fed ad libitum to the insects following the blood meal 
to determine the inhibitory effects of a test drug on oocyst development. Usually, a batch of 10 
surviving mosquitos for each drug concentration and each control is sufficient to provide data from 
which the level of drug activity can be calculated from a comparison of mean oocyst counts in 
treated and control batches (Ager, 1984; Kalra, 2006). 
 
1.8.2. HUMANIZED MOUSE MALARIA MODEL 
Humanized mice are the mice that express human genes and comprise human tissues (Siu 
and Ploss, 2015). Humanized mice models often employ mutations and genetically deficient 
backgrounds which maintain the immunocompromised status of mice and further enable 
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engraftment with human cells and tissues (Kaushansky et al., 2014). These models are important 
tools to understand the biology, and development of malaria and may have potential in the 
development of antimalarials drugs and vaccines (Kaushansky et al., 2014; Siu and Ploss, 2015). 
The blood and liver stages of human malaria infection are compartmentalized in nature, and thus 
independent studies can be done for each stage. The blood and liver stage can be replicated in a 
human erythroid and liver chimeric mouse respectively. Also, a dual engraftment of erythroid/liver 
would allow replicate the complete Plasmodium life cycle in vivo (Siu and Ploss 2015). 
 
1.8.2.1. BLOOD STAGE MODEL 
As mentioned earlier, human erythroid chimeric mice are used to replicate Plasmodium 
asexual blood stage infection. In the present, there are two ways to generate human erythroid 
chimeric mice infection 1) to infuse human RBCs and 2) to transplant hematopoietic stem cell 
(Vaughan et al., 2012). The most effective and successful method to generate a human erythroid 
chimeric mouse is to engraft human RBCs in immuno-deficient mice (Siu and Ploss, 2015). The 
severe combined immunodeficiency (SCID) mice contain a point mutation in the Prkdc kinase 
(PrkdcSCID), which hampers with the development and functions of B and T lymphocytes. Thus, 
these SCID mice accept xenogenic grafts of human RBCs and are used to establish P. falciparum 
asexual blood-stage infection for up to 2 weeks (Tsuji et al., 1995). The non-obese diabetic (NOD) 
mice background is often used with SCID mice further facilitate the engraftment of human RBCs 
(Siu and Ploss, 2015; Vaughan et al., 2012). 
Another model that would support asexual blood infection of Plasmodium is through 
transplant of hematopoietic stem cells (HSCs) in the bone marrow of mice. Practically, this model 
has produced limited success. To produce human hematolymphoid mice, SCID mice are 
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transplanted with HSCs isolated from human fetal tissues, human peripheral blood, or human bone 
marrow (Rongvaux et al., 2013; Strowig et al., 2011). 
 
1.8.2.2. LIVER STAGE MODEL 
The human liver chimeric mice are generated by injecting human primary adult 
hepatocytes in Xeno recipient SCID mice. To further boost the growth of human hepatocyte, the 
liver injury is induced in the mice (Billerbeck et al., 2013; Siu and Ploss, 2015).  The SCID mice 
expressing urokinase-type plasminogen activator transgene (UPA) using the albumin promoter 
(Alb) (SCID Alb-UPA) are the well-distinguished human liver chimeric mice model. The cells 
which do not contain the toxic urokinase-type plasminogen activator transgene, for example, 
engrafted human hepatocytes get a selective advantage to grow. This humanized mouse model is 
successfully used to engraft human hepatocytes with almost 90% engraftment (Sandgren et al., 
1991). Importantly, this model is shown to maintain P. falciparum infection effectively (Sacci et 
al., 2006). 
 
1.8.3. NON-HUMAN PRIMATE (NHP) MODELS 
Aotus trivirgatus (Owl monkey) and the Saimiri sciureus (squirrel monkey) have served as 
experimental models for antimalarial drug research. Primate models are more advanced animal 
models than rodent models. NHP models have utility for re-confirmation of rodent efficacy results 
with a more clear prediction of drug effect in humans and evaluating the efficacy against malaria. 
These primate hosts are primarily used for screening of antimalarial drugs. A. trivirgatus is one of 
the WHO recommended a model for studies in malaria research, and these are the only models 
which can sustain malarial infection caused by human malaria parasites, P. falciparum and P. vivax 
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and rhesus malaria parasite P. cynomolgi. The progression of P. vivax infection in this primate 
model is similar to P. vivax infection in man. The same model could evaluate the prophylactic, 
schizonticidal, and hypnozoitocidal effect of test drug (Peters, 1987).   
The NHP in vivo experiments started with young, tuberculin-negative rhesus monkeys (3.5 
to 6 kg). The infected female anopheles mosquitos are ground in a 1:1 mixture of saline and normal 
monkey serum to initiate the infection in monkey. The debris is removed by light centrifugation. 
The sporozoites are counted, and each primate inoculated intravenously with approximately 
500,000 sporozoites in 2 ml of fluid. The suspension of drug in water is prepared and administered 
with the help of stomach tube once daily, starting the day before infection and up to day 8. Blood 
smears are prepared, and parasitemia analyzed daily until 46 weeks. At the end of 6 weeks, if the 
animals are still negative, they are rechallenged with another inoculum to check their susceptibility 
to infection (Kalra, 2006; Peters, 1987). 
All the animals become infected during 4-6 weeks of the period are treated with test 
compounds as soon as the parasitemia level reaches 0.1 to 0.5%.The infected animals receive seven 
daily oral doses of the drug and blood smear slides are prepared and analyzed daily during and 
after the treatment up to 30 days. If the animals found negative for malaria parasite, they examined 
twice weekly until they parasite relapse. If the parasites are not cleared by the drug during the 
primary treatment, the animals are given seven daily doses of 5mg/kg of chloroquine. If no relapse 
follows chloroquine administration, it indicates that the test drug has destroyed the hypnozoites. 
When no relapse occurs within 8-12 weeks, the animals are splenectomized. Failure to develop 
further parasitemia within four weeks of this procedure indicates that the animals are radically 
cured since, in 99% of those that are not splenectomized, the infection relapses within three weeks 
of splenectomy (Fidock et al., 2004; Kalra, 2006). 
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A particularly valuable model for the study of hypnozoites has been established with the 
simian parasite P. cynomolgi in Macaca mulatta (rhesus monkeys), enabling efficacy tests of drugs 
against the dormant liver stages(Deye et al., 2012; Dow et al., 2011).  
The rhesus macaque P. knowlesi infection model remains a preferred model used to study 
Plasmodium liver stages since it approximates the P. falciparum course of infection in young 
children and adults and parallels P. falciparum in having a longer liver stage duration of parasite 
development, in contrast to the rodent malaria parasites. The animal model for P. falciparum 
infection in the Aotus spp. monkey host is suboptimal because cycles of transmission through 
sporozoites are unreliably maintained and the availability of Aotus spp. monkeys are also 
low(Galinski et al., 2017; Hobbs et al., 2014; Pasini et al., 2016). 
This close relatedness between human and non-human primate hosts and between human 
and simian Plasmodium parasites makes non-human primates models of choice for human malaria 
for the biomedical research community. The main simian Plasmodium parasites infecting Old 
World primates include P. knowlesi,  P. coatneyi, P. fragile, P. cynomolgi, P. inui, P. fieldi, and 
P. simiovale, in South East Asia, as well as P. gonderi in Africa, while simian Plasmodium 
parasites infecting New World primates comprise P. brasilianum and P. simium in South America 
(Galinski, 2012). Simian Plasmodium parasites sharing similarities with human parasites were 
reported at the beginning of the 20th century (Coatney, 1971). Deciphering the evolutionary 
history of Plasmodium parasites and their primate hosts' restrictions is a matter of intensive 
research, to determine the origin of human Plasmodium parasites and when they emerged (Beignon 
et al., 2014). 
Infections with P. coatneyi, a simian malaria species that is closely related to P.  knowlesi 
(Singh and Daneshvar, 2013; Vargas-Serrato et al., 2003), mirror the biology and pathogenesis of 
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falciparum malaria, with severe forms of pathology including anemia. A procedure was established 
to measure the turnover of in vivo biotinylated RBCs in rhesus macaque (Macaca mulatta) to study 
mechanisms of the onset and recovery of anemia (Moreno et al., 2013). These macaques had been 
experimentally infected for the first time (i.e., when malaria naïve) with P. coatneyi infected RBCs 
and, then again, while partially immune, nine months after curative anti-malarial drug treatment 
(Fonseca et al., 2016). This model also permits the quantification of the production of newly 
generated RBCs and of the different processes leading to the removal of RBCs in the absence or 
presence of a P. coatneyi infection in malaria naïve or semi-immune rhesus macaque (Fonseca et 
al., 2016; Teja-Isavadharm et al., 2016). The model can be employed as a tool for predicting and 
exploring disease severity and evaluating host-directed interventions. This capability includes the 
study of other species of Plasmodium that cause malaria in primates, each with their unique blood-
stage biology and pathogenic characteristics (Fonseca et al., 2016). 
Several species of New World Monkeys belonging to the genus Aotus and Saimiri are 
susceptible to infection by the five species mentioned above (Collins, 2002b). P. falciparum, P. 
vivax, and P. malariae require a process of adaptation in vivo to grow reproducibly in New World 
monkeys. Also, splenectomy is often necessary to obtain significant parasitemias and production 
of infective gametocytes (Collins, 2002a, b). Conversely, P. knowlesi, a natural parasite of 
monkeys, readily infects Aotus, Saimiri and Rhesus monkeys (Macaca mulatta). As a major 
advantage of nonhuman primates, all stages of the biological cycle of the human parasites can be 
reproduced for drug evaluation by choosing appropriate host-parasite pairs (Collins, 2002a; 
Stewart, 2003). Nonetheless, the use of monkey models is quite limited due to ethical concerns 
and experimental complexity because highly specialized facilities are required (Jimenez-Diaz et 
al., 2014). 
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Macaques are the natural host of P. cynomolgi, a malaria parasite that has a biological cycle 
similar to P. vivax and can infect humans (Coatney et al., 1961; Jimenez-Diaz et al., 2014). P. 
cynomolgi has a cycle of maturation in the blood of 48 h with reticulocytes being the preferred 
cells for malaria of infection. The blood-stage infection is self- limited but presents characteristic 
relapses (Kocken et al., 2009). P. cynomolgi is also noteworthy as it can also form hypnozoites 
upon liver infection. All these characteristics make P. cynomolgi an interesting surrogate model 
for P. vivax infection (Jimenez-Diaz et al., 2014). Different models for malaria drug discovery are 
summarized in Table 1.4. 
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Table 1.4: Models for malaria drug discovery. Table adapted from Jimenez-Diaz et al., 2014 
(Jimenez-Diaz et al., 2014). The intensity is defined in + sign. Single + is lowest and +++++ is 
the highest intensity.  
 
 
 
 
 
 In vitro Rodent Humanized 
mouse 
Non-human 
primates 
Plasmodium 
spp. 
 
P. 
falciparum 
(Chloroquine 
sensitive and 
resistance 
strains) 
P. berghei, P. 
yoelii, 
P. chabaudi, P. 
vinckei 
 
P. falciparum P. falciparum, P. 
vivax, P. 
malariae, P. 
ovale, and 
P. knowlesi, are 
infectious for both 
Old and new 
World Monkey. 
P. cynomolgi 
infectious in New 
World monkeys 
Parasite 
cycle stage 
for assay 
 
Blood stage 
only 
Full cycle 
Gametocyte 
Blood stage 
Liver stage 
Gametocyte 
Full cycle. 
P. cynomolgi for 
hypnozoite stage 
Parasite 
maintenance 
 
In vitro In vivo passage In vitro/in vivo 
passage 
 
In vitro/in vivo 
passage 
Host 
immunity 
Not applied Immuno-deficient 
Immuno-
competent 
 
Immuno-
deficient 
Immunocompetent 
Complexity + ++ +++ +++++ 
Facilities + ++ +++ +++++ 
Accessibility ++++ ++++ +++ Highly restricted 
Animal 
handling 
No animal 
handling 
+ ++++ ++ 
Cost + ++ +++ +++++ 
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1.9. CONCLUDING REMARKS 
 Visceral leishmaniasis is one of manifestation of leishmaniasis with very high mortality 
and morbidity. Several phenotypic cells-based in vitro models are available for antileishmanial 
screening. Intracellular amastigotes represent the pathophysiological scenario of leishmaniasis 
diseases. Screening against intracellular amastigotes is more logical for in vitro/ex vivo 
antileishmanial drug discovery than promastigotes or axenic amastigotes form of parasites. 
Screening assays for intracellular amastigotes are complex as they require both host and parasite 
cells. THP1 cells can be differentiated to form a monolayer of macrophage cells and are most 
appropriate host cells with non-dividing nature as of cells with homogeneous cell population. 
Similarly, several in vivo models are available for antileishmanial screening, based on rodents 
(mice, Hamster), dogs and non-human primate animals as the host for the leishmania parasite. 
Both in vitro and in vivo antileishmanial screenings assays rely on growth analysis the intracellular 
amastigotes. The currently available in vitro/ex vivo screening methods have significant limitations 
and shortcomings, which should be addressed by developing better phenotypic better models. In 
case of visceral leishmaniasis, the parasite penetrates into the visceral organs. Analysis of growth 
of leishmania parasite in internal visceral organs becomes challenging. Generation of stably 
transfected transgenic parasite cell lines with a strong and sustained expression of reporter proteins 
which can monitor in the deep visceral organs with minimal background interference. 
 Similarly, malaria is a fatal disease if left untreated and is a major cause of deaths globally. 
Several screening assays are available for in vitro antimalarial screening based on P. falciparum 
cultures maintained in human erythrocytes. Most of the currently employed assays are complex as 
the parasite grows inside the erythrocytes through multiple developmental stages. Several in vivo 
experimental animal models have been developed with rodent and non-human primates host 
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animals and different species of the malaria parasite.  Both in vitro and in vivo models rely on the 
intra-erythrocytic growth analysis of the malaria parasite. Most of the current lab and even clinical 
diagnostic centers for malaria around the world rely on microscopy for observing the malaria 
parasite in the blood sample. Several other parasitemia analysis methods have been developed, but 
most of these models have significant limitations. To accelerate the antimalarial drug discovery 
research, there is a significant need for the development of methods for parasitemia analysis, which 
are robust, cost-effective and can be applied for automated high-throughput screening.  
The research project have addresses the critical need for development and standardization 
of novel models and assays for phenotypic screening for visceral leishmaniasis and malaria. The 
project includes the development of high throughput screening assay against intracellular 
amastigotes of L. donovani which is the causative agent of visceral leishmaniasis. The utility of 
the developed assay was confirmed by applying the developed assay for high throughput screening 
for a big natural product fraction library. Furthermore, the two new transgenic L. donovani 
parasites, one with a citrine reporter gene and another with the mCherry reporter gene were 
developed by stable transfection method. The developed transgenic parasite was utilized as 
promastigote and intracellular screening models. The project also includes the development of a 
noble method for malaria parasite-infected red blood cells analysis based on LDS-751 nucleic acid 
staining.  The method was implemented here in in vitro and in vivo settings of antimalarial 
screening assays. These newly developed assay will contribute significantly to accelerating the 
current search for noble pharmacophores with antileishmanial and antimalarial activity. The new 
models will also have important applications in understanding biology, virulence, and 
pathogenesis of malaria and leishmania pathogens, host-parasite interactions and in vitro/in vivo 
screening for new drug discovery.   
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CHAPTER II 
DEVELOPMENT OF AN IN VITRO MACROPHAGE CELLS INTERNALIZED 
LEISHMANIA AMASTIGOTES ASSAY AND SCREENING OF A NATURAL 
PRODUCTS LIBRARY 
 
2.1. INTRODUCTION 
Leishmania donovani, the causative agents of visceral leishmaniasis (VL), are intracellular 
parasitic protozoa that cycle between phagolysosomes of mammalian macrophages and alimentary 
tract of sand flies (Chang and Fong, 1983). New antileishmanial drug discovery approaches 
primarily rely on the availability of suitable in vitro and in vivo screening models. In vitro 
promastigotes (Mikus and Steverding, 2000) and axenic amastigotes assays (Callahan et al., 1997) 
have been used for anti-leishmanial drug screening. However, the promastigotes-based assays may 
not be appropriate due to significant cellular, physiological, biochemical and molecular differences 
in comparison to intracellular amastigotes. Macrophage-internalized amastigotes are responsible 
for  pathophysiological conditions of leishmaniasis (Croft et al., 2006a). Therefore, the assays 
based on intracellular macrophage-amastigotes are more appropriate for in vitro screening. 
Screening based on intracellular amastigotes gives essential information on the capacity of the 
drugs to target intracellular microorganisms (Sereno et al., 2007). Macrophage-amastigotes 
models are complex, as they require host macrophages cells and parasite (Leishmania spp.) cells. 
Quantitative analysis of viability, growth, and proliferation of leishmania amastigotes within 
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macrophages cells is challenging.  Differentiated nondividing THP1 cells make an attractive 
alternative to primary macrophage cells and can be used for assaying the anti-leishmanial activity 
of different compounds against intracellular amastigotes (Croft et al., 2006a). Currently available 
macrophage-amastigote assays have several limitations.  Classical microscopic assays, based on 
the microscopic counting of amastigotes/cell are labor-intensive. Further, the absence of 
automation limits the utility of this assay. 
   To overcome above demerits and limitations of the available macrophage-amastigote 
assays, we have developed a parasite rescue and transformation (PRT) assay with differentiated 
THP1 cells infected in vitro with L. donovani for screening pure compounds and natural products 
extracts (Jain et al., 2012). The assay involves the following steps: (1) terminal differentiation of 
THP1 cells to non-dividing macrophages, (2) infection of macrophages with L. donovani 
metacyclic promastigotes, (3) treatment of infected cells with test drugs, (4) controlled lysis of the 
infected macrophages, (5) release/rescue of amastigotes and (6) transformation of live amastigotes 
to promastigotes (7) quantitative analysis of growth of promastigotes.   
The assay was optimized using detergent treatment for controlled lysis of Leishmania-
infected THP1 cells to achieve almost complete rescue of viable intracellular amastigotes with 
minimal effect on their ability to transform into promastigotes. Different 
macrophage:promastigotes ratios were tested to achieve maximum infection. Quantification of the 
infection was performed through the transformation of living, rescued Leishmania amastigotes to 
promastigotes and evaluation of their growth by an AlamarBlue fluorometric assay in 96-well 
microplates. This protocol has been optimized for 384 well plates, and its applicability as high 
throughput assay has been established by the screening a natural products fractions library.  
Further, the assay was modified for simultaneity evaluation of the test samples for THP1 
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cytotoxicity (Jain et al., 2016b).  
The use of natural products for treatment and cure of  diseases has its roots in pre-historic 
times (Newman and Cragg, 2012).  Despite significant advancement in synthetic medicinal 
chemistry, the natural products remain to be the unmatched source of drugs with novel 
pharmacophore structures (Cragg and Newman, 2013). Most of the currently available drugs have 
their genesis, directly or indirectly, from natural products. Amphotericin B used for the treatment 
of leishmaniasis originates from natural source Streptomyces nodosus, a filamentous bacterium. 
Several new assays were up-graded to 384 well format and applied for screening of a natural 
products fractions library generated by high throughput fractionation (Rocha et al., 2005; Sen and 
Chatterjee, 2011; Tu et al., 2010).  
A natural products library of 13584 plant fractions obtained from 958 plant extracts was 
developed. Fractions were generated using a high throughput preparative fractionation (HTPF) of 
plant-extracts, coupled with a collection of UPLC-MS-ELSD-PDA data for each fraction.  This 
UPLC-MS-ELSD-PDA data for each fraction will be helpful in identification of novel 
pharmacophores with potent leishmanicidal activity against intracellular amastigotes. This natural 
products library of plant fraction was utilized in high throughput screening against intracellular 
amastigotes with the help of parasite rescue and transformation assay.  
 
2.2. HYPOTHESIS 
The internalized leishmania amastigotes rescued by controlled lysis of the infected host 
macrophage cells transformed into cell-free promastigotes forms. The numbers and growth of 
transformed promastigotes correlate with the numbers of live amastigotes rescued from the 
leishmania infected macrophages cells. 
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2.3. OBJECTIVES 
Purpose of this study to develop an in vitro method for screening against macrophage 
internalized L. donovani amastigotes. THP1 cells, terminally differentiated into adherent 
macrophages, were employed as the host cells. The transformed THP1 cells were infected with L. 
donovani promastigotes. The infected THP1 cells were treated with the test compounds. The 
macrophage internalized amastigotes were rescued by controlled lysis. Live amastigotes were 
transformed to promastigotes. The growth of  promastigotes was analyzed by AlamarBlue assay. 
The library of natural products fractions were screened, and outcome of hits for any particular 
target was further evaluated. 
 
2.4. MATERIALS AND METHODS. 
 
2.4.1. L. DONOVANI PROMASTIGOTE CULTURE 
Promastigote culture L. donovani (S1 strain) in RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS) is maintained at the 26oC incubator.  
 
2.4.2. THP1 CELLS CULTURE 
THP1 cell culture in RPMI medium supplemented with 10% FBS was maintained at 37oC 
in 5% CO2 incubator. 
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2.4.3. DIFFERENTIATION OF THP1 CELLS 
A 3-days old culture of THP1 cells in the exponential phase was diluted with RPMI 
medium to 2.5 X 105 cells/mL. Phorbol 12-myristate 13-acetate (PMA) was added to the cell 
suspension to achieve a final concentration of 25 ng/mL (Jain et al., 2016a). The final concentration 
of PMA was standardized with different concentrations ranges from 10ng/mL to 100ng/mL. No 
toxicity was observed at any PMA concentrations in this range. PMA concentration of 25 ng/mL 
concentration was selected for differentiation of 100% THP1 cells. THP1 cells treated with PMA 
were seeded onto clear flat-bottom experimental plates (50,000 cells/well in 96 wells plate or 
12,500 cells/well for 384 wells plate) or chamber slides (50,000 cells/well in 16 well chamber 
slides). Plates/chamber slides were incubated in a 5% CO2 incubator at 37oC for at least 12 h for 
differentiation of the THP1 cells to adherent macrophages. After overnight incubation, the medium 
from each well was discarded, and adherent cells were gently washed at least twice with serum-
free RPMI1640 medium. 
 
2.4.4.  PARASITE RESCUE AND TRANSFORMATION (PRT) ASSAY 
2.4.4.1.   INFECTION OF DIFFERENTIATED THP1 CELLS WITH L. DONOVANI 
The plates/chamber slides with differentiated THP1 cells were washed with serum-free 
medium. The L. donovani promastigotes culture was harvested at the stationary phase (metacyclic 
infective stage) and diluted to a density of 5X106 cells/mL in RPMI1640 medium with 4% FBS. 
The 100 µL (96 well plate) of promastigotes were added over serum-free medium in plates. The 
final density of promastigote parasite remained 2.5X106, parasites/mL in plates (5X105 
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parasites/well). The THP1 cells were infected with promastigotes in the ratio of 1:10.   Plates with 
THP1 cells with promastigotes were incubated at 37oC with 5% CO2 for 24 h to allow the 
promastigote parasite to infect the THP1 cells and transform to amastigotes. Plates were washed 
after 24 h with serum-free medium to remove external (non-internalized) parasites. 
  
2.4.4.2. TREATMENT OF INFECTED THP1 CELLS WITH TEST DRUGS 
Standard antileishmanial drugs amphotericin B, pentamidine and miltefosine, were 
selected for testing against intracellular amastigotes by both PRT assay and compare with digital 
image analysis assay. Stock solutions of the drugs/test compounds were prepared in water or 
dimethyl sulfoxide (DMSO). Each drug/compound was tested at six different concentrations. The 
standard drugs and test compounds were serially diluted in a fresh 96-well plate with RPMI-1640 
medium with 4% FBS. The drugs/test compound concentrations were prepared in 2 times of the 
final concentrations. The serially diluted samples (100µl) were transferred to the experimental 
plate over 100µl serum-free medium. The plates were incubated at 37oC and 5% CO2 for 48 h. The 
plates were washed again with serum-free RPMI medium. The infected THP1 cells control without 
drugs were set up simultaneously in each plate/chamber slide. 
 
2.4.4.3. CONTROLLED LYSIS AMASTIGOTES-INFECTED MACROPHAGES 
The serum-free medium was removed from plates (Figure 2.1A) and infected THP1 cells were 
treated with 0.05% sodium dodecyl sulfate (SDS) in serum-free RPMI medium for 30 seconds 
(20µL/well). The plate was shaken for 30 sec duration (Figure 2.1B).  The 0.05% Sodium dodecyl 
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sulfate (SDS) in serum-free RPMI medium diluted with the RPMI medium with 10% FBS 
(180µl/well).  After treatment of all wells for controlled SDS lysis, the plates were transferred to 
an incubator at 26oC for 48 h. This allowed transformation of rescued live amastigotes to 
promastigotes.  
 
2.4.4.4. QUANTITATIVE ANALYSIS OF TRANSFORMED PROMASTIGOTES  
After a 48 h incubation at 26°C, the rescued live amastigotes were transformed into 
promastigotes (Figure 2.1D).  AlamarBlue (10 µL) was added to each well, and the plates were 
incubated at 26oC for overnight. The plates were read for standard fluorescence on a Fluostar 
Galaxy fluorimeter (BMG Lab Technologies) at 544 nm excitation, 590nm emission. The dose-
response curved was prepared with XLfit software, and IC50 (concentration of the test compound 
causing 50% inhibition of growth) IC90 (concentration of the test compound causing 90% 
inhibition of growth) were computed.    
 
2.4.5.  THE DIGITAL IMAGE ANALYSIS (DIA) ASSAY 
2.4.5.1. INFECTION OF THP1 CELLS WITH L. DONOVANI AND TREATMENTS WITH 
TEST DRUGS 
The chamber slides with differentiated THP1 Cells were washed with serum-free medium 
infected with the L. donovani promastigotes as described in section 2.4.4. Chamber slides with 
infected THP1 cells were treated with test samples or standard drugs (Amphotericin B and 
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Pentamidine) at different concentrations for 48 h.    
 
2.4.5.2. FLUORESCENT MICROSCOPE IMAGING AND IMAGE ANALYSIS  
The chamber slides were washed with serum-free RPMI medium. The plastic well inserts 
were peeled off from the glass slides. The slides with infected THP1 cells were fixed by immersing 
the slides in methanol for 30 sec,  dried under air flow and stained with 5 X SYBR Green I 
(prepared in water from the stock of 10,000X) for 15 minutes in a dark chamber at room 
temperature.  The slides were washed to remove the extra stain and dried for 30 min under airflow. 
A full glass coverslip was placed over the stained slide with the mounting medium. The images of 
the control, infected and treated THP1 cells were collected with a Nikon 90i eclipse fluorescent 
microscope in FITC and DIC filters. The macrophage nuclei and parasite nuclei were counted with 
the help of ImageJ software (Figure 2.3). The infectivity in particular sample images was 
calculated as  
 The dose-response curves were generated with XLfit software for computation of IC50 and IC90 
values.  
 
2.4.6.  STANDARDIZATION OF THP1 CELLS TO PARASITES RATIO 
The THP1 cells to parasites ratio to determine the sensitivity of the assay was Standardized. 
Low parasites numbers/infection may compromise with sensitivity and selectivity of the screening. 
To acquire an optimum infection in THP1 cells, the ratio of THP1 cells to infecting promastigote 
Infectivity= Number of amastigotes nuclei counted X 100                       
.                    Number of THP1 cells nuclei counted 
 
72 
parasite were standardized in 96 well plates and 16 well chamber slides. The plates/chamber slides 
with differentiated THP1 Cells were washed with serum-free medium and 100µl of medium 
remain left over the cells. These differentiated THP1 cells infected with L. donovani promastigotes 
in different ratios of THP1 cells to parasites (1:1.25, 1:2.5, 1:5 and 1:10). The L. donovani 
promastigotes culture was harvested at the stationary phase (metacyclic infective stage) and diluted 
to a density of 5X106 parasites/mL in RPMI1640 medium with 4% FBS. The promastigotes 
parasite were further serially diluted (1:1) from 5X106 parasites/mL. The 100µl of serially diluted 
promastigotes were added over serum-free medium in separate wells of plates or chamber slides. 
The number THP1 cells/ well remained constant (50,000cells/mL).  Plates/chamber slides with 
THP1 cells with promastigote were incubated at 37oC in 5% CO2 incubator for 24 h. 
Plates/chamber slides were washed after 24 h with serum-free medium to remove external 
(uninfected) parasites and added with RPMI medium with 2% FBS. The plates/chamber slides 
were incubated for 48 h. The plates were washed again with serum-free RPMI medium and treated 
accordingly for PRT assay, and chamber slides were fixed with methanol and stained with 5X 
SYBR green for 15 min for digital image analysis assay. 
 
2.4.7. STANDARDIZATION OF CONTROLLED CELL LYSIS 
Controlled lysis of the THP1 cells was to achieve maximum/complete THP1 cells lysis 
without significantly affecting the viability of the rescued amastigote parasites. Infected THP1 
cells were achieved by following the previous protocols (2.4.4.). Different detergents such as 
Tween 20, Tween 80, Triton X-100, NP-40 and SDS at different concentrations (0.5 and 0.05) and 
different durations of treatment (from 10sec to 60 sec) (Figure 2.2) were tested for control lysis 
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of L. donovani amastigotes infected THP1 cells. The effect of detergent was diluted immediately 
after the treatment time with RPMI medium with 10% FBS. 
 
2.4.8. PLANT MATERIALS 
Most of all samples were collected by botanists at Missouri Botanical Garden (MOBOT) 
in St. Louis, Missouri and some are collected by Elray Nixon. All the information NP ID, Sample 
Name, Sample Code, Genus, Species, Family, Source Common Name, Plant Part, Geographical 
Location, Collector,  Collector number, Collection Reference and MOBOT Link for every extract 
have been mentioned in the compound library. Bulk plant samples are dried and frozen in the field 
and freeze dried at the University of Mississippi before extracting. 
 
2.4.9. EXTRACTS PREPARATIONS 
Extracts were prepared in National Center for Natural Products Research at the University 
of Mississippi by Dr. Melisa Jacob and his team. Extraction of the sample by was done by Dionex 
ASE 300. Extraction was done in 100% methanol. Each sample was placed in a specific ASE cell 
and extracted at 1500psi, at 40oC for three times with 10-minute static time/Extraction. 100% 
volume get flushed out. Moreover, ASE cells purged for 120 Seconds. After extraction, all extract 
was dried and weighed and then dissolved in DMSO at a concentration of 20mg/mL. 
 
2.4.10. FRACTIONATION OF EXTRACTS 
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Fractionation of the plant extracts was done in Chemical Biology and Therapeutics, St. 
Jude Children Research Hospital, Memphis Tennessee, by Dr. Kip Guy and his team.  Natural 
products fractions library was generated using AHTS from various plant extracts (Tu et al., 2010; 
Tu and Yan, 2012). UPLC-MS-ELSD-PDA data were obtained with a Waters Acquity UPLCMS 
system (Waters Corp., Milford, MA, USA). An Acquity UPLC BEH C18 column (2.1 × 50 mm, 
1.7 μm) was used. The mobile phase consisted of H2O containing 0.1% HCOOH and CH3CN or 
MeOH. The total run time for each analysis was 3.0 min. Ionization and detection of natural 
products were carried out on a Waters SQ mass spectrometer using both the positive and negative 
ESI modes. The capillary voltage was set at 3.4 kV. The extractor voltage was 2 V. Nitrogen was 
used as the nebulizing gas, and the source temperature was set at 130 °C. The scan range was m/z 
130-1400. Data processing was performed automatically with OpenLynx by extracting all graphics 
information, such as retention times and UV and ELSD peak areas, and converted to text to allow 
transfer to a database for storage and analysis. Each 384-well plate could be analyzed in 20 h (Yang 
et al., 2014).  
 
2.4.11. HIGH-THROUGHPUT PRT AND THP1 CELLS CYTOTOXICITY ASSAYS 
The THP1 treated with PMA were seeded for differentiation in clear flat bottom 384 wells 
plates. Duplicate plates were set up, one each for leishmania and THP1 cytotoxicity assays. In one 
plate THP1 cells were infected with L. donovani promastigotes. After 24 h non-internalized 
promastigotes were washed off with serum-free RPMI1640 medium with the help of Aquamax 
4000 microplate washer and left with 25µL/well of serum-free medium in plates. The test samples 
(plant extracts fractions) were diluted in separate plates in RPMI medium with 4% FBS. The test 
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samples (25 µL each) were transferred to the experimental plates with infected THP1 cells for 
antileishmanial assay and uninfected THP1 cells for cytotoxicity assay. The plates were placed in 
a CO2 incubator at 37oC for 48 h. After 48 h the plates were washed  with serum-free RPMI 
medium with Aquamax 4000 microplate washer. Infected THP1 cells were subjected to controlled 
lysis with 0.05% SDS solution for 30 sec to rescue live amastigotes. The amastigotes were allowed 
48 h to transform into promastigotes. Growths of leishmania promastigotes and THP1 cells were 
quantified with AlamarBlue (see section 2.4.4.).   
 
2.4.12. HIGH-THROUGHPUT THP1 CELLS CYTOTOXICITY ASSAY 
384 plates with differentiated THP1 cells (follow the method of section 2.4.3.) were 
washed at least twice with serum-free RPMI1640 medium. The 25µl of RPMI medium with 4% 
FBS were added over 25µl of serum-free medium and incubated the plates back to 37oC with 5% 
CO2 for 24 h. Plates were washed serum-free medium. 25 µl of Plant fractions, diluted in daughter 
plates in RPMI medium with 4% FBS and transferred into experimental plates with THP1 cells. 
Cytotoxicity of Active fractions was performed at range from 10ug/mL to 0.0032ug/mL. The plate 
was incubated in a 5% CO2 incubator at 37oC for 48hr. After 48 of treatment, AlamarBlue was 
added to the plates, and the plates were incubated back in a 5% CO2 incubator at 37oC for overnight 
and read on a BMG Fluostar microplate reader (BMG Lab Technologies) at an excitation 
wavelength of 544 nm and an emission wavelength of 590 nm. Each compound was tested in 
duplicates at six concentrations, IC50 and IC90 values were computed from the dose-response 
curves developed by XLfit software.  
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2.5. RESULTS 
2.5.1. COMPARATIVE ANALYSIS OF DIGITAL IMAGE ASSAY AND PRT ASSAY 
A quantitative analysis was done for both Digital-Image-Analysis-Direct-Counting-Assay 
and PRT Assay for 24, 48, 72 and 96 h post standard antileishmanial drug treatment. In the direct 
counting method, level of infection of L. donovani infected macrophages (THP1 cells) was 
calculated by the amastigotes (determined by counting amastigotes nuclei)/100 transformed THP1 
cells (determined by counting THP1 cell nuclei) (Figure 2.6) is a more accurate measure to analyze 
the effect of different standard or test compounds than the percentage of infected THP1 cells, as 
reported in some previous papers (Sereno et al., 2007), because this number is directly related to 
overall effect of compounds either through a decrease in number of parasites in macrophage cells 
or total removal of parasite from the macrophage cells. Infection was calculated from digital 
images of infected THP1 cells treated with different standard drugs at different dilutions for 
various time intervals (Figure 2.6 and Table 2.1). The read-out for the Digital-Image-Analysis-
Direct-Counting-Assay was amastigotes infection/100 transformed THP1 cells, while the read-out 
for the Parasite- Rescue-Transformation-Assay was relative fluorescence units (RFU), which is 
directly proportional to the number of live Leishmania amastigotes rescued from the infected 
macrophages and transform into promastigotes. The AlamarBlue assay is routinely used for 
Leishmania promastigotes anti-leishmanial drug screening. 
 
2.5.2. CONTROLLED LYSIS OF INFECTED DIFFERENTIATED THP1 CELLS 
The assay was initially standardized and optimized for controlled lysis of Leishmania-
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infected THP1 cells. The objective was to optimize the conditions for detergent treatment, which 
yield almost complete lysis of THP1 cells with minimal effect on the viability of the rescued 
amastigotes. Treatment with NP-40 (Figure 2.2A) and Triton X-100 (Figure 2.2B) lysed the 
infected THP1 cells; however, it also influenced the viability and transformation of the rescued 
amastigotes. Treatment with Tween 20 (Figure 2.2C) and Tween 80 (Figure 2.2D) did not cause 
optimal lysis of THP1 cells resulting in an incomplete rescue of amastigotes as indicated by low 
numbers of transformed promastigotes. Treatment with 0.05% SDS for 30 sec (Figure 2.2E) 
yielded almost complete lysis of Leishmania-infected THP1 cells and did not affect viability and 
transformation of rescued amastigotes. Further optimization showed that treatment of cells with 
0.05% SDS for 20-30 sec yielded the highest rescue of viable Leishmania amastigotes (Figure 
2.2F). Because of the better yield of rescued parasite and maximum lysis of THP1 cell membrane, 
in subsequent experiments, treatment with 0.05% SDS for 30 sec was used. Figure 2.1 depicts a 
microscopic view of the complete control lysis protocol. Intact THP1 cells infected with 
Leishmania amastigotes can be seen in Figure 2.1A. Figure 2.1B shows lysis of the THP1 cells 
after detergent treatment. Figure 2.1C shows rescued Leishmania amastigotes, which have been 
partially transformed into promastigotes and Figure 2.1D shows the almost complete 
transformation of amastigotes into promastigotes and their subsequent proliferation. The growth 
of these transformed promastigotes can be quantitatively monitored with the addition of 
AlamarBlue and measurement of fluorescence on a microplate reader. Procedure for SDS 
treatment was same for single or multiple plates. In multiple plates, SDS treatment was 
implemented column by column with a multichannel pipette. Serum-free medium was removed 
from all eight wells of one column of the plate, and 20 μl of 0.05% SDS was added to 8 wells of 
the same column and diluted after 30 sec with RPMI-1640 with 10% FBS. During initial 
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standardization of the assay, the plates were checked under the microscope for non-internalized 
promastigotes. A minimum of five items of washing was necessary for removal of parasites before 
step 5 of treatment of infected macrophage cells with standard compounds and three items of 
washing were necessary before step 7 of SDS treatment. Thus, the cells were washed eight times, 
and no visible non-internalized promastigotes remained before control lysis of infected THP1 cells. 
 
2.5.3. DIGITAL IMAGE ANALYSIS AND DIRECT COUNTING 
The digital images of Leishmania-infected THP1 cells were captured on Nikon Eclipse 90i 
fluorescent microscope after staining with SYBR Green I. Both macrophage nuclei and 
intracellular Leishmania nuclei with characteristic kinetoplast DNA were observed under the 
fluorescent filters (Figure 2.3). Further, the images of infected THP1 cells were also captured 
under DIC. When both the images were merged, the outlines of THP1 cells with intracellular 
amastigotes were seen more clearly (Figure 2.3). The ImageJ software was used to analyze these 
images. ImageJ is public domain, Java-based, image-processing program developed at the 
National Institutes of Health (http://rsb.info.nih.gov/ij/download.html). ImageJ has been designed 
with an open architecture that provides extensibility via Java plugins and recordable macros. 
Custom acquisition, analysis, and processing plugins can be developed using ImageJ's built-in 
editor and a Java compiler. For differential counting of THP1 cells nuclei and parasite nuclei by 
ImageJ, the image was opened in ImageJ. Cell counter was found in Analyze option in a plugin of 
the Software. The image was initialized, and cell counter type 1 was selected for THP1 cell nuclei 
and cell counter type 2 was selected for parasite nuclei (Figure 2.3). Differential counting was 
done for at least 200 THP1 cells nuclei and the intracellular amastigotes present in these THP1 
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cells nuclei. A comparison of the PRT assay and image analysis method was made for evaluating 
the infectivity of THP1 cells with different macrophage:promastigotes ratios (Figure 2.4). Figure 
2.5 represents the differential infectivity in THP1 cells at different macrophage:promastigote 
ratios. Both the methods showed comparable results and the macrophage:promastigote ratio of 
1:10 yielded optimum and reproducible infectivity. 
Once the conditions for PRT assay and the digital image analysis were optimized, the utility 
of these assays was evaluated for anti-leishmanial drug screening. The Leishmania-infected THP1 
cells were treated with different concentrations of standard antileishmanial drugs namely 
Amphotericin B, Pentamidine and Miltefosine for different time intervals ranging from 24 to 96 
hr. The experiment for PRT assay was done in triplicate, and the experiment for direct cells 
counting method was done in duplicate. Figure 2.6 shows microscopic images of the control 
uninfected, control infected untreated and Leishmania-infected, treated THP1 cells. The dose-
response curves were prepared from the PRT assay (concentration of the drug vs. transformed 
parasites) and the image analysis assay (number of amastigotes/100 THP1 cells) (Figure 2.7-2.9). 
The IC50 of the drugs were computed by ExcelFit and are presented in Table 2.1. Digital-Image-
Analysis-Direct-Counting-Assay and PRT assay showed comparable results. Digital-Image-
Analysis-Direct-Counting-Assay was less optimal during the early time points of 24 and 48 h drug 
treatments. While the PRT assay showed results more consistent with the reported values at all the 
time points during the 24-96 h after drug treatments. This difference in results with Digital-Image-
Analysis-Direct-Counting-Assay and PRT assay may be due to the presence of non-viable 
amastigotes during early periods of drug treatment in Digital-Image-Analysis-Direct-Counting-
Assay. 
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2.5.4. HTS OF NATURAL PRODUCTS FRACTIONS LIBRARY 
Total 13584 plant extract fractions from 958 extracts were screened out in both L. donovani 
macrophage amastigote assay and cytotoxicity assay using differentiated THP1 cell lines at 
10µg/mL concentration. Out of these 13584 fractions, only 243 plant extract fractions shows more 
than 50 percent inhibition of intracellular L. donovani amastigotes. The active 243 plant extract 
fractions were further screened for dose-response analysis. The selective antileishmanial activity 
of 64 plant extract fractions was re-confirmed with IC50 values less than ten µg/mL (Supporting 
Table 2.1).  19 fractions with IC50s < 2µg/mL (Table 2.2), 20 with IC50s between 2 and 5µg/mL 
and 25 with IC50s between 5 and 10µg/mL (Figure 2.10). Only 13 plant fractions out of 13584 
fractions show cytotoxicity on differentiated THP1 cells with % inhibition more than 50 %.  Most 
active  plant extract fractions with antileishmanial activity less than 2µg/mL were Thuja 
occidentalis c9 (0.25 µg/mL),  Asclepias asperula c3 (0.33 µg/mL), Inga laurina c5 (0.86 µg/mL), 
Gymnocladus dioica c7 (1.69 µg/mL), Rhodea japonica c5 (1.08 µg/mL), Rhodea japonica c6 
(0.70 µg/mL), Rhodea japonica c7 (0.39 µg/mL), Rhodea japonica c8 (0.41 µg/mL), Nerium 
oleander c3 (0.25 µg/mL), Nerium oleander c4 (0.53 µg/mL), Nerium oleander c6 (0.03 µg/mL), 
Nerium oleander c7 (0.54 µg/mL), Marah macrocarpus c8 (1.66 µg/mL), Marah macrocarpus c9 
(1.07 µg/mL), Juniperus californica c5 (1.75 µg/mL), Juniperus deppeana c5 (1.85 µg/mL),  
Eclipta prostrata c5 (0.80 µg/mL), Oplopanax horridus c6 (1.98 µg/mL), Falcataria moluccana 
c7 (1.29 µg/mL) (table 2.2). 
 Some fractions were further analyzed and compared with the QC-MS data of inactive 
fractions of the same plants.  This most active fraction belongs to Thuja occidentalis, Asclepias 
asperula, Rhodea japonica and Nerium oleander plant extracts. QC-MS data of Nerium oleander 
active fractions suggest Oleandrin as an active chemical constituent. QC-MS data of Thuja 
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occidentalis active fractions suggest Deoxypodophylotoxin as an active chemical constituent.    
 
2.5.5. QC-MS DATA OF FRACTIONS OF N. OLEANDER PLANT EXTRACT 80089 
 For Nerium oleander plant extract 80089, a total of four active plant factions 80089-c4, 
80089-c5, 80089-c6, 80089-c7and 80089-c8 derived from AHTS fractionation of the ethanolic 
extract, shows antileishmanial activity against Leishmania donovani amastigote with IC50 values 
8.31 μg/mL, 5.84 μg/mL, 0.03 μg/mL, 0.54 μg/mL and 7.72μg/mL respectively (supporting table 
2.1). They were found to be devoid of cytotoxicity against differentiated THP1 cells. 80089 C6 is 
the most active fraction in all active fractions of Nerium oleander plant extract. Peaks were shown 
in fractions 80089-c6 at tR 1.17 to 1.19 min and tR 1.24 min in the ELSD chromatogram (Figure 
2.11). These peaks were not detected in other inactive plant fractions for other Nerium oleander 
plant extract (plant extract number 80089). Therefore, peaks in QC-MS spectra at tR 1.17, 1.19, 
and 1.24 will be helpful in the prediction of active constituents of the plant fraction 80089-c6. The 
complete QC-MS analysis for the most active fraction 80089-c6 at tR 1.17, 1.19, and 1.24 minute 
is given in figure 2.12. 
 
2.5.6. QC-MS DATA OF FRACTIONS OF T. OCCIDENTALIS PLANT EXTRACT 79863 
In Thuja occidentalis plant extract 79863, only one active plant fraction 79863-c9 derived 
from AHTS fractionation of the ethanolic extract shows antileishmanial activity against 
Leishmania donovani amastigote with IC50 values 0.25 μg/mL. The fraction was found to be 
devoid of cytotoxicity against differentiated THP1 cells. Peaks were shown in fraction 79863-c9 
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at tR 1.18 and 1.24 min in the ELSD chromatogram (Figure 2.13). This peak was not detected in 
other inactive plant fractions for other Nerium oleander plant extract (plant extract number 79863). 
Therefore, peaks in QC-MS spectra at tR 1.18 and 1.24 min will be helpful in the prediction of 
active constituents of the plant fraction 79863-c9. The complete QC-MS analysis for the most 
active fraction 79863-c9 at tR 1.18 and 1.24 minute is given in Figure 2.14. 
 
2.5.7. QC-MS DATA OF FRACTIONS OF A. ASPERULA PLANT EXTRACT 78826 
In Asclepias asperula plant extract 78826, only one active plant fraction 78826-c3 derived 
from AHTS fractionation of the ethanolic extract shows antileishmanial activity against L. 
donovani amastigote with IC50 values 0.33 μg/mL. The fraction was found to be devoid of 
cytotoxicity against differentiated THP1 cells. Peaks were shown in fraction 78826-c3 at tR 0.9 
and 1.0 minute in the ELSD chromatogram (Figure 2.15). This peak was not detected in other 
inactive plant fractions for other Asclepias asperula plant extract (plant extract number78826). 
Therefore, peaks in QC-MS spectra at tR 0.9 and 1.0 min will be helpful in the prediction of active 
constituents of the plant fraction 79863-c9. The complete QC-MS analysis for the most active 
fraction 78826-c3 at tR 0.9 and 1.0 minute is given in Figure 2.16. 
 
2.5.8. QC-MS DATA OF FRACTIONS OF R. JAPONICA PLANT EXTRACT 81020 
In 81020 Rhodea japonica plant extract 81020, a total of five fractions, 81020-c5, 81020-
c6, 81020-c7, 81020-c8, and 81020-c9 derived from AHTS fractionation of the ethanolic extract, 
shows antileishmanial activity against Leishmania donovani amastigote with IC50 values 1.08 
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μg/mL, 0.70 μg/mL, 0.39 μg/mL, 0.41 μg/mL and 2.58 μg/mL respectively (supporting table 
2.1).  Fractions were found to be devoid of cytotoxicity against differentiated THP1 cells. 81020-
c8 is one of the most active fractions in all active fractions of Rhodea japonica plant extract. Peaks 
were shown in fractions 81020-c8 at tR 2.10 and 2.21 minute in the ELSD chromatogram (Figure 
2.17). This peak was not detected in other inactive plant fractions for other Rhodea japonica plant 
extract (plant extract number 81020). Therefore, peaks in QC-MS spectra at tR 2.10 and 2.21 min 
will be helpful in the prediction of active constituents of the plant fraction 81020-c8. The complete 
QC-MS analysis for the most active fraction 81020-c8 at tR 2.10 and 2.21 minute is given in 
Figure 2.18. 
 
2.5.9. RE-FRATIONATION OF N. OLEANDER AND T. OCCIDENTALIS  
 Nerium oleander plant extract was fractionated, and Oleandrin was confirmed as one of 
the active constituent in the active fraction (Unpublished data). The activity of Oleandrine was 
confirmed with PRT assay and as well as digital-image-analysis assay (Figure 2.19).   Thuja 
occidentalis plant extract was fractionated, and Deoxypodophylotoxin was confirmed as one of 
the active constituent in the active fraction (Yang et al., 2014). 
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FIGURES AND TABLES 
 
 
Figure 2.1: A microscopic view of the PRT assay. A - Adherent THP1cells infected with 
Leishmania amastigotes; B - Adherent, infected THP1 cells after controlled lysis with SDS C - L. 
donovani promastigotes transformed from the rescued live amastigotes D - Growth, and 
proliferation of transformed L. donovani promastigotes. Figure from Jain et al., JoVE, 2012 (Jain 
et al., 2012). 
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Figure 2.2: Optimization of controlled lysis of THP1 cells to achieve maximum rescue of live L. 
donovani amastigotes and their transformation to promastigotes with different detergents. Two 
concentrations (0.05% and 0.1%) of detergents and two time periods (30 sec and 60 sec) for 
treatment were tested. RFU (Relative fluorescence units). Each bar represents the mean of 
duplicate observations. [A] NP-40 [B] Triton X-100 [C] Tween 80 [D] Tween 80 and [E] SDS 
treatment caused almost complete lysis of THP1 cells and did not affect the viability of the rescued 
amastigotes at 0.05%/30 sec. [F] Treatment with 0.05% SDS for 20-30 sec caused almost complete 
lysis of THP1 cells and rescued viable parasite amastigotes to transform into promastigotes. Figure 
from Jain et al., JoVE, 2012 (Jain et al., 2012). 
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Figure 2.3: The fluorescent digital image of a differentiated THP1 cell infected in vitro with L. 
donovani amastigotes. A- Uninfected differentiated THP1 cells. B- L. donovani amastigote 
infected differentiated THP1 cells. The characteristic kDNA can also be seen with each parasite 
nucleus. The macrophage nucleus (mN) (1) and the parasite nuclei (pN) (2) can be differentially 
marked. C- Differentially counted by of macrophage nuclei and parasite nuclei with the help of 
ImageJ analysis software for quantitative evaluation of the infection. The quantification was done 
as a number of amastigotes/100 THP1 cells. Figure from Jain et al., JoVE, 2012 (Jain et al., 2012). 
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Figure 2.4: Different THP1 cells to parasite ratio in PRT assay (4A) and Digital-Image-Analysis-
Direct-Counting-Assay (4B). The macrophage:promastigote ratio of 1:10 yielded optimal 
infection. Both showed comparable results. The PRT assay showed some background values. Each 
bar shows mean of duplicate values. Figure from Jain et al., JoVE, 2012 (Jain et al., 2012). 
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Figure 2.5: Comparative images of THP1 cells infected with different ratios of amastigotes. THP1 
cells were infected by leishmania promastigotes by different THP1: Parasites ratio from uninfected 
THP1 cells (1:0, A) to maximum infected (1:10, E). Each different image was taken at 40 X 
magnification with 2X2 area. Images have taken by FITC filter with DIC. Figure from Jain et al., 
JoVE, 2012 (Jain et al., 2012). 
  
A B C 
D E  
A-Uninfected THP1 cells (1:0) 
B-THP1: Parasite ratio (1:1.25) 
C-THP1: Parasite ratio (1:2.5) 
D-THP1: Parasite ratio (1:5) 
E-THP1: Parasite ratio (1:10) 
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Figure 2.6: Digital images (FITC + DIC) of THP1 cells infected with L. donovani amastigotes 
after treatment with standard antileishmanial drugs for different time periods. Results were 
quantified as a number of amastigotes/100 THP1 cells and used to compute the percent growth 
compared to untreated controls and determine the IC50 values. Figure from Jain et al., JoVE, 2012 
(Jain et al., 2012). 
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Figure 2.7: Comparison of Digital-Image-Analysis-Direct-Counting-Assay and PRT assay for 
anti-leishmanial drug screening (Amphotericin B). The infected macrophages were treated with 
different concentrations of standard anti-leishmanial drug for different periods. IC50 (μg/mL) 
values were computed from the dose-response curve by Excelfit. Figure from Jain et al., JoVE, 
2012 (Jain et al., 2012). 
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Figure 2.8: Comparison of Digital-Image-Analysis-Direct-Counting-Assay and PRT assay for 
anti-leishmanial drug screening (Pentamidine). The infected macrophages were treated with 
different concentrations of standard anti-leishmanial drug for different periods. IC50 (μg/mL) 
values were computed from the dose-response curves by Excelfit. Figure from Jain et al., JoVE, 
2012 (Jain et al., 2012). 
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Figure 2.9: Comparison of Digital-Image-Analysis-Direct-Counting-Assay and PRT assay for 
anti-leishmanial drug screening (Miltefosine). The infected macrophages were treated with 
different concentrations of standard anti-leishmanial drug for different time periods. IC50 (μg/mL) 
values were computed from the dose-response curves by Excelfit. Figure from Jain et al., JoVE, 
2012 (Jain et al., 2012). 
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Figure 2.10. Flow diagram for the screening of natural products fractions library. Total of 13580 
fractions was screened with PRT assay for intracellular amastigotes of L. donovani at a single 
concentration. 234 plant fractions have more than 50% inhibition for intracellular amastigotes. 234 
active fraction was again screened at 6 different concentrations for concentration-response curve 
analysis. The 64 plant fraction was confirmed with an IC50 value of <10µg/ml. Total 19 plant 
fractions have potent activity with IC50 value <2µg/ml. 
 
 
 
 
94 
 
 
 
 
 
Figure 2.11: ELSD data for fractions of Nerium oleander plant extract 80089.  % LEM inhibition- 
Inhibition of intracellular amastigotes growth in PRT assay. The ELSD data of all fractions of 
Nerium oleander plant extract 80089 are compared. The retention time of peaks in ELSD spectra 
of active fraction those are not present in inactive fractions was selected for further mass spectra 
analysis. The active fraction 80089-C6 have peaks with retention time 1.17 and 1.24 those are not 
present in other inactive fraction. 
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Figure 2.12: UPLC-MS-ELSD-PDA data for Nerium oleander plant extract fraction 80089-c6.   
Panel A have ELSD, PDA and ESI data of active fraction 80089-c6. Panel B and Panel C are the 
mass spectra at retention time 1.24 and 1.17 respectively. 
Panel B 
Panel C 
Panel A 
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Figure 2.13: ELSD data for fractions of Thuja occidentalis plant extract 79863.  % LEM inhibition 
- inhibition of intracellular amastigotes in PRT assay. The ELSD data of all fractions of Thuja 
occidentalis plant extract 79863 are compared. The retention time of peaks in ELSD spectra of 
active fraction those are not present in inactive fractions was selected for further mass spectra 
analysis. The active fraction 79863-C9 have peaks with retention time 1.18 and 1.24 those are not 
present in other inactive fraction. 
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Figure 2.14: UPLC-MS-ELSD-PDA data for Thuja occidentalis plant extract fraction 79863-c9.   
Panel A have ELSD, PDA and ESI (Positive and negative) data of active fraction 79863-c9. Panel 
B and Panel C are the mass spectra at retention time 1.24 and 1.18 respectively. 
Panel A 
Panel C 
Panel B 
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Figure 2.15: ELSD data for fractions of Asclepias asperula   plant extract 78826.  % LEM 
inhibition - Inhibition of intracellular amastigotes in PRT assay. The ELSD data of all fractions of 
Asclepias asperula plant extract 78826 are compared. The retention time of peaks in ELSD spectra 
of active fraction those are not present in inactive fractions was selected for further mass spectra 
analysis. The active fraction 78826-C3 have peaks with retention time 0.90 and 1.00 those are not 
present in other inactive fraction. 
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Figure 2.16: UPLC-MS-ELSD-PDA data for Asclepias asperula plant extract fraction 78826-c3.   
Panel A have ELSD, PDA and ESI (Positive and negative) data of active fraction 78826-c3. Panel 
B and Panel C are the mass spectra at retention time 0.089 and 1.00 respectively. 
Panel A 
Panel B 
Panel 
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Figure 2.17: ELSD data for fractions of Rhodea japonica plant extract 81020.  % LEM inhibition 
- inhibition of intracellular amastigotes in PRT assay. The ELSD data of all fractions of Rhodea 
japonica plant extract 81020 are compared. The retention time of peaks in ELSD spectra of active 
fraction those are not present in inactive fractions was selected for further mass spectra analysis. 
The active fraction 81020-C8 have peaks with retention time 2.216 and 2.095 those are not present 
in other inactive fraction. 
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Figure 2.18: UPLC-MS-ELSD-PDA data for Rhodea japonica plant extract fraction 81020-c8. 
Panel A have ELSD, PDA and ESI (Positive and negative) data of active fraction 81020-c8. Panel 
B and Panel C are the mass spectra at retention time 2.216 and 2.095 respectively.  
 
Panel A 
Panel B 
Panel C 
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Figure 2.19:  The antileishmanial activity of oleandrin by SYBR Green I nucleus DNA staining 
digital image analysis assay.  
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Table 2.1: Comparison of Digital-Image-Analysis-Direct-Counting-Assay and PRT assay for anti-
leishmanial drug screening. The infected macrophages were treated with different concentrations 
of standard anti-leishmanial drug for different periods. IC50 (μg/mL) values were computed from 
the dose-response curves by Excelfit (Figures 7-9). ahours post drug treatment; bIAC = Image 
Analysis and Direct-Counting assay; cPRT = Parasite Rescue and Transformation assay. Values 
given are IC50 (concentration of the drug causing 50% inhibition of parasite growth) as μg/mL 
and are the mean ± S.D. of at least three experiments. * Statistically different (<0.05) compared to 
IC50 values with IAC assay. Table from Jain et al., JoVE, 2012 (Jain et al., 2012). 
 
 
  
Test 
drug 
24 hra IC50  
µg/ml 
48 hra IC50  
µg/ml 
72 hra IC50  
µg/ml 
96 hra IC50  
µg/ml 
IAC 
assayb 
PRT 
assayc 
IAC 
assayb 
PRT 
assayc 
IAC 
assayb 
PRT 
assayc 
IAC 
assayb 
PRT 
assayc 
Amphot
ericin B 
0.24± 
0.03 
0.17± 
0.01* 
0.12± 
0.04 
0.20± 
0.07 
0.06± 
0.01 
0.06± 
0.01 
0.11± 
0.03 
0.10± 
0.03 
Pentami
dine 
>10 2.55± 
1.16* 
2.88± 
0.58 
1.43± 
0.91 
1.24± 
0.35 
1.52± 
0.16 
0.71± 
0.63 
0.98± 
0.33 
Miltefos
ine 
0.38± 
0.02 
0.19± 
0.08* 
0.24± 
0.06 
0.30± 
0.08 
0.36± 
0.02 
0.16± 
0.06 
0.21± 
0.15 
0.17± 
0.10 
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Table 2.2: Antileishmanial activity and THP1 toxicity of the most active plant extract fractions. 
NP=Natural Product number. Parent Extract= Original extract that was fractionated into several 
fractions. The ic50= inhibitory concentration at which 50 % parasite growth inhibited compared 
to the untreated positive control of parasite. IC90= inhibitory concentration at which 90 % parasite 
growth inhibited compared to the untreated positive control of parasite. 
Sample information THP1 cells 
internalized 
Amastigotes 
THP1 
Cytotoxicity 
NP 
number 
Parent 
extract 
number 
Sample Name Sample 
Code 
IC50 
µg/mL  
IC90 
µg/mL 
IC50 
µg/mL 
IC90 
µg/mL 
86064 79863 Thuja occidentalis c9 79863-c9 0.25 >10 >10 >10 
85901 78826 Asclepias asperula c3 78826-c3 0.33 0.69 >10 >10 
90057 81079 Inga laurina c5 81079-c5 0.86 4.00 >10 >10 
89396 81004 Gymnocladus dioica c7 81004-c7 1.69 3.29 >10 >10 
89480 81020 Rhodea japonica c5 81020-c5 1.08 2.56 >10 >10 
89481 81020 Rhodea japonica c6 81020-c6 0.70 3.37 >10 >10 
89482 81020 Rhodea japonica c7 81020-c7 0.39 1.13 >10 >10 
89483 81020 Rhodea japonica c8 81020-c8 0.41 0.53 >10 >10 
86328 80088 Nerium oleander c3 80088-c3 0.25 0.70 >10 >10 
86329 80088 Nerium oleander c4 80088-c4 0.53 3.04 >10 >10 
86344 80089 Nerium oleander c6 80089-c6 0.03 0.15 >10 >10 
86345 80089 Nerium oleander c7 80089-c7 0.54 2.69 >10 >10 
88490 80620 Marah macrocarpus c8 80620-c8 1.66 >10 >10 >10 
88491 80620 Marah macrocarpus c9 80620-c9 1.07 >10 >10 >10 
88571 80625 Juniperus californica c5 80625-c5 1.75 >10 >10 >10 
88928 80650 Juniperus deppeana c5 80650-c5 1.85 >10 >10 >10 
91657 79612 Eclipta prostrata c5 79612-c5 0.80 >10 9.34 >10 
93627 81341 Oplopanax horridus c6 81341-c6 1.98 >10 >10 >10 
97654 83352 Falcataria moluccana c7 83352-c7 1.29 4.75 >10 >10 
103651 
 
Amphotericin B AmB 0.10 0.11 >10 >10 
103650 
 
Pentamidine Pent 2.51 3.12 >10 >10 
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2.6. DISCUSSION 
There are several methods available for anti-leishmanial drug screening based on 
macrophage-amastigote models. Assays can be done with the peritoneal exudate cells (PEC) 
collected from mice, peripheral blood monocyte cells (PBMC) (Seifert et al., 2010), bone marrow-
derived macrophages (BMM), monocytic cell lines (J774 and RAW264.7) (Kolodziej and 
Kiderlen, 2005) and human  monocytic cells (THP1, U937, HL-60) (Maia et al., 2007). The 
assays, which use dividing host cells, must ensure that the confounding effects of drug activity on 
both parasite and host cells number are considered. The differentiated primary macrophages 
collected from various sources such as mice and rats are non-dividing in nature. These cell 
preparations may not have homogeneous cell populations. Monocytic cells-derived cell lines are 
homogenous in nature and are a better model for the macrophage-amastigote-based screening. 
Differentiated THP1 cells (human acute monocytic leukemia cell line) can form a non-dividing 
monolayer and offer an attractive alternative to primary isolated macrophages. 
To overcome the demerits and limitations of previous macrophage-amastigote-based 
screening assays (Gupta and Nishi, 2011), we have developed and optimized a parasite rescue 
and transformation (PRT) assay. This assay is based on the application of differentiated THP1 
cells as the host macrophages. The differentiated THP1 cells have good homogeneity and are 
non-dividing in nature, as the host cells. The PRT assay described here is comparable to the assay 
based on Digital-Image-Analysis-Direct-Counting of the intracellular amastigotes. Fluorescent 
and DIC microscopy, digital image analyses by ImageJ for differential counting of the 
macrophage nuclei and the parasite nuclei has been further refined. Capturing the images under 
fluorescent light filters and differential interference contrast (DIC) filters have improved the 
quality of digital images for more accurate counting of the intracellular amastigotes. The 
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fluorescent and DIC images can be merged to obtain the digital images with clear macrophage 
cell outlines and fluorescent intracellular nuclei. The macrophage nuclei and the parasite nuclei 
can be differentially recognized with ImageJ. Therefore, both Digital Image Analysis (DIA) 
Assay and PRT Assay have the potential for automation and application to large-scale  screening. 
Critical steps in the PRT Assay are: (a) repeated washings of THP1 cell cultures after exposure 
to Leishmania promastigotes, to ensure almost complete removal of the non-internalized 
promastigotes and (b) controlled lysis of the infected THP1 cells with SDS. Both the steps may 
also be controlled with automation and should not compromise with a throughput of the assay. 
The second step of washings, after exposure of the Leishmania-infected THP1 cells to the test 
drugs/compounds remove the remaining non-internalized parasites, if any. The PRT Assay offers 
significant advantages over existing microscopic, reporter gene and image analysis assays. The 
assay is simple, robust, and reproducible, can be automated for large-scale screening and 
therefore should have important application in screening of large compounds libraries for new 
anti-leishmanial drug discovery. Further, the assay can also be applied for evaluating infectivity 
of clinical, as well as, laboratory isolates of Leishmania in vitro (Hendrickx et al., 2015; Paape 
et al., 2014; Price et al., 2013). 
The PRT assay and cytotoxicity assay against differentiated THP1 cells were applied for 
screening of a library of 13584 natural products fractions. A total of 243 fractions were identified 
with 50% or higher inhibition vs. leishmania intracellular amastigotes. The active 240 fractions 
were screened further for dose-response analysis, and 64 fractions were confirmed with IC50 
<10µg/mL. Notably, the most active anti-leishmanial fractions originated from  Thuja occidentalis 
(IC50-0.25 µg/mL), Asclepias asperula (IC50-0.33 µg/mL), Rhodea japonica (IC50-0.41µg/mL) and 
Nerium oleander (IC50-0.03 µg/mL). The active fractions from Thuja occidentalis and Nerium 
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oleander were selected for further analysis. Oleandrin was confirmed as an active constituent from 
the active fraction of Nerium oleander (Unpublished). Similarly, Deoxypodophylotoxin was 
confirmed as an active constituent from the active fraction of Thuja occidentalis (Yang et al., 
2014). Oleandrin is an inhibitor of p-type ATPase (Jortani et al., 1996) and deoxypodophyllotoxin 
is a topoisomerase inhibitor (Wang et al., 1992).  
Further original plant of active extract fractions was investigated in the literature. Thuja 
occidentalis is an evergreen coniferous ornamental tree, which is native to the eastern Canada and 
the Northeastern United States. Several anticancer activities have been reported in Thuja 
occidentalis (Biswas et al., 2011; Mazzio et al., 2014; Sunila and Kuttan, 2006). Even a protective 
action of Thuja occidentalis has been reported against the damage induced by gamma radiations 
(Sunila and Kuttan, 2005). Clinical efficacy of Thuja occidentalis has been reported in the 
treatment of upper respiratory tract infections (Naser et al., 2005). Thuja occidentalis and its active 
compound, thujone have an anticancer effect and promising effects in the treatment of polycystic 
ovary syndrome (Biswas et al., 2011; Kupeli Akkol et al., 2015). Thuja occidentalis also shows 
antioxidant potential (Yogesh and Ali, 2014) and ability to counteract oxidative-induced damage 
has been reported in isoquercitrin from Thuja orientalis (Jung et al., 2010). Anti-inflammatory 
activity is also reported in Thuja orientalis. Asclepias asperula is reported as an ingredient in 
Hispanic folk medicine preparations (Kelley et al., 1988). Desglucouzarin, a cardenolide reported 
in Asclepias asperula has Na+, K+-ATPase inhibition activity (Abbott et al., 1998). Antimicrobial 
and cytotoxic activities are reported in Inga laurina plant (Furtado et al., 2014). Cytotoxic activity 
has been reported in rhodexin A, which is a cardiotonic agent in Rhodea japonica (Masuda et al., 
2003). Several cardenolides have been reported in Nerium oleander, which may be responsible for 
its toxicity and also pharmacological activity (Bai et al., 2010; Zhao et al., 2011). The anticancer 
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activities have been reported in isolated cardenolides particularly oleandrin from N. oleander 
which acts through inhibition of the plasma membrane-bound Na+K+-ATPase (Pan et al., 2015; 
Rashan et al., 2011). Bioactive pregnanes and triterpenes from Nerium oleander have shown the 
anti-inflammatory and cytotoxic activity (Bai et al., 2007; Fu et al., 2005; Zhao et al., 2006). 
Hepatoprotective and neuro protective activity have been reported in Nerium oleander (Dunn et 
al., 2011; Singhal and Gupta, 2012). Antifungal activity against plant fungal diseases has been 
reported in Nerium oleander (Hadizadeh et al., 2009). The anticancer activity has been reported in 
Juniperus communis (Van Slambrouck et al., 2007). Leishmanicidal activity has already been 
reported in saponins isolated from the leaves of Eclipta prostrate (Khanna et al., 2009). In vivo 
Antiplasmodial activity has been reported in palladium nanoparticles of Eclipta prostrata extract 
(Rajakumar et al., 2015). Eclipta prostrata has shown anti-angiogenic and antitumor activity also 
(Kim et al., 2015; Lirdprapamongkol et al., 2008; Liu et al., 2012). Extract of Eclipta prostrata 
has been used for its anti-venom potential (Melo et al., 1994; Pithayanukul et al., 2004). Eclipta 
prostrata also found effective in reducing serum lipid levels (Dhandapani, 2007; Zhao et al., 2015). 
antibacterial and antifungal activities also reported in Eclipta prostrata (Wiart et al., 2004). 
Echinocystic acid, Thiophenes, polyacetylenes and terpenes from Eclipta prostrate has shown 
anti-inflammatory properties (Ryu et al., 2013; Xi et al., 2014). Oplopanax horridus is an 
ethnobotanical plant used by the indigenous people native to the Pacific Northwest of North 
America (Calway et al., 2012). Potential anticancer activity has been reported in compounds 
(falcarindiol and oplopantriol A) isolated from Oplopanax horridus (Jin et al., 2014; Wang et al., 
2013; Zhang et al., 2014). Antimycobacterial effect has also been reported in Oplopanax horridus 
(Kobaisy et al., 1997; Qiu et al., 2013).  
In conclusion, the in vitro screening of more than 13584 plant fractions, prepared from 958 
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plants extracts has been done against macrophage cells internalized L. donovani amastigotes. 
Macrophage cells internalized amastigote form of parasite represent the real pathophysiology of 
leishmaniasis disease.  Most of the active plant fractions have good antileishmanial activity with 
no cytotoxicity to THP1 cells. The active fractions of plants extracts namely, Thuja occidentalis, 
Asclepias asperula, Inga laurina, Rhodea japonica, Nerium oleander, Eclipta prostrata represent 
new antileishmanial leads. Most of the leadplant fractions have very limited phytochemical and 
pharmacological data available. Further, follow up studies with these plant fractions are likely to 
provide novel compounds as potential antileishmanial drug leads.  
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CHAPTER III 
DEVELOPMENT OF TRANSGENIC LEISHMANIA DONOVANI PARASITES WITH 
STABLE EXPRESSION OF CITRINE AND MCHERRY REPORTER PROTEINS AND 
THEIR UTILITY FOR IN VITRO ANTILEISHMANIAL DRUGS SCREENING.  
 
3.1. INTRODUCTION 
Phenotypic parasite culture-based in vitro screening and in vivo preclinical evaluation are 
the hallmark of new antileishmanial drug discovery (Gupta and Nishi, 2011; Reguera et al., 2014; 
Sereno et al., 2007). The reporter gene is a segment of DNA containing a gene sequence that has 
been isolated from one organism and is introduced into a different organism. This non-native 
segment of DNA has retained the ability to express the protein that has a readily measurable 
phenotype and is easily distinguishable over endogenous cellular background. Transgenic 
parasites expressing reporter proteins are valuable tools to perform robust high throughput 
screening (HTS) and to understand the underlying mechanisms of pathogenesis (Dube et al., 2009; 
Lang et al., 2009). The technologies based on genetically modified pathogens represent valuable 
complementary tools for in vitro screening as well as real-time in vivo imaging. As long as the 
transgenic parasite retains the virulence of the parent parasite, they can be used for studies of 
pathogenesis and therapy in several ways. Several attempts have been made to develop transgenic 
cell lines that express bioluminescent and/or fluorescent reporter proteins (Hutchens and Luker, 
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2007; Lang et al., 2009). Reporter transgenic parasite can be developed by episomal transfection 
or by stable transfection methods. The reporter gene retained in the transfected plasmid in the 
transgenic parasite. While, the reporter genes, which get integrated into the genome of the parasite, 
the stably transfected transgenic cells retain the genetic information of reporter gene for a longer 
duration. The transgenic parasite cell lines with fluorescent reporter genes offer several 
advantages. Fluorescent reporters do not require specific substrates to convert the reporter protein 
to a measurable phenotype.  The fluorescence emitted is stable over the time and reliable for studies 
involving longer durations. This approach is also useful when studying the tissue harvested from 
infected animals since parasites can be individually identified (Shaner et al., 2005).  
The first transgenic Leishmania species was developed with the green fluorescent protein 
(GFP) as a reporter protein (Ha et al., 1996) by episomal transfection. Several other researchers 
have developed GFP transgenic cell lines of  L. infantum (Kamau et al., 2001), L. donovani (Singh 
and Dube, 2004) and L. amazonensis (Chan et al., 2003) by episomal transfection and further 
addressed the application of HTS methods.  Significant research has been done for developing the 
HTS methods for amastigotes forms using transgenic GFP amastigotes of L. donovani (Dube et 
al., 2005), and L. Major (Kram et al., 2008).  Automation for large compounds library screening 
may be possible using reporter genes. The majority of transgenic parasite cell lines requires drug 
selection for maintaining the episomal expression of the reporter genes. This may not be ideal for 
a drug screening experiments (Sereno et al., 2007). In case of episomal reporters, the relative 
expression of the reporter gene may depend on the number of copies of the transfected plasmid, 
rather than on the activity of the drug (Buckner and Wilson, 2005). The assays based on transgenic 
parasites with luciferase reporter gene required substrate and cell lysis buffer, which make the 
assays expensive for large-scale screening (Calvo-Alvarez et al., 2015; Roy et al., 2000). BALB/c 
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mice and Syrian golden hamsters are commonly used experimental animal models for evaluating 
antileishmanial effects and host-parasite interactions (Gupta and Nishi, 2011). For visceral 
leishmaniasis, most of the in vivo studies have been done by classical microscopic methods. 
A stable transfection method in which the GFP gene was integrated downstream of the 18S 
ribosomal promoter region of Leishmania genome was developed (Misslitz et al., 2000). Different 
transgenic leishmania parasite (L.donovani, L.major, and L. infantum) have been developed by 
stable transfection method (Bolhassani et al., 2011; Singh et al., 2009).  However, the stable 
transfection of the enhanced GFP (EGFP) reporter has been found suitable for both in vitro and in 
vivo leishmania parasite related studies (Pulido et al., 2012). Although native GFP produces bright 
fluorescence and is extremely stable, the excitation maximum is close to the ultraviolet range, 
which can damage the live cells. 
Transgenic Leishmania mexicana expressing red fluorescence (RFP) has been used to 
determine the early stages of cutaneous leishmaniasis pathogenesis at the infection site (Millington 
et al., 2010). Transgenic L. major with RFP-1 has been used to identify the site of sand-fly bites 
in vivo in a mouse model. These studies reveal essential roles for both neutrophils and dendritic 
cells in early leishmania infections (Peters et al., 2008; Ribeiro-Gomes et al., 2012). Transgenic 
mCherry L. infantum chagasi a parasite of visceral leishmaniasis (VL) revealed the recruitment of 
neutrophils and role of dendritic cells in VL (De Trez et al., 2009; Lecoeur et al., 2010; Thalhofer 
et al., 2011). Transgenic L. donovani cells, stably expressing either EGFP or RFP, have been used 
to identify hybrid parasites produced during the early development of the sandfly (Sadlova et al., 
2011). Similarly, transgenic L. infantum parasite stably expressing either citrine or mCherry have 
been used to show the intraclonal genetic exchange in Trypanosomatids (Calvo-Alvarez et al., 
2014). A  L. major strain, which episomally expressed the DsRed protein, was used for quantifying 
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the infectious dosage transmitted by a sandfly bite (Kimblin et al., 2008).  
mCherry has improved photostability as well as suitability for intravital imaging (Graewe 
et al., 2009).  mCherry is a protein derived from the coral Discosoma striata RFP. It has a 
maximum emission peak at 610 nm with a 587 nm excitation wavelength. Despite the fact that it 
is 50% less bright than EGFP, it is more photostable and has higher tissue penetration [12].  
mCherry is a suitable choice for applications of single-molecule fluorescence or multicolor 
fluorescent imaging [34]. Transgenic mCherry L. major has been developed by stable transfection 
method and used for in vitro and in vivo screening for cutaneous leishmaniasis (Calvo-Alvarez et 
al., 2012). Recently transgenic mCherry L. donovani (stably transfected) based screening method 
was developed for promastigote forms of the parasite (Vacchina and Morales, 2014).  
    Intracellular amastigotes represent the real pathophysiology of leishmaniasis 
disease. Parasite resides in deep visceral organs particularly in liver and spleen in visceral 
leishmaniasis disease state. That warrants a need for the development of transgenic cells, which 
could be utilized for in vitro, ex-vivo well as in vivo intracellular amastigotes antileishmanial 
screening. Ideally, the fluorescent reporter gene model should be free of ultraviolet excitation 
range and should have good penetration. Considering these requirements, two different stably 
transfected transgenic L. donovani cell lines by integrating mCherry or citrine open reading frames 
(ORFs) into the 18S rRNA ssu locus of L. donovani parasite genome, which constitutively 
expresses Citrine or mCherry fluorophore-proteins. We selected Citrine, a green fluorescent 
protein derivative, derived from the jellyfish Aequorea victoria (Haas et al., 2012; Roura et al., 
2013) and mCherry, a red fluorescent protein derived from the tetrameric Discosoma (Campbell 
et al., 2002) as the reporter genes. There are several advantages of these reporter genes. The 
excitation spectra of these fluorophores are free of ultraviolet region. The proteins expressed from 
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mCherry and Citrine genes have high photostability, resistance to photobleaching and bright 
fluorescence. Both proteins constitutively expressed in the leishmanial cytoplasm mature rapidly, 
allowing fluorescence detection shortly after the gene is expressed. This is appropriate for real-
time analysis. Integration of mCherry and citrine ORFs was done using LEXSY plasmid. LEXSY 
has been constructed based on the protozoan host, which combines eukaryotic protein synthesis 
and modification with simplicity and ease of handling. This system promises protein synthesis 
with correct folding with a full range of post-translational modifications. This vector also gives 
high expression success rate (LeBowitz, 1994).  LEXSY is a constitutive type of LEXSY plasmid, 
which has 3’ and 5’ end ssu regions. These regions direct the linearized DNA with target gene and 
marker gene for homologous recombination at ssu locus of Leishmania parasite genome.  
 
3.2 HYPOTHESIS 
 The bright fluorescence of Citrine or mCherry fluorescent reporter proteins allows 
detection and quantification of stably transfected transgenic leishmania cells by different 
fluorescence-based techniques like fluorescence reading, fluorescent microscopy, and flow-
cytometry. 
   
3.3 OBJECTIVES 
 Stable transfection of mCherry and Citrine reporter genes was done using leishmania 
expression plasmid vector (LEXSY). A plasmid with mCherry reporter gene with blasticidin 
marker and another plasmid with Citrine reporter genes with hygromycin B marker were 
electroporated into wild-type of L. donovani cells. The strong fluorescent signal from mCherry 
and Citrine transgenic L. donovani parasite indicated the successful development of transgenic 
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parasites. Both mCherry and Citrine transgenic parasite could be analyzed by different 
fluorescence-based techniques. The fluorimetric measurements, fluorescent microscopy and flow 
cytometry were applied for growth analysis of promastigotes and macrophage-internalized 
transgenic L. donovani amastigotes. 
 
3.4. MATERIALS AND METHODS 
 
3.4.1. LEISHMANIA DONOVANI PROMASTIGOTE CULTURE  
The cell cultures of promastigote forms of wild type  L. donovani (WT-Ld) (S1 strain) were 
maintained  in M199 medium supplemented with 25 mM HEPES pH 7.2, 0.1 mM adenine, 
0.0005% (w/v) hemin, 2 mg/mL biopterin, 0.0001% (w/v) biotin, 10% (v/v) antibiotic cocktail (50 
U/mL penicillin, 50 mg/mL streptomycin) and 10% fetal bovine serum.  
 
3.4.2.   THP1 CELLS CULTURE AND DIFFERENTIATION   
 THP1 cells are being grown in RPMI medium supplemented with 10% fetal bovine serum. 
The culture is maintained at 37oC in 5% CO2 incubator. Subculture is being done on every 3-4 
days or cell growth of 0.8 million cells/mL. THP1 cells were differentiated using Phorbol 12-
myristate 13-acetate (PMA) as described previously. After differentiation, the medium with PMA 
from each well was discarded, and adherent cells were gently washed at least twice with serum-
free RPMI1640 medium (Jain et al., 2016b; Jain et al., 2012). 
 
 
116 
3.4.3.  LEXSY PLASMID WITH MCHERRY AND CITRINE GENE INSERTS 
 The plasmids were adapted from a previous study (Calvo-Alvarez et al., 2014). In short, 
two fluorescent proteins namely, mCherry (excitation 587 nm; emission 610 nm) and Citrine 
(Excitation 516 nm; emission 529 nm), were selected to develop two different transgenic L. 
donovani cell lines. For the CITRINE-HYGROMYCIN (CTN-HYG) construct, the 720-bp CTN 
coding region was amplified by PCR. The amplified DNA fragment was cut with BglII-NotI and 
inserted into the pLEXSY-hyg2 vector (Jena Bioscience GmbH, Germany) to yield pLEXSY-CTN-
HYG construct. For the mCherry-BLASTICIDIN (CHR-BSD) construct, the 711-bp CHR coding 
region was amplified by PCR. The resulting fragment was digested with BglII-NotI and inserted 
into the pLEXSY-hyg2 vector (Calvo-Alvarez et al., 2012). The HYG selection drug cassette was 
replaced by the BSD ORF, which confers resistance to the antibiotic blasticidin S (Goyard and 
Beverley, 2000) (Figure 3.1). 
 
3.4.4.  GENERATION OF MCHERRY AND CITRINE TRANSGENIC L. DONOVANI 
PARASITES 
 Plasmids pLEXSY-CTN-HYG and pLEXSY-CHR-HSP70-BSD with Citrine and mCherry 
gene respectively were transformed into XL10-Gold ultracompetent Escherichia coli cells. The 
mCherry and citrine gene inserts in the respective plasmids were confirmed by BglII and NotI 
double digestion and analysis by agarose gel electrophoresis. The isolated plasmids were digested 
with SwaI restriction enzyme to linearize the plasmid DNA with mCherry and citrine genes. 
Linearization of the plasmids was confirmed by agarose gel electrophoresis. The linearized DNA 
was electroporated into wild-type L. donovani promastigotes. 20 ml L. donovani promastigote 
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culture (~ 5X106 parasites/mL) was centrifuged at 3000 rpm for 10min at 4oC in two 15 ml tubes. 
The cell pellets were re-suspended in a total of 10 mL of pre-chilled cytomix. (~ 10X106 
parasites/mL). The cells were centrifuged again at 3000 rpm for 10min at 4oC in two 15 ml tubes. 
Cell pellets were finally re-suspended in 0.5 mL of ice-cold cytomix (~ 200X106 parasites/mL). 
The cell suspensions were chilled on ice for 10 min. BioRad gene pulser was set for electroporation 
of L. donovani with linearized DNA from mCherry and citrine constructs. The electroporation 
conditions used (450 μF, 900V) that require a capacitance extender module with the gene pulsar 
unit (For 4mm distance cuvette 2.25kV/cm). 0.5 ml of the cell suspension (1 x 108 parasites) was 
mixed with the DNA to be electroporated in the pre-chilled centrifuge tube by pipetting up and 
down and transferred to a pre-chilled (4°C) 4mm electroporation cuvette and electroporated at 
selected pulse settings. The cuvette was returned to the ice after electroporation. The cells 
electroporated with CHR-BSD and CTN-HYG reporters linked to their corresponding antibiotic-
resistance cassettes were obtained after the electroporation of L. donovani promastigotes with the 
large SwaI fragment from pLEXSY-CHR-BSD and pLEXSY-CTN-HYG vectors and plated on 
semisolid M199 medium. Transgenic L. donovani promastigotes derived from the integration of 
reporter genes into the leishmanial 18S rRNA locus were selected on semisolid medium containing 
200 µg/mL of hygromycin B or blasticidin S, respectively. The colonies appeared after 2-3 weeks 
on semisolid M199 medium with respective resistance antibiotic. The colonies were transferred to 
M199 liquid medium without selection drugs for 24 h and then transferred to M199 liquid medium 
with selection drugs. The transgenic parasites were grown in M199 medium with selection drug to 
10 generations. After 10 generations both transgenic parasites were transferred to M199 medium 
without selection drugs.  
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3.4.5.  THE CONFIRMATION OF GENE INTEGRATION AND EXPRESSION IN 
TRANSGENIC L. DONOVANI CELLS 
 The confirmation of the presence of reporter genes in L. donovani, as well as integration 
of these reporter genes in L. donovani genome, was done by primer Polymerase chain reaction 
(PCR) method. Forward mCherry primer (P1), reversed mCherry primer (P2), forward citrine 
primer (P4) reverse citrine primer (P5) and forward integration primer (P3) were selected 
according to previously published research (Calvo-Alvarez et al., 2014). The linearized DNA with 
5’ and 3’ ssu region get integration in ssu locus of L. donovani genome. So forward integration 
primer was selected from L. donovani genome ssu region and integration reverse primer was 
selected from the reporter gene either citrine or mCherry in linearized DNA 5’ and 3’ ssu integrated 
region (Figure 3.2). The genomic DNA was isolated by citrine transgenic, mCherry transgenic 
and wild-type L. donovani parasites and PCR was done using given primers. 
Confirmation of gene expression was done by a strong fluorescent signal from mCherry or 
Citrine by fluorescence microscopy. The microscopic images were collected under Nikon 90i 
Eclipse fluorescence microscope. Citrine transgenic L. donovani (Citrine-Ld) cells were analyzed 
under Differential Interference Contrast (DIC), and Fluorescein isothiocyanate (FITC) filter and 
mCherry transgenic L. donovani (mCherry-Ld) cells were analyzed under DIC and TEXAS-RED 
(TXR) filter in a fluorescent microscope. Both citrine and mCherry transgenic L. donovani 
promastigotes were also run underflow cytometric analysis. Thirty thousand promastigotes per 
sample were analyzed in a flow cytometer for all promastigote parasites types including both 
mCherry-Ld and citrine-Ld promastigotes and WT-Ld promastigotes. Citrine-Ld promastigotes 
were analyzed in FL-1 channel histogram plot, and transgenic mCherry-Ld promastigotes were 
analyzed in FL-3 channel histogram plot. BD FACS Calibur flow cytometer.  
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3.4.6. DIRECT FLUORESCENT ANALYSIS (DFA) BASED IN VITRO SCREENING 
FOR TRANSGENIC PROMASTIGOTES PARASITES 
  Both mCherry-Ld and citrine-Ld parasites were serially diluted in 1:1 ratio from 20 
million/mL to 0.625 million/mL in the M199 medium in 96 wells plates. Plates were read by the 
fluorimeter. For citrine-Ld parasites, plates were read at excitation 486 nm and emission 535nm. 
For mCherry-Ld parasites, plates were read at excitation 544 nm and emission 590nm.  Based on 
this DFA of transgenic parasites, an assay has been applied to assess the activity of control drugs 
amphotericin B and pentamidine for 96 h. Simultaneously, AlamarBlue assay was applied for WT-
Ld, mCherry-Ld and Citrine-Ld promastigotes parasites. Three-day-old cultures of mCherry-Ld 
citrine-Ld and WT-Ld promastigote parasites were diluted to 1 million parasites/mL. 196 µl of 
diluted culture was added to each well of the 96 well plate. 4 µl of diluted amphotericin B and 
pentamidine samples were added in plate culture. Assay for control drugs was done in triplicates. 
The plates were incubated in 26oC for 96 h. The plates with mCherry-Ld and citrine-Ld 
promastigotes parasites were analyzed directly by the fluorimeter.  The other plates with wild-type 
and both transgenic promastigote parasites with AlamarBlue assay were read on a fluorimeter All 
the IC50, and IC90 values were computed, and dose-response curves were developed by XLfit 
5.2.2 software. 
 
3.7.7.  INFECTIVITY OF TRANSGENIC L. DONOVANI CELLS IN DIFFERENTIATED 
THP1 CELLS 
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 Fifty thousand cells/well of THP1 cells were differentiated in chamber slides. For infecting 
differentiated THP1 cells, a 5-6 day old culture of mCherry-Ld and citrine-Ld stationary 
promastigote parasite were diluted to 2.5x106 parasite cells/mL. 200 µl of diluted cultures were 
dispensed on differentiated THP1 cells in separate chamber slide. All chamber slides were 
incubated at 37°C in a 5% CO2 incubator for 24 h to allow parasites to infect differentiated THP1 
cells. All chamber slides with THP1 cells infected with L. donovani promastigotes were washed 
with serum-free, RPMI-1640 medium to remove the external parasite. Chamber slides were 
incubated again at 37°C, 5% CO2 for 48 hr. After a 48 h incubation, chamber slides were washed 
three times with serum-free RPMI-1640 medium and washed once with warm (37oC) Dulbecco's 
phosphate-buffered saline (DPBS). Four percent formaldehyde (v/v) was prepared from 16% (v/v) 
formaldehyde (methanol free, Polysciences, Inc) by diluting 1 to 4 in warm 1X PBS to make a 4% 
formaldehyde solution. DPBS was aspirated, and 200 µl warm 4% formaldehyde was dispensed 
on differentiated THP1 cells. Cells were allowed to fix for 15 min at 37oC. Fixed differentiated 
THP1 cells were washed again with warm (37oC) DPBS. Digital images have been captured from 
slides in different filters (DIC + FITC filter for Citrine-Ld and DIC + Texas red filter mCherry-Ld 
parasites. The number of differentiated THP1 cells and number of amastigotes in all images was 
calculated with the help of ImageJ software and infectivity were calculated by the ratio of infected 
amastigote THP1 cells. 
 
3.4.8.  FLOW CYTOMETRIC ANALYSIS OF INTRACELLULAR L. DONOVANI 
AMASTIGOTES  
 Fifty thousand cells/well of THP1 cells were differentiated in 96 well plates. For infecting 
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differentiated THP1 cells, a five to six-day-old promastigote cultures of both transgenic (both 
citrine-Ld and mCherry-Ld) and wild-type L. donovani were diluted to 2.5x106 cells/mL. The 
diluted culture of mCherry-Ld, citrine-Ld and WT-Ld parasites was added over differentiated 
THP1 cells in separate 96 well plates. All 96 well plates were incubated at 37oC in 5% CO2 
incubator for 24 hr. External parasites were washed with incomplete RPMI medium, and infected 
THP1 cells were treated with control drugs for 96 hr. Plates were again washed to remove the 
external parasites. Infected differentiated THP1 cells were detached by treating them with 20µl of 
1X trypsin solution (0.25% trypsin (w/v)) for 5 min. Cells were gated from middle regions of 
SSC/FSC (Side scatter/forward scatter) plot for analysis to avoid the cell clumps and debris, and 
10,000 gated events were analyzed on relevant histogram plot for the fluorescent peak. Peak in 
FL1-H (Green fluorescence) histogram plot was observed for the citrine-Ld parasite. Peak in FL3-
H (Red fluorescence) histogram plot was observed for the mCherry-Ld parasite.  Assay for control 
drugs was done in triplicates.  
A parasite rescue and transformation (PRT) assay for macrophage cells internalized 
amastigote (Jain et al. 2012) with 96 h of treatment with control drugs (amphotericin B and 
pentamidine) were also performed using wild-type, transgenic citrine, and transgenic L. donovani 
parasites. Assay for control drugs was done in triplicates. A comparative analysis is given between 
PRT assay and FACS analysis in Table 3.3. 
 
3.4.9. MICROSCOPIC ANALYSIS OF INTRACELLULAR TRANSGENIC 
AMASTIGOTES 
 The microscopic method was followed as mentioned above in 3.2.6. Section. The assay 
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has been done in triplicate for control drugs amphotericin B and pentamidine. Effect of control 
drugs was observed for 96 h medium with drug dilutions was replaced daily. The assay has been 
applied for both mCherry-Ld and citrine-Ld parasites. After 96 h, chamber slides were fixed with 
4% formaldehyde. Digital images have been captured from slides in different filters (DIC + FITC 
filter for Citrine and DIC + Texas red filter mCherry Leishmania Parasite). (Jain et al., 2012). The 
infectivity was calculated from the ratio of total infected amastigote count to total THP1 cells 
count.  
 
3.4.10. IN VITRO MACROPHAGE AMASTIGOTE ASSAY 
 A recently developed promastigote rescue assay was applied for both mCherry and citrine 
L. donovani parasites and wild-type of L. donovani parasite (Jain et al., 2012). The plates with 
differentiated THP1 cells were washed with serum-free medium with the help of 384 well plate 
cell washing system (Molecular device AquaMax 4000). L. donovani promastigotes were 
harvested at the stationary phase (metacyclic infective stage) and suspended into RPMI1640 
medium with 2% FBS at the density of 2.5X106 cells/mL. After 24 h the non-adherent 
macrophages and external Leishmania promastigotes were washed off with the serum-free 
RPMI1640 medium. Control drugs amphotericin B and pentamidine (six different concentrations 
in triplicate) were diluted in separate plates and transferred to plates with infected THP1 cells. The 
plates were placed again in a CO2 incubator at 37oC for 96 hr. After 96 h, the plates were washed 
again with serum free RPMI medium. Infected differentiated THP1 cells subjected to control lysis 
by 0.05% (w/v) SDS solution in incomplete RPMI medium for 30 seconds. SDS solution was 
diluted with completed RPMI medium after control lysis. Control lysis confirm the lysis of THP1 
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cells membrane lysis without affecting the viability of amastigote. Plates with rescued amastigotes 
allowed to grow and transform to promastigotes for 48 h at 26oC incubator. After 48 h AlamarBlue 
was added to the plates and again incubated at 26oC for overnight.  Plates were read on a 
fluorimeter (BMG Lab Technologies) at an excitation wavelength of 544 nm and an emission 
wavelength of 590 nm. IC50 and IC90 values were computed from the dose-response curves. 
Dose-response curves were developed by XLfit 5.2.2 software.  
 
3.5. RESULTS 
 
3.5.1. STABLE TRANSFECTION OF L. DONOVANI CELLS WITH MCHERRY AND 
CITRINE REPORTER GENES 
 The LEXSY plasmids were constructed, one with a mCherry reporter gene in a 
combination of blasticidin marker gene and another with a citrine reporter gene in a combination 
of hygromycin marker gene (Figure 3.1). The mCherry and citrine gene inserts in pLEXSY 
plasmids were confirmed by BglII and NotI double restriction enzyme digestion. The mCherry 
and citrine genes inserts were confirmed by agarose gel electrophoresis with a band of 711bp for 
mCherry and band of 717bp for the citrine gene (Figure 3.1). Both plasmid constructs were 
linearized by SwaI digestion, and the linearization of plasmid construct (with 5’SSU and 3’SSU 
region) was confirmed by agarose gel electrophoresis by bands of ~5700bp for both CHR-BSD 
and CTN-HYG LEXSY plasmid (Figure 3.1). The linearized plasmid DNA (with 5’ssu and 3’ssu 
regions) were electroporated in WT-Ld promastigotes. The confirmation of gene integration was 
done by primer PCR method. A band of 1790pb was observed for primers P2, and P3 and a band 
of 711 pb was observed for primers P1 and P2 for genomic DNA isolated from mCherry-Ld 
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parasites. Similarly, a band of 1790pb was observed for primers P5, and P3 and a band of 717 bp 
was observed for primers P4 and P3 for genomic DNA isolated from citrine-Ld parasites (Table 
3.1). 
 
3.5.2. EXPRESSION OF REPORTER GENES 
 Expression of the mCherry gene in mCherry-Ld parasites and citrine gene in citrine-Ld 
parasites was confirmed by both fluorescent microscopy and flow cytometry. The mCherry-Ld 
parasite was detected under DIC + TEX RED filter, and the citrine-Ld parasite was detected under 
DIC + FITC filter of Nikon 90i Eclipse fluorescent microscope (Figure 3.3) (Supporting file 3.1). 
The WT-Ld parasites have not shown any fluorescence either in FITC filter or in TEXAS RED 
filter. However, the citrine-Ld parasites have shown strong fluorescence in FITC filter (represent 
by Green color). Similarly, mCherry-Ld parasites have shown strong fluorescence in the TEXAS-
RED filter (represented by red color). In flow cytometry, The mCherry-Ld parasites have shown 
two peaks in FL-3 (Red fluorescence) dot plot and histogram plot, one for auto fluorescence and 
another for the fluorescence signals from reporter protein from mCherry-Ld. Similarly, The 
citrine-Ld parasites have shown two peaks in FL-1 (green fluorescence) dot plot and histogram 
plot, one for auto fluorescence and another for the fluorescence signals from reporter protein from 
citrine-Ld. (Figure 3.4). 
 
3.5.3. TRANSGENIC PROMASTIGOTES BASED IN VITRO SCREENING  
 Because of high expression of the reporter gene, the growth of both mCherry-Ld and 
citrine-Ld parasites could be analyzed by the fluorimeter. Relative fluorescence unit (RFU) 
increased with the increase in parasite number for both mCherry-Ld and citrine-Ld promastigote 
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parasites. A scatter plot between a number of mCherry-Ld promastigote parasites and RFU value.  
A linear trend line was drawn which has a correlation coefficient (R square) value 0.9983 (Figure 
3.5A).  Similarly, a scatter plot between a number of citrine-Ld promastigote parasites and RFU 
value.  A linear trend line was drawn which has correlation coefficient (R square) value 0.9994 
(Figure 3.5B).  Here, >0.9900 of correlation coefficient proofs an excellent correlation in the 
manual counting of parasite and RFU value. Based on this fluorimetric growth analysis, a 
screening method was developed for in vitro promastigote screening using both transgenic 
mCherry-Ld and citrine-Ld parasites. The assay was validated using six different concentrations 
of control drugs amphotericin B and pentamidine in triplicates. A similar assay was done by 
AlamaBlue assay for both mCherry-Ld and citrine-Ld promastigote parasite and WT-Ld 
promastigote parasites. The IC50 values for amphotericin B against mCherry-Ld and citrine-Ld 
were 0.15 ± 0.02 µg/mL, 0.25 ± 0.06 µg/mL and 0.20 ± 0.06 µg/mL respectively in DFA method. 
The IC50 values for amphotericin B against WT-Ld, mCherry-Ld, and citrine-Ld were 0.16 ± 0.01 
µg/mL and 0.34 ± 0.03 µg/mL respectively in AlamarBlue based method (Table 3.2). Similarities 
in IC50 values of control drugs amphotericin B and pentamidine in both DFA and AlamarBlue 
based method prove the validity of fluorimetry based in vitro promastigote screening assay. 
 
3.5.4. INTRACELLULAR TRANSGENIC AMASTIGOTES BASED IN VITRO 
SCREENING 
3.5.4.1. MICROSCOPIC EVALUATION 
Infectivity of transgenic parasites was confirmed in differentiated THP1 cells. The images 
of differentiated THP1 cells infected with either mCherry-Ld amastigotes or by citrine-Ld 
amastigotes were collected by Nikon 90i Eclipse fluorescence microscope. The THP1 cells are 
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represented in DIC filter (Grey colored). The citrine-Ld intracellular amastigotes have shown 
strong fluorescence in FITC filter (represent by Yellow color) inside the THP1 cells. Similarly, 
mCherry-Ld parasites have shown strong fluorescence in the TEXAS-RED filter (represented by 
red color) inside the THP1 cells (Figure 6). Infectivity was calculated by the ratio of amastigote 
count to THP1 cells counts with the help of ImageJ software.  
Based on above transgenic intracellular microscopic analysis, a microscopic assay for 
intracellular amastigote was developed for both mCherry-Ld and citrine-Ld amastigotes as 
parasites. Both transgenic intracellular amastigotes were treated with the standard antileishmanial 
drugs amphotericin B and pentamidine from 2µg/mL to 0.016µg/mL concentration. The images 
of both mCherry-Ld and citrine-Ld intracellular amastigotes treated with different concentration 
of standard antileishmanial drugs were collected by Nikon 90i Eclipse fluorescent microscope 
(Figure 3.8). The infectivity was calculated for each treated samples and compared with 
uninfected THP1 cells (Negative control) and untreated infected THP1 cells (Positive control). 
Infectivity of untreated infected THP1 cells was considered as 100%, and the infectivity of other 
treated samples was compared to calculate the IC50 values using the XLfit software. The IC 50 
values of amphotericin B against mCherry-Ld amastigotes and citrine-Ld amastigotes were 0.08± 
0.05µg/mL and 0.06± 0.012 µg/mL respectively (Table 3.3). The IC 50 values of pentamidine 
against mCherry-Ld amastigotes and citrine-Ld amastigotes were 0.45± 0.12 µg/mL and 0.34± 
0.15 µg/mL respectively (Table 3.3). 
 
3.5.4.2.   FLOW CYTOMETRIC EVALUATION 
Macrophage internalized amastigote growth can be analyzed with the help of flow 
cytometry (Figure 3.7).  The differentiated THP1 cells infected with mCherry-Ld amastigotes 
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come with shift the peak toward the right side in FL3 channel histogram plot in flow cytometry 
compared to the peak for uninfected differentiated THP1 cells (Figure 3.7 A). Similarly, the 
differentiated THP1 cells infected with citrine-Ld amastigotes come with shift the peak toward the 
right side in FL1 channel histogram plot in flow cytometry compared to the peak for uninfected 
differentiated THP1 cells (Figure 3.7 B). The mean fluorescence of the pick area M1 was utilized 
to compare the infectivity of the parasites. Based on this flow cytometric analysis, a macrophage-
internalized amastigote screening method was developed. The differentiated THP1 cells infected 
with either mCherry or citrine transgenic L. donovani parasites were treated with control drug 
amphotericin B and pentamidine in 6 different concentrations from 10µg/mL to 0.0032µg/mL. 
The IC 50 values of amphotericin B against mCherry-Ld amastigotes and citrine-Ld amastigotes 
were 0.08± 0.05µg/mL and The IC 50 values of amphotericin B against mCherry-Ld amastigotes 
and citrine-Ld amastigotes were 0.08± 0.05µg/mL and 0.06± 0.012 µg/mL respectively (Table 
3.3). The IC 50 values of pentamidine against mCherry-Ld amastigotes and citrine-Ld amastigotes 
were 0.13 ± 0.015 µg/mL and 0.12 ± 0.02 µg/mL respectively (Table 3.3). The IC 50 values of 
pentamidine against mCherry-Ld amastigotes and citrine-Ld amastigotes were 1.3 ± 0.05 µg/mL 
and 1.1 ± 0.02 µg/mL respectively (Table 3.3). 
 
3.5.4.3.   EVALUATION BY PARASITE RESCUED AND TRANSFORMATION ASSAY 
The control drugs amphotericin B and pentamidine activity was also analyzed against WT-
Ld, mCherry-Ld and citrine-Ld intracellular amastigotes by PRT assay (Jain et al., 2012). The IC 
50 values of amphotericin B were 0.039 ± 0.028µg/mL, 0.044 ± 0.027µg/mL and 0.061 ± 
0.025µg/mL against WT-Ld, mCherry-Ld and citrine-Ld intracellular amastigotes respectively. 
The IC 50 values of pentamidine were 0.389 ± 0.012 µg/mL, 0.360 ± 0.010 µg/mL and 0.332 ± 
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0.008 µg/mL against WT-Ld, mCherry-Ld and citrine-Ld intracellular amastigotes respectively.   
The activities of control drugs by fluorescent microscopy and flow cytometry for both 
mCherry and citrine internalized amastigotes, and PRT assay for wild-type of internalized 
amastigotes of L. donovani was evaluated and compared in Table 3.3. The comparative IC50 
values of control drugs Amphotericin B and Pentamidine validated the screening assay for 
transgenic internalized amastigotes. 
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FIGURES AND TABLES 
 
 
 
 
 
 
Figure 3.1: (A) LEXSY plasmid with a mCherry reporter gene and blasticidin (BSD) resistance 
marker gene. (B) LEXSY plasmid with a citrine reporter gene and hygromycin (hyg) resistance 
marker gene. (C) Confirmation of mCherry and Citrine gene in plasmids isolated from XL10 gold 
ultra-competent E.coli cells. The plasmids were digested with bgl II and Not I double restriction 
enzyme digestion. (D) Linearization of 5’ssu to 3’ssu fragment of the plasmid by Swa I restriction 
enzyme digestion.  
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Table 3.1: Primer sequence used for PCR method to confirm the reporter genes and their 
integration in L. donovani genome. 
 
Primer Purpose Sequence 
P1 mCherry 
Forward 
CCGCTCGAGGAAGATCTCCACCATGGTGAGCAAGGGCG 
P2 mCherry 
Reverse 
ATAAGAATGCGGCCGCTTACTTGTACAGCTCGTCCATGC 
P3 Citrine 
Forward 
CCGCTCGAGGAAGATCTCCACCATGGTGAGCAAGGGCGAGG 
P4 Citrine 
Reverse 
ATAAGAATGCGGCCGCTTACTTGTACAGCTCGTCCATG 
P5 Integration 
Forward 
CTTGTTTCAAGGACTTAGCCATG 
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Figure 3.2: (A) Schematic view of the integration of the DNA fragment with the 5’ssu end and 
3’ssu end with a mCherry reporter gene and a BSD resistance marker gene (previously linearized 
with SwaI LEXSY-MCHERRY plasmid) into the 18S rRNA locus of wild-type L. donovani genome. 
The confirmation of mCherry gene in leishmania genomic DNA was done by PCR using mCherry 
forward (P1) and mCherry Reverse (P2) primers (711bp band). The confirmation of integration of 
linear DNA with 5’ssu end and 3’ssu end was done by PCR using integration forward (P3, primers 
of Leishmania genomic region) and mCherry reverse (P2) primers (Band of 1785bp). (B) 
Schematic view of the integration of the DNA fragment with the 5’ssu end and 3’ssu end with a 
citrine reporter gene and hyg resistance marker gene (previously linearized with SwaI LEXSY-
CITRINE plasmid) into the 18S rRNA locus of wild-type L. donovani genome. The confirmation 
of citrine gene in leishmania genomic DNA was done by PCR using citrine forward (P4) and 
citrine Reverse (P5) primers (717 bp band). The confirmation of integration of linear DNA with 
5’ssu end and 3’ssu end was done by PCR using integration forward (P3) and citrine reverse (P5) 
primers (Band of 1794 bp).  
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Figure 3.3: (A) Image of WT-Ld promastigote parasites. The image has been taken in 
DIC+FITC+TXR filters. (B) Image of Citrine-Ld promastigote parasites. The image has been 
taken in DIC+FITC filters. (C) Image of mCherry-Ld promastigote parasites. The image has been 
taken in DIC+TXR filters. All images collected by Nikon 90i Eclipse fluorescent microscope. 
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Figure 3.4: (A) FL3 Histogram plot with no fluorescent signal peak in flow cytometry for WT-Ld 
promastigote parasites. (B) FL1 Histogram plot with no fluorescent signal peak in flow cytometry 
for WT-Ld promastigote parasites. (C) FL3 Histogram plot with a prominent fluorescent signal 
peak in flow cytometry for mCherry-Ld promastigote parasites. (D) FL1 Histogram plot with a 
prominent fluorescent signal peak in flow cytometry for citrine-Ld promastigote parasites. 
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Figure 3.5: (A) Scatter plot between a number of mCherry-Ld promastigote parasites and Relative 
fluorescent unit (RFU).  A linear trend line was drawn which has a correlation coefficient (R 
square) value 0.9983. (B) Scatter plot between a number of citrine-Ld promastigote parasites and 
Relative fluorescent unit (RFU).  A linear trend line was drawn which has a correlation coefficient 
(R square) value 0.9994. 
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Figure 3.6: (A) Differentiated THP1 cells infected with citrine-Ld amastigotes. The image has 
been taken in DIC+FITC filter. (B) Differentiated THP1 cells infected with mCherry-Ld 
amastigotes. Image has been taken in DIC+TXR filter. A single image here is a montage of 4X4 
area. The images have been taken at 400X magnification.  
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Figure 3.7: (A) FL1 Histogram plot with no fluorescent signal peak in M1 area flow cytometry 
for uninfected differentiated THP1 cells (B) FL3 Histogram plot with no fluorescent signal peak 
in M1 area flow cytometry for uninfected differentiated THP1 cells (C) FL1 Histogram plot with 
prominent fluorescent signal peak in M1 area flow cytometry for differentiated THP1 cells infected 
with citrine-Ld amastigotes. (D) FL3 Histogram plot with a prominent fluorescent signal peak in 
M1 area flow cytometry for differentiated THP1 cells infected with mCherry-Ld amastigotes. 
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Figure 3.8: (A) Images of transgenic L. donovani infected differentiated THP1 cells treated with 
different concentrations of control drugs Amphotericin B and Pentamidine and compared with 
infected THP1 cells without treatment (Positive control) and uninfected THP1 cells (Negative 
control). In panel (A) differentiated THP1 cells infected with mCherry-Ld parasites and in panel 
(B) differentiated THP1 cells infected with citrine-Ld parasites. Images were collected in 
DIC+TXR filter for mCherry transgenic leishmania infected Cells and images were collected in 
DIC+FITC filter for citrine transgenic leishmania infected Cells. 
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Table 3.2: Promastigote assay for WT-Ld, citrine-Ld, and mCherry-Ld. Direct Florescence 
analysis based activity assessment for Amphotericin B and pentamidine was done on both citrine-
Ld and mCherry-Ld promastigote parasites which was based on expression of citrine and mCherry 
fluorophore protein. Activity assessment of Amphotericin B and pentamidine was also done by 
alamarBlue assay for WT-Ld, and both citrine-Ld and mCherry-Ld promastigote parasites. 
 
 
Direct Florescence analysis AlamarBlue assay 
Compoun
ds 
Citrine-Ld mCherry-Ld Wild-Type  
Ld 
Citrine-Ld mCherry-Ld 
 
IC 50 µg/mL IC 50
 
µg/mL IC 50 µg/mL IC 50
 
µg/mL IC 50 µg/mL 
Amphote
recin B 
0.34 ± 0.03 0.16 ± 0.01 0.15 ± 0.02 0.20 ± 0.06 0.25 ± 0.06 
Pentamid
ine 
1.73 ± 0.11 1.63 ± 0.05 1.30 ± 0.27 1.76 ± 0.05 1.73 ± 0.09 
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Table 3.3: L. donovani intracellular amastigote assay using WT-Ld, citrine-Ld, and mCherry-Ld. 
Activity assessment for Amphotericin B and pentamidine was done on both citrine-Ld, and 
mCherry-Ld amastigote parasites infected in differentiated THP1 cells was done by flow 
cytometry and fluorescent microscopy. Activity assessment of Amphotericin B and pentamidine 
was also done by PRT assay for WT-Ld, and both citrine-Ld and mCherry-Ld amastigote parasites 
infected in differentiated THP1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Compou
nds 
PRT assay FACS analysis assay microscopic 
analysis assay 
WT- Ld Citrine-
Ld 
mCherry- 
Ld 
Citrine-Ld mCherry- 
Ld 
Citrine- 
Ld 
mCherry
- Ld 
IC 50 
µg/mL 
IC 50 
µg/mL 
IC 50 
µg/mL 
IC 50 
µg/mL 
IC 50 
µg/mL 
IC 50 
µg/mL 
IC 50 
µg/mL 
Amphote
ricin B 
0.04 ± 
0.03 
0.06 ± 
0.02 
0.04 ± 
0.03 
0.12 ± 
0.02 
0.13 ± 
0.01 
0.06 ± 
0.01 
0.08 ± 
0.05 
Pentami
dine 
0.39 ± 
0.01 
0.33 ± 
0.01 
0.36 ± 
0.01 
1.10 ± 
0.02 
1.30 ± 
0.05 
0.34 ± 
0.15 
0.45 ± 
0.12 
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3.6. DISCUSSION  
In this study transgenic, L. donovani parasites were developed with mCherry and citrine 
fluorophore gene by stable transfection approaches. The leishmania cells developed through stable 
transfection method do not require the selection drug to maintain the expression level (Roy et al., 
2000). Stable integration of reporter genes into the ribosomal locus represents a valuable tool for 
assessing phenotypes related to parasite intracellular infectivity in ex-vivo or  in vivo models when 
a long period of growth without selection is required (Misslitz et al., 2000). The reporter gene is 
integrated into the parasite genome, so the relative output of expression of reporter gene does not 
depend on the number of copy of transfected plasmid (Misslitz et al., 2000). This increases the 
advantages for application of these transgenic cell lines for complex macrophage amastigote 
infection model. Citrine, a yellow fluorescent protein ( a derivative of green fluorescent protein), 
and mCherry, a red fluorescent protein, are suitable due to better photo-stability, sensitivity, 
resistant to photo-bleaching and bright fluorescence of these reporter proteins.  These fluorescent 
Proteins can be constitutively expressed in the leishmanial cytoplasm and mature rapidly. These 
properties are appropriate for the real-time analysis of the reporter proteins. Stable transfection of 
both mCherry and Citrine reporter genes was done using leishmania expression system (LEXSY) 
plasmid vector. LEXSY plasmid is based on the protozoan host that combined the eukaryotic 
protein synthesis with correct folding and Full range of post-translational modifications. LEXSY 
plasmid has a high expression-success rate with higher yield. The transgenic cells developed by 
LEXSY based stable transfection does not require selection drug in medium to maintain the 
expression level. The Linear DNA with reporter and marker gene integrated into to leishmanial 
genome at 18S ssu locus by recombination.  Here, LEXSY plasmid with mCherry reporter gene 
with blasticidin marker and another LEXSY plasmid with Citrine reporter genes with hygromycin 
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B marker will be electroporated separately into wild-type of L. donovani cells. The reporter gene 
and its integration were confirmed by PCR. The expression of the reporter gene was confirmed by 
the strong fluorescent signal from both mCherry and Citrine transgenic L. donovani parasites. Both 
mCherry and Citrine transgenic parasite can be analyzed by different fluorescence-based 
techniques. A fluorimetry, fluorescent microscopy, and flow cytometry were applied for growth 
analysis of promastigotes and macrophage-internalized transgenic L. donovani amastigotes. 
Screening methods were developed for both transgenic mCherry and citrine L. donovani 
promastigotes, and internalized amastigotes using these fluorescence-based techniques and 
screening methods were validated by the activity of control drugs Amphotericin B and 
Pentamidine and compared the activity of these drugs in previously available older screening 
methods.  
 In conclusion, two transgenic cell lines of L. donovani have been developed with mCherry 
and Citrine fluorophore genes by stable transfection approach using LEXSY plasmid vector. Both 
the transgenic cell lines have a stable and constitutive expression of fluorescentent reporter 
proteins. Further, the screening methods have been developed with promastigotes, and THP1 cells 
internalized amastigote forms of the transgenic parasites cell lines employing flowcytometric 
analysis and fluorescent microscopy. Furthermore, these transgenic parasites have the potential for 
other applications that include understanding the parasite biology, host-parasite interactions and 
in vitro/in vivo screening for new drug discovery. 
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CHAPTER IV 
FLUORESCENCE-BASED ASSAYS FOR MONITORING INTRA-ERYTHROCYTIC 
MALARIA PARASITES USING LDS-751, A NUCLEIC ACID STAIN 
 
4.1. INTRODUCTION 
There are many challenges in malaria control, particularly diagnosis and treatment of 
malaria. The current conditions of emerging resistance against available antimalarials alarm the 
further possibility of an increase in malaria fatalities. There is an urgent need of better alternative 
treatment for malaria and necessitate the discovery of new drugs and drug leads. The majority of 
malaria cases worldwide rely on clinical diagnosis to define the type of treatment (Landier et al., 
2016). Diagnosis of malaria is primarily based on the confirmation of malaria parasites in RBCs 
of patients. New antimalarial drug discovery approaches primarily rely on in vitro screening of 
compound libraries against malaria parasite culture and further activity assessment of lead 
compounds in preclinical in vivo animal models. In vitro and in vivo antimalarial screening 
methods were initially based on analysis of  parasitemia, which is the ratio of the malaria parasite-
infected RBCs to total RBCs. The method for analysis of parasitemia based on microscopic 
examination of Giemsa stained blood smears was developed in 1904 (Shute and Maryon, 1963). 
Since that time it has remained as the official gold standard for malaria diagnosis (Makler et al., 
1998). Most of the laboratories in the field still depend on microscopy for confirmation of malaria 
in blood and also identification of the parasite species. Microscopy is the major method for malaria 
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diagnosis in the clinical laboratories as well as malaria parasitemia analysis in antimalarial 
screenings (Makler et al., 1998). However,  microscopic analysis has potentials problem with 
clinical diagnosis as well as laboratory parasitemia analysis. Significant misdiagnoses namely,  
false positives (7–36%), false negatives (5–18%), and wrong identification of species  (13–15%) 
have been reported in the microscopic  diagnosis of malaria in the United Kingdom (Milne et al., 
1994) and Thailand (Beadle et al., 1994; Fix et al., 1988).  A high frequency of technical errors 
(e.g., wrong pH of the staining solution or a poor quality the smears) has also been reported. 
Therefore, microscopy is an imperfect ‘Gold Standard’ method for diagnosis as well as parasitemia 
analysis in antimalarial drug screenings (Collier and Longmore, 1983; Makler et al., 1998). 
The parasitemia analysis method based on incorporation of radioactive hypoxanthine was 
developed as an alternative to laborious and time-consuming microscopic assays (Desjardins et 
al., 1979). Although this method could be used for high-throughput screenings, there are several 
challenges in this assay. The assay requires specific needs for a radioactive lab. Incorporation of 
radioactive hypoxanthine by other proliferative cells in blood may cause high background. The 
hypoxanthine uptake assay does not measure parasitemia directly, as its incorporation is dependent 
on DNA synthesis which only occurs in the later stages of the parasite life cycle (Yayon et al., 
1983). This assay measures the further growth of the malaria parasite. 
Additional methods have been developed for monitoring malaria growth based on the 
enzymatic activity of parasites lactate dehydrogenase (pLDH) (Knobloch and Henk, 1995) or 
ELISA assay for malarial histidine-rich protein 2 (HRP2) (Beadle et al., 1994). The pLDH assay 
is based on selective utilization of 3-acetyl pyridine NAD (APAD) as co-factor by the malaria 
LDH. The colorimetric methods have been developed based on the pLDH assay(Makler and 
Hinrichs, 1993). These assays may be performed in microplates and can be used for high-
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throughput screening. However, there is a low degree of concordance between LDH based assay 
and standard microscopy based determinations of parasitemia (Jelinek et al., 1996; Knobloch and 
Henk, 1995). The parasite's histidine-rich protein 2 (HRP2)-based ELISA assay has a good 
correlation with the hypoxanthine uptake (Desakorn et al., 1997). However, these assays are not 
cost-effective, especially for large-scale screening.  
The methods based on flow cytometric analysis (FCA) of the malaria parasite have been 
developed for diagnosis and the parasitemia analysis. These methods can be applied to automation 
and high throughput parasitemia analysis (Woodrow et al., 2015). However, application of FCA 
methods  for routine clinical diagnosis of malaria has not been reported for automated screening 
(Grimberg, 2011). The FCA methods take  advantage of the absence of DNA in uninfected RBCs 
and presence of parasite DNA in malaria-infected RBCs. The intraerythrocytic malaria parasite 
could be detected by flow cytometry by staining with an appropriate DNA-binding fluorescent 
dye. Different fluorescent dyes namely, Hoechst 33258 (van Vianen et al., 1990), SYTO-9 
(Izumiyama et al., 2009), SYTO-61 (Fu et al., 2010), ethidium bromide (Staalsoe et al., 1999), 
propidium iodide (Pattanapanyasat et al., 1997), acridine orange (Hare, 1986),  4,6-diamidino-2-
phenylindole (Baniecki et al., 2007), YOYO-1 (Campo et al., 2011; Xie et al., 2007) and SYBR 
Green I (Izumiyama et al., 2009)  have been used for analysis of  parasitemia in in vitro cultures 
of Plasmodium falciparum by FCA. YOYO-1 (Xie et al., 2007), SYTO-16 (Jimenez-Diaz et al., 
2009) and SYBR Green I (Somsak et al., 2012) have also been employed for the determination of 
parasitemia in in vivo blood samples from the Plasmodium berghei infected mice. The parasitemia 
analysis directly from the human or mice blood sample is particularly difficult because blood 
samples have a mixed population of erythrocytes, neutrophils, lymphocytes, monocytes, and 
reticulocytes. The currently used FCA methods for parasitemia analysis show high background 
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values due to the mixed cell populations in the blood. The blood cell populations may be analyzed 
by gating in the FSC/SSC dot plots in FCA. However, separation of reticulocyte and erythrocyte 
populations in FSC/SSC dot plot is challenging (Terstappen and Levin, 1992; Wiczling and 
Krzyzanski, 2008). Therefore, the varing population of circulating reticulocytes pose may result 
in high background and false signals  for parasitemia analysis by FCA. This problem occurs due 
to significant levels of RNA in the reticulocytes. The fluorescent probes YOYO-1, SYTO-16 and 
SYBR Green I  bind with RNA, even though less prominently compared to binding to DNA. This 
problem may be solved by treatment of blood cells samples with RNase. In case of a nonpermeant 
fluorescent nucleic acid dye, an additional processing for  permeabilization the cells are required. 
Current FCA methods require cells fixation, permeabilization, RNase treatments, nucleic acid dye 
staining and complex flow cytometric analysis (Jimenez-Diaz et al., 2009; Xie et al., 2007).  
Laser dye styryl–751 (LDS-751) (Fig 4.1) is a cell-permeant nucleic acid stain that has 
been used to discriminate intact nucleated cells from nonnucleated and damaged nucleated cells, 
as well as to identify distinct cell types in mixed populations of neutrophils, leukocytes and 
monocytes by flow cytometry (Nicholson et al., 2007). LDS-751 in combination with other nucleic 
acid stains has been used for accurate enumeration of  erythrocytes, reticulocytes, platelets, 
neutrophils, eosinophils, monocytes, lymphocytes, nucleated erythrocytes, and immature 
nucleated cells by flow cytometry (Terstappen and Levin, 1992). LDS-751 binds to RNA 
(excitation/emission maxima approx 590/607 nm) and to DNA (excitation/emission maxima 
approx 543/approx 712 nm) with an approx 20-fold increase in fluorescence on binding to double-
stranded DNA (Terstappen and Loken, 1988). Due to its differential excitation/emission spectra, 
LDS-751 permit its use to discriminate DNA and RNA in cells. This advantage of LDS-751 allows 
differentiation of reticulocyte populations from nucleated cells as well infected erythrocytes 
 
146 
(Wiczling and Krzyzanski, 2008). The LDS-751 is a cell-permeable stain, which produces 
differential fluorescence signals on binding with RNA (ex/em 590/607 nm) and DNA (ex/em 
543/712 nm). Due to the differential excitation/emission spectra, LDS-751 permits its use to 
discriminate DNA and RNA in cells. LDS-751 can be utilized in the flow cytometric analysis of 
the malaria-infected blood samples. The LDS-751 based parasitemia analysis will be-be quick and 
simple because the staining of erythrocytes with LDS-751 may not require fixation, 
permeabilization, and RNase pre-treatment to remove background due to reticulocytes.   
  
4.2. HYPOTHESIS 
 Staining of malaria-infected blood cells with LDS-751 (a cell-permeant nucleic acid stain) 
allows differential detection of malaria parasite-infected and uninfected erythrocytes, which may 
be implemented for malaria parasitemia analysis in in vitro and in vivo settings without misleading 
reticulocytes background signals.  
 
4.3. APPROACH 
 We have developed the FCA and fluorescent microscopy methods with LDS-751, a 
fluorescent cell-permeant DNA binding probe,   for  determination of parasitemia in the blood 
from malaria-infected mice and in vitro P. falciparum culture. The FCA method was implemented 
for in vivo antimalarial screening assays. The classical Giemsa-staining based microscopic method 
was standardized with digital images analysis of parasitemia with ImageJ software.  
 
4.4. MATERIALS AND METHODS 
4.4.1. ANIMAL HOST AND P. BERGHEI PARASITE 
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Most the in vivo work has been done under the protocol for in vivo antimalarial evaluation. 
This protocol was approved by the University of Mississippi Institutional Animal Care and Use 
Committee (IACUC). Male mice (Swiss Webster strain) with 18-20g body weight were obtained 
from ENVIGO.inc. All animals were quarantined for at least seven days before infection. Mice were 
divided into different groups with five mice in each group and were housed in top filter cages with 
food and water supplied ad libitum. P. berghei parasite was maintained in malaria mice model. To 
initiate the malaria infection in new mice, 0.5ml of highly parasitized blood (>20% parasitemia) of 
infected mouse stored in liquid nitrogen was thawed and injected intraperitoneally. Blood with high 
parasitemia level (18-20%) was collected from an infected donor mouse at 14th post-infection day by 
cardiac puncture method in Acid citrate dextrose (ACD) buffer. A new group of mice was 
intraperitoneally inoculated with 4 × 107 parasitized RBCs from infected blood. All group of infected 
mice was regularly observed for change in weight, change in appearance and change in behavior. 
 
4.4.2. MICROSCOPIC CONFIRMATION OF LDS-751 FLUORESCENCE  
The blood samples were collected on the slides from uninfected mice and highly infected mice 
by tail snipping method. Thin smears were prepared from collected blood samples. The slides were 
fixed with the help of methanol for 30 sec and dried for 30 min. The fixed slides were stained with 
LDS-751 at 2µg/mL concentration in DPBS for 20 min. Slides were washed and dried and observed 
under Nikon 90i Eclipse fluorescent microscope at 1000X magnification with the help of emergen 
oil. The images were collected in TEXAS-RED (TXR) and Differential interference contrast (DIC) 
filter. The TXR filter was used to collect the fluorescence of LDS-751 and DIC to collect the sample 
surface image. Differential interference contrast microscopy is similar to phase contrast microscopy 
but without the bright diffraction halo in images. 
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4.4.3. DIGITAL IMAGES ANALYSIS METHOD (DIAM) IN P. BERGHEI BLOOD 
SAMPLES  
This is microscopic parasitemia analysis method based on the counting of infected RBCs and 
total RBCs in thin smears of blood samples on glass slides. The blood samples were collected on the 
slides from infected mice by tail snipping method. Thin smears were prepared from collected blood 
samples. Slides were fixed with the help of methanol for 30 sec and dried for 30 min. All dried slides 
were stained with 1X Giemsa stain for 45 min. Slides were washed and dried.  All blood smears 
images were collected by Nikon i90 light microscope at 1000X magnification with the help of 
emergency oil. In digital images based parasitemia analysis, the images were analyzed with ImageJ 
software. Parasitemia is the ratio of malaria-infected RBCs to total RBCs. Images were opened in 
ImageJ software. Infected RBCs were counted by manual cells counter in image J software. The total 
RBC were counted by automated counting protocol in ImageJ software. The ImageJ software protocol 
for manual and automatic counting is given in figure 4.8.  
 
4.4.4. FCA of PARASITEMIA IN P. BERGHEI INFECTED MOUSE BLOOD SAMPLES 
 Most the in vivo work has been done under the protocol for in vivo antimalarial evaluation. 
The whole blood was collected from a 14-day post infection mice and uninfected normal mice in 
ACD buffer. The blood samples were washed with Dulbecco's phosphate-buffered saline (DPBS). 
RBCs counting of both kinds of the sample was done by Bio-Rad TC 10 Automated cell counter. The 
uninfected samples RBCs counting was adjusted to equal to infected samples RBCs counting. The 
infected blood sample was serially diluted in 1:1 ratio by uninfected blood samples with same RBCs 
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counting. The slides were prepared for undiluted an infected blood samples for microscopic 
parasitemia analysis. 5µl of serially diluted samples were stained for 20 min with LDS-751 1.0 µg/mL 
in DPBS that was diluted from its stock solution of 1mg/mL in DMSO. All samples were centrifuged 
and resuspended in DPBS. All the blood samples were run in a flow cytometer in FSC/SSC dot plot. 
RBCs population was gated in FSC/SSC dot plot. 100,000 gated population was analyzed on 
SSC/FL4 dot plot and as well as FL4 channel histogram plot. Parasitemia is the ratio of malaria-
infected RBCs to total RBCs. So parasitemia was calculated based on the percent gated population in 
the upper right region of SSC/FL4 dot plot or by a percent gated population change in the second 
peak in FL4 channel histogram. Thin smears were also prepared from uninfected, and P. berghei 
infected mice blood sample samples. Slides were fixed and stained with Giemsa. The images were 
collected by Nikon 90i eclipse light microscope at 600X magnification. 
 
4.4.5. MODIFIED PETER’S TEST BASED ANTIMALARIAL ASSAY 
Most the in vivo work has been done under the University of Mississippi IACUC approved the 
protocol for in vivo antimalarial evaluation. The four days’ Peter’s test has been modified for this 
study. Mice were divided into different groups with five mice in each group. Blood with high 
parasitemia level (18-20%) was collected from infected donor mice at 14th post-infection day by 
cardiac puncture method in ACD buffer. The slide was prepared, and parasitemia level was calculated 
by Giemsa staining method. The high parasitemia blood was diluted in PBS to 8X107 parasitized 
RBCs per ml. All the mice in all groups were inoculated with 4 × 107 parasitized RBCs (0.5ml) 
intraperitoneally at day 0. One group of 5 infected mice were treated with vehicle control. Separate 
groups of mice were treated with Chloroquine and amodiaquine at three different doses (33mg/kg, 
11mg/kg, and 3.7mg/kg). For each dose, one group of 5 mice are treated once daily from day 0 to 2 
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post infection. Blood samples from mice of control and treated groups were collected on slides 
(~10µl) as well as tubes (~2µl) with 500 µl of ACD buffer by tail snipping method on day 5, 7, 10, 
14, 21, and 28 post-infection. Timeline for infection, dosing and blood sample collections are given 
in Figure 4.2. All mice were observed for the change in appearance, behavior, and weight of the mice. 
Mice those lost equal or more than 25% of their weight were euthanized by CO2 gas euthanization 
method.  
 
4.4.6. DIA AND FCA BASED PARASITEMIA ANALYSIS IN BLOOD SAMPLES IN 
ANTIMALARIAL ASSAY 
Slides were prepared from all blood samples. Slides were fixed with methanol for 30 sec and 
stained with Giemsa 1X for 45 min. Slides were washed and dried. For digital analysis of parasitemia, 
all blood smears images were collected by Nikon i90 eclipse light microscope at 600X magnification 
with Emerson oil, and parasitemia was calculated with the help of ImageJ software as mentioned 
earlier. For Flow cytometric analysis of parasitemia, all blood samples were collected in 500 µl of 
ACD buffer. All samples were centrifuged at 2000rpm, and blood sample pellets were re-suspended 
in 500µl of DPBS. All the samples were stained with LDS-751 stain in 1.0 µg/mL concentration for 
20 min at room temperature. After staining, all samples were again centrifuged and resuspended in 
DPBS and run on flow-cytometer. All the samples were run in FSC/SSC dot plot. RBCs population 
was gated in FSC/SSC dot plot. 100,000 gated population was analyzed on SSC/FL4 dot plot and 
FL4 channel histogram. Here parasitemia was calculated based on percent gated population in the 
upper-right region in SSC/FL4 quadrangle dot plot or by percent gated population under the second 
peak in FL4 channel histogram. Parasitemia and mean survival time of mice in untreated control and 
treated groups are determined.  
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4.4.7. RETICULOCYTES RICH BLOOD SAMPLES PARASITEMIA ANALYSIS 
A high number of reticulocyte appeared in the blood of Chloroquine (33.3mg/kg) Treated mice 
at 28 days of post-infection. Blood samples were collected on the slide as well as a tube with ACD 
solution.  Slides were prepared and stained with Giemsa, and the images were collected by NIKON 
90i Eclipse microscope. The Giemsa-stained images of blood smears with high reticulocytes are given 
in Figure 4.10. The blood samples collected in the tube in ACD buffer were stained with LDS-751 
and run in a flow cytometer for parasitemia analysis (similar to section 4.2.4.). 
 
4.4.8. P. FALCIPARUM CULTURE MAINTAINANCE 
 The continuous culture of a chloroquine-susceptible P. falciparum strain (D6, Sierra Leone) 
was routinely maintained in the 25cm2 flask. The parasite was grown in RPMI 1640 medium 
supplemented with 0.23% sodium bicarbonate, 0.006% Amikacin, 10% A+ human serum and A+ 
human erythrocytes (6% hematocrit). Culture flasks were incubated in a 37oC incubator with 5% O2, 
5% CO2, and 90% N2. A fresh subculture waw initiated with an initial parasitemia of ~1% and 6% 
hematocrit. The medium was changed every 48 h, and the parasite was subcultured with fresh RBCs 
after every 6 to 7 days. Slides were prepared before every subculture. Slides were fixed and stained 
by a quick stain to evaluate the parasitemia level. 
 
4.4.9. PARASITEMIA ANALYSIS IN P. FALCIPARUM INFECTED CULTURES BY LDS-
751 
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 For microscopic parasitemia analysis, thin smear slides were prepared from infected RBCs of 
P. falciparum culture. The slides were fixed with the help of methanol for 30 sec and dried for 30 
min. The fixed slides were stained with LDS-751 at 2µg/mL concentration in DPBS for 20 min. Slides 
were washed and dried and observed under Nikon 90i Eclipse microscope in TXR and DIC filter 
(similar to section 4.2.2.). For flow cytometric analysis, 10µl of infected RBCs diluted to 500µl with 
PBS and stained with LDS-751 at 1.0 µg/mL concentration. The stained sample run through Flow 
cytometer (similar to section 4.2.4.). Thin smears were also prepared from uninfected and P. 
falciparum-infected human RBCs samples. Slides were fixed and stained with Giemsa. The images 
were collected by Nikon 90i eclipse light microscope at 600X magnification. 
 
4.4.10. DIA AND FCA BASED PARASITEMIA IN P. FALCIPARUM INFECTED RBCs 
An assay was set up with standard antimalarial drugs chloroquine (CQ) and artemisinin (ART). 
Stock solutions of the drugs or compounds were prepared in water (CQ) or DMSO (ART) and diluted 
further with serum-free RPMI to achieve appropriate concentrations. The parasite cultures (mainly 
with ring stage) were diluted with fresh human erythrocytes to achieve 2% hematocrit and 2% 
parasitemia. The assays were performed in clear flat-bottom 96-well plates. Each well-received 190μl 
of the parasite culture and 10μl of the test compound. Each compound was tested at 6 different 
concentrations (238-1 ng/mL). The plates were placed in an incubator with a gas mixture containing 
90% N2, 5% O2, and 5% at 37 °C for 72 h. 10µl of RBCs were collected from each well including 
all well of treated infected RBCs, untreated infected RBCs and uninfected RBCs. These samples were 
stained with LDS-751 (see section 4.2.4.) and run in a flow cytometer. 3µl of RBCs were collected 
from each well including all well of treated infected RBCs, untreated infected RBCs and uninfected 
RBCs on slides. I thin smears were prepared and fixed with methanol. These fixed slides were stained 
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with Giemsa (Blue colored nucleic acid stain). Images of Giemsa stained RBCs were collected by 
Nikon 90i eclipse light microscope in 600X magnification.  
 
4.5. RESULTS 
4.5.1. MICROSCOPIC CONFIRMATION OF LDS-751 FLUORESCENCE 
 The blood samples were collected, and thin smear slides were prepared from infected and 
uninfected mice.  The LDS-751 have excitation wavelength 543nm and an emission wavelength of 
712nm. So, the LDS-751 stained slides of P. berghei infected blood samples were observed under the 
fluorescent microscope under TXR and DIC filters. The TXR filter was used to collect the 
fluorescence of LDS-751 (Red colored in Figure 4.3) and DIC to collect the sample surface image 
(Grey colored in figure 4.3). Both TXR and DIC images were merged. Fluorescence of LDS-751 
could be seen inside RBCs. Images of different stages of P. berghei parasite in peripheral blood 
sample slide could be seen in red color inside the RBCs (Figure 4.3.  
 
4.5.2. FCA OF PARASITEMIA IN P. BERGHEI BLOOD SAMPLES 
 The LDS-751 stained P. berghei infected blood samples, and uninfected blood samples were 
run in a flow cytometer.  RBCs population was gated in FSC/SSC dot plot, and 100,000 gated 
population was analyzed further in SSC/FL4 dot plot as well as FL4 channel histogram plot. The 
SSC/FL4 dot plot was converted in the quadrangle. Panel (A) of Figure 4.4 represents the flow 
cytometric analysis of uninfected blood samples. The Most of the gated population located in the 
upper-left area of the quadrangle of SSC/FL4 plot and only one peak observed for uninfected RBCs 
population in FL4 channel histogram.  Panel (B) of Figure 4.4 represents the flow cytometric analysis 
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for P. berghei infected blood samples. When the gated population was analyzed in quadrangle dot 
plot, the population appeared partly in both upper-left and upper-right region of the quadrangle. The 
uninfected RBCs appeared in the upper-left region of the quadrangle and the P. berghei infected 
RBCs appeared in in the upper-right area of the quadrangle in SSC/FL4 dot plot. Similarly, there were 
two peaks appear in FL4 channel histogram plot. The first peak appeared for the uninfected RBCs 
population while the other peak appeared for infected RBCs population. The percent Gated population 
in the upper-right region of quadrangle dot plot show the level of parasitemia. The percent gated 
population under peak area under M1 region in FL4 histogram plot also represent the level of 
parasitemia. Parasitemia analysis of P berghei infected serially diluted blood samples was done by 
LDS-751 flow cytometric analysis method. Parasitemia was calculated for the highly infected blood 
sample without dilution by microscopy. Two separate area in thin smear slide were counted separately 
for infected and uninfected RBCs (Figure 4.5). The average parasitemia (ratio of P.berghei infected 
RBCs to total RBCs) was found 30.02 percent by microscopy. So expected parasitemia for with 
microscopic analysis was 30.02, 15.01, 7.51, 3.75, 1.88, 0.94, 0.47, 0.23, and 0.12 in up to 9 serially 
dilutions of the sample including the first sample. The parasitemia was analyzed for these samples 
were 30.55, 15.85, 8.28, 4.22, 2.26, 1.19, 0.67, 0.28, 0.18 and 0.12 (Table 4.1) The accuracy of the 
flow cytometric parasitemia analysis was calculated by comparing with microscopic parasitemia 
analysis. A correlation graph was prepared between flow cytometric parasitemia and microscopic 
parasitemia. The correlation coefficient (R2) of the linear regression line was 0.9995 proof the validity 
of the flow cytometric method of parasitemia analysis (Figure 4.6). The microscopic comparative 
images of uninfected and P. berghei infected mice blood samples is given in Figure 4.5. 
 
4.5.3. DIA AND FCA BASED PARASITEMIA ANALYSIS IN MICE BLOOD SAMPLES  
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The microscopic digital images based parasitemia analysis was developed using ImageJ 
software. Figure 4.7 represents the P. berghei infected blood smear image, manual counting of 
parasite-infected RBCs and automatic counting of total RBCs.  A whole Rodent in vivo antimalarial 
assay was done using P. berghei parasite in 3 different doses of chloroquine and amodiaquine in 
separate groups of mice. The blood samples were collected by tail snipping method simultaneously 
on glass slides (~10µl) and in tubes (~2µl) ACD buffer. The parasitemia in slides was calculated using 
a digital images analysis method (DIAM) using ImageJ software. The average parasitemia in blood 
samples collected from different groups of mice for different dose treatment at different days (day 5, 
7, 10, 14, 21 and 28) is given in Figure 4.9.A. The parasitemia was calculated using LDS-751 based 
FCA. The average parasitemia in blood samples collected from different groups of mice for different 
dose at different days (day 5, 7, 10, 14, 21 and 28) is given in Figure 4.9.B. The correlation scatters 
plot was prepared to compare the flow cytometric parasitemia and microscopic parasitemia for all 
different treatment groups of mice. The parasitemia by FCA and microscopic method for samples of 
all days for particular treatment groups were analyzed on the scattered plot. There were total seven 
treatment groups namely, Vehicle control group, Chloroquine 33.3 mg/kg treatment group, 
Chloroquine 11.1 mg/kg treatment group, Chloroquine 3.7 mg/kg treatment group, Amodiaquine 33.3 
mg/kg treatment group, Amodiaquine 11.1 mg/kg treatment group and Amodiaquine 3.7 mg/kg 
treatment group. The correlation scattered plot for six groups is given in Figure 4.10. There were 
maximum 30 parasitemia samples were compared. Some group may have lesser samples because few 
mice were died before day 28 due to high parasitemia. The correlation plot for amodiaquine 33.3 
mg/kg treatment group is not provided in Figure 4.10 as no parasitemia appeared in any mice of this 
treatment group.  The average correlation coefficient (R-square) of all scattered plots is 0.9230. That 
show good correlation in both flow cytometric and microscopic method of parasitemia analysis.  
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4.5.4. RETICULOCYTES RICH BLOOD SAMPLES PARASITEMIA ANALYSIS 
Giemsa-stained images of blood smears with high reticulocytes are given in Figure 4.11. The 
high reticulocyte population could be misdiagnosed as false positive in microscopy for malaria 
parasitemia analysis. The microscopic image looks like high parasitemia, but most of the blues cells 
are reticulocytes. The parasitemia was analyzed by both DIAM and LDS-751 based FCAM. SSC/FL4 
quadrangle dot plot of gated RBCs population of same blood sample do not have a high percent of 
gated populations in upper right regions which represent the parasitemia level in blood samples. So 
the real parasitemia is less than 1 and flows cytometric assay counted accurately here. So Even though 
blood sample may have high reticulocytes but the LDS-751 can differentiate the infected RBCs from 
reticulocyte in flow cytometric analysis. 
 
4.5.5. MICROSCOPIC CONFIRMATION OF LDS-751 FLUORESCENCE IN P. 
FALCIPARUM INFECTED RBCS 
 The human infected RBCs samples were collected from in vitro P. falciparum culture. The 
thin smear slides were prepared for infected as well as uninfected human RBCs.  The slides were 
fixed with methanol. The fixed slides were stained with LDS-751. The slides were observed under 
the fluorescent microscope under TXR and DIC filters. The TXR filter was used to collect the 
fluorescence of LDS-751 (Red colored) and DIC to collect the sample surface image (Gray colored). 
Both TXR and DIC images were merged. Fluorescence of LDS-751 could be seen inside RBCs. 
Images of different stages of P. falciparum parasite in peripheral blood sample slide could be seen in 
red color inside the RBCs (Figure 4.12).  
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4.5.6. FLOW CYTOMETRIC ANALYSIS OF LDS-751 STAINED P. FALCIPARUM 
INFECTED RBCS 
 The human uninfected and infected RBCs samples stained with LDS-751 were run through a 
flow cytometer. RBC population was gated in FSC/SSC plot, and 100,000 gated RBCs population 
was analyzed in SSC/FL-4 quadrangle dot plot. Panel (A) of Figure 4.13 represents the flow 
cytometric analysis of uninfected blood samples. The Most of the gated population located in the 
upper-left area of the quadrangle of SSC/FL4 plot.  Panel (B) of Figure 4.13 represents the flow 
cytometric analysis for P. falciparum-infected blood samples. When the gated population was 
analyzed in quadrangle dot plot, the population appeared partly in both upper-left and upper-right 
region of the quadrangle. The uninfected RBCs appeared in the upper-left region of the quadrangle 
and the P. falciparum-infected RBCs appeared in in the upper-right area of the quadrangle in 
SSC/FL4 dot plot. The percent Gated population in the upper-right region of quadrangle dot plot show 
the level of parasitemia. The microscopic comparative images of uninfected and P. berghei infected 
mice blood samples is given in Figure 4.14.  The uninfected RBCs presented in pink colored cells 
and infection P. falciparum presented blue/purple dot inside pink RBCs. 
 
4.5.7. LDS-751 STAINING BASED IN VITRO P. FALCIPARUM ANTIMALARIAL ASSAY 
 The in vitro antimalarial assay was set up using standard antimalarial drugs chloroquine and 
artemisinin at six different concentrations in triplicate against P. falciparum. Treated infected RBCs 
samples were stained with LDS-751 and analyzed by flow cytometer. Blood smears also prepared 
from the same treated infected RBCs samples and analyzed by microscopy after Giemsa staining. The 
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parasitemia by both flow cytometry and microscopy of treated infected RBCs was compared with 
untreated infected RBCs to calculate the IC50 values. IC 50s for chloroquine were 1.71µg/mL and 
1.67µg/mL by microscopic and flow cytometric assay respectively (Table 4.2). IC 50s for 
chloroquine were 10.08µg/mL and 9.90µg/mL by microscopic and flow cytometric assay respectively 
(Table 4.2). The similarity in IC50 values proof the utility of the LDS-751 based flow cytometric 
assay. 
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Figure 4.1: Chemical Structures of Laser dye styryl–751 (LDS-751). 
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Figure 4.2. Modified Peter’s test timeline of infection, test sample dosing and blood sampling in 
each group of mice. Yellow is marked as the day post infection (from 0 to 28), Infection (4X107 P. 
berghei infected RBCs inoculated intraperitoneally) was given on day 0. The doses of the test 
samples were given orally once daily on day 0, day1, and day 2. Blood samples were collected on 
day 5, 7, 10, 14, 21 and 28 for parasitemia analysis. 
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Figure 4.3: P. berghei infected RBCs. Images were collected under TXR and DIC filter. LDS-751 
fluorescence (Red) enables the detection of different stages of P. berghei parasite inside the RBCs 
(Gray). A and B= Schizont (multiple parasites), C= Trophozoite and multiple infection in an RBC, 
D= White blood cell, E =Ring stage, F=uninfected RBCs. 
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Figure 4.4: Flow cytometric analysis of P. berghei infected mice blood samples. A. uninfected 
mice blood samples run in FSC/SSC plot. B. P. berghei infected mice blood samples run in 
FSC/SSC plot. Gated RBCs population analyzed on an SSC/FL4 quadrangle dot plot and FL4 
channel histogram plot. The percent gated population in the upper-right SSC/FL4 quadrangle and 
the percent population under M1 region in FL4 histogram plot show the parasitemia in the running 
sample. 
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Figure 4.5: Microscopic analysis of P. berghei infected mice blood samples. A. Smear of 
uninfected mice blood sample. B.  Smear of P. berghei infected mice blood sample. 
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Figure 4.6: Comparison of parasitemia analysis my microscopy and LDS-751-based flow 
cytometry. The high parasitemia mice blood was serially diluted with uninfected mice blood in 1:1 
ratio. A linear trend line was drawn in the scattered plot. (Correlation coefficient R2 is 0.9995).  
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Figure 4.7: Parasitemia analysis by ImageJ software. The infected RBCs were counted by the 
manual cell counting tool, and the total RBCs were counted by automated total cell counting tool 
of ImageJ software. A. ImageJ software interface. B. Digital image of infected RBCs. C. Manual 
counting on image B. D. Manual cell counting module of ImageJ software. E Outline of total 
RBCs. F. Result of automated counting module in ImageJ software 
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Figure 4.8: ImageJ software step by step protocol for infected and uninfected RBC Counting. 
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Figure 4.9: The parasitemia analysis in samples collected from different treatment group of P. 
berghei infected mice on day 5, 7, 10, 14, 21 and 28 of post-infection. A. Parasitemia analysis by 
ImageJ software-based digital image analysis method. B. Parasitemia analysis by LDS-751-based 
flow cytometric analysis method. 
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Figure 4.10: Scattered plot for parasitemia on day 5,7, 10, 14, 21 and 28 samples from all five 
mice for a particular treatment group. A maximum number of samples are 30. Some treatment 
groups have lesser samples because of earlier death due to parasitemia. The average correlation 
coefficient (R2) is 0.9230 that proof a good correlation between flow cytometric and microscopic 
data in real in vivo antimalarial assay. AMQ 33.3 mg/kg treatment group is not presented here 
as no parasitemia appears in all five mice till day 28. CQ = Chloroquine. AMQ = Amodiaquine. 
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Figure 4.11: A- Blood smears of mice blood sample with high reticulocyte population which could 
be considered as false positive in microscopy for malaria parasitemia analysis. B- Dot plot of gated 
RBCs population of same blood sample does not have a high percent of gated populations in upper 
right regions which represent the parasitemia level in blood samples. 
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Figure 4.12: P. falciparum-infected RBCs. Images were collected in TEXAS-RED and DIC filter. 
LDS-751 fluorescence (Red) enables the detection of different stages of P. falciparum parasite 
inside the RBCs (Gray). A- Ring stage (multiple parasites), B- missing C-schizont, D- Ring to 
trophozoite stage E – Trophozoite, F-uninfected RBCs. 
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Figure 4.13: Flow cytometric analysis of P. falciparum-infected mice blood samples. The Panel 
A. uninfected human RBCs samples run in FSC/SSC plot. The Panel B. P. falciparum-infected 
human RBCs samples run in FSC/SSC dot plot. Gated RBCs population analyzed on SSC/FL4 
quadrangle FL4 channel histogram plot. The percent gated population in the upper-right area in 
SSC/FL4 quadrangle plot shows the parasitemia. 
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Figure 4.14: Microscopic analysis of P. falciparum-infected human RBCs samples. The Image 
A and B are stained with Giemsa nucleic acid stain. The Image A is uninfected human RBCs 
samples. The Panel B. is P. falciparum-infected human RBCs sample.  
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Table 4.1. Comparison of Parasitemia by flow cytometric method (FCA) and microscopic method 
for blood samples from P. berghei infected mice. Accuracy was calculated by comparing average 
parasitemia by flow cytometric analysis with microscopic analysis. The mean accuracy is above 
100% Proof the accuracy of Flow cytometric assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parasitemia by 
FCA 
Parasitemia by 
Microscopy 
FCA vs Microscopy 
Accuracy 
30.55 ± 0.32 30.02 ± 1.70 101.84 
15.85 ± 0.25 15.01 ± 0.85 105.66 
8.28 ± 0.22 7.51 ± 0.42 110.36 
4.22 ± 0.08 3.75 ± 0.21 112.54 
2.26 ± 0.07 1.88 ± 0.11 120.75 
1.19 ± 0.10 0.94 ± 0.05 126.46 
0.67 ± 0.03 0.47 ± 0.03 143.24 
0.28 ± 0.06 0.23 ± 0.01 117.66 
0.18 ± 0.07 0.12 ± 0.01 151.59 
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Table 4.2. In vitro activity comparison of control antimalarial drugs chloroquine and Artemisinin 
against P. Falciparum D6 strain. Microscopic parasitemia analysis is based on Giemsa staining. 
Flow cytometric analysis is based on LDS-751 staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Name Microscopic data Flow cytometry data 
IC 50 Average STD IC 50 Average STD 
Chloroquine 1.71 ± 0.94 1.67 ± 0.67 
Artemisinin 10.08 ± 2.93 9.90 ± 2.93 
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4.6.  DISCUSSION 
There are two flow cytometric based parasitemia analysis methods developed in the past 
those have utility in both in vivo antimalarial screening and clinical diagnosis. Flow cytometric 
method was developed in 2007 using YOYO-1 stain for parasitemia analysis (Xie et al., 2007). 
Similar other flow cytometric methods developed using SYTO-16 (Cell-permeant stain) (Jimenez-
Diaz et al., 2009). Both methods have very complex analysis in which blood samples with different 
cells population like erythrocytes, reticulocytes, white blood cells, and lymphocytes. The YOYO-
1 based parasitemia analysis method requires large volume of the blood sample (10µl in 1% 
heparinized buffer). The blood samples pass through several steps in YOYO-1 based parasitemia 
analysis method. The blood cells are fixed with glutaraldehyde.  And treated with 0.25% Triton X 
for permeabilization. The fixed and permeabilized blood samples are treated with RNase 
(1mg/mL) for two hours to minimize the background effect of the reticulocytes (RNA-containing 
cells). The RNase treated samples are stained with YOYO-1 (0.5 µg/mL). The analysis was also 
very complex in YOYO-1 based assay using FL2/FL-1 compensation. The flow cytometric assay 
for parasitemia analysis based on SYTO-16 also follow similar protocol except for 
permeabilization, since SYTO-16 is a cell-permeable stain. The complex processing causes loss 
of samples, increase the duration for the parasitemia analysis, high cost of analysis and increased 
labor (Jimenez-Diaz et al., 2009; Xie et al., 2007).  
We have developed a new FCA method based on the LDS-751 stain that has utility in both 
in vivo and in vitro antimalarial screening. This novel method addresses the important challenges 
as pointed above. LDS-751 is a cell-permeable stain and does not require cell fixation and 
permeabilization for binding with the DNA of intra-erythrocytic malaria parasites. LDS-751 binds 
with RNA (excitation/emission maxima approx. 590/607 nm) and DNA (excitation/emission 
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maxima approx. 543/ 712 nm) with an approx 20-fold increase in fluorescence on binding with 
double-stranded DNA. Due to its differential excitation/emission spectra, LDS-751 differentiates 
between reticulocyte (RNA-containing cells) and malaria-infected erythrocytes populations. The 
RNase treatment is not required in LDS-751 based parasitemia analysis. The complete protocol 
requires single-step staining with LDS-751. Previously, the YOYO-1 methods did the flow 
cytometric analysis by a flow cytometer in FL2 and FL1 dot plot for whole blood population. 
However, here we gated the RBCs population only in FSC/SSC dot plot.100,000 RBCs were 
analyzed in SSC/FL4 dot plot or FL4 channel histogram plot. The LDS-751 FCA method requires 
simple flow cytometric analysis, in which parasitemia are directly calculated from percent gated 
population in the upper-right area of the quadrangle of SSC/FL4 dot plot or percent gated 
population under M1 region of FL4 channel histogram plot (Figure 4.3). The LDS-751 based FCA 
method is the simple, fast, and requires a low volume of the blood (≤2µl) with good sensitivity 
(till 0.2 percent of parasitemia, Table 4.1). The correlation coefficient (R-square) for linear line in 
scattered plot between flow cytometric parasitemia and microscopic parasitemia is 0.9995. That 
shows a good correlation between the two new assays. To further prove the utility of this method, 
it was applied for in vivo assay using different doses of standard antimalarial drugs chloroquine 
and amodiaquine. Chloroquine and amodiaquine are primary antimalarial drugs used solely in 
clinics for complete treatment of malaria. So these drugs are the most suitable control antimalarial 
drugs for in vivo antimalarial screening with wide therapeutic window. The average correlation 
coefficient for different blood samples from mice of the different treatment group was 0.9230 that 
further validate the flow cytometric parasitemia analysis method. A digital images analysis assay 
was also developed with the help of ImageJ software. This assay could be useful in a clinical 
setting that will help in reducing human biases and error in parasitemia calculation. The similarity 
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in parasitemia level calculated in both digital image analysis and flow cytometric analysis method 
proove the validity and utility of the assay. This LDS-751 based flow cytometric parasitemia 
analysis method has the potential for diagnosis of malaria in clinical isolates. 
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CHAPTER 5 
FUTURE STUDIES 
 
Presently, The PRT assay was successfully developed, and the assay was successfully 
applied to high throughput screening. There are several other applications are possible based on 
PRT assay.  
The concept of control lysis of PRT assay could be applied for collecting the amastigotes 
and evaluating infectivity of clinical as well as, laboratory isolates. Molecular level of studied in 
amastigote is possible in axenic amastigotes, but these amastigotes are artificially created by 
providing optimal physiological condition like pH 5.5 and temperature 37oC. These axenic 
amastigotes have several molecular level differences from amastigote growing inside the phago-
lysosomal vacuoles in macrophages cells. To collect these intracellular amastigotes, a control lysis 
can be applied to rescue the amastigote from macrophages cells and separate the amastigotes by 
centrifugation. The PRT assay can use to evaluate the infectivity of clinical isolates. Here, the 
differentiated THP1 cells were infected with of promastigote parasites in different ratio cells to 
parasites. Infectivity was calculated with PRT assay and microscopic assay (Figure 2.6). 
Similarly, the PRT assay can be applied for evaluating the level of infection in clinical samples 
collected from VL patients.  
A leishmania promastigote culture has mixed populations of promastigotes with high 
virulence, low virulence, and no virulence. So the overall population comes with reduced 
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infectivity in macrophages cells. The parasite with high virulence power can infect the 
macrophages and transform to amastigote. In PRT assay, macrophage cells infected with 
amastigotes are subjected to control lysis to rescue amastigote. Infected amastigotes have high 
virulence power. So the promastigotes transformed from rescued amastigote have high virulence 
power. Thus promastigote parasites with low infectivity can be run in PRT assay, and the rescued 
parasite comes with better infectivity. Thus PRT assay can be useful in increasing infectivity of 
leishmania parasite. 
In the screening of natural product fractions library, the Oleandrin was confirmed as an 
active constituent from the active fraction of Nerium oleander. Similarly, Deoxypodophylotoxin 
was confirmed as an active constituent from the active fraction of Thuja occidentalis. Oleandrin is 
an inhibitor of P-type ATPase and deoxypodophyllotoxin is a topoisomerase inhibitor. Oleandrin 
is a cardiac glycoside and is known for its cardiac toxicity. So oleandrin as such cannot be further 
study in in vivo antileishmanial screening. However, a library of similar compounds can be further 
screen against intracellular amastigotes, and structure-activity analysis (SAR) can be done to 
search compounds with less cardiac effect and better antileishmanial efficacy. The compounds 
with less cardiac effect and potent antileishmanial effect on intracellular amastigote in vitro 
screening could be further evaluated in in vivo rodent models for leishmaniasis. Similarly, 
Deoxypodophylotoxin induced G2/M Cell Cycle Arrest and known for its severe gastrointestinal 
side effects and bone marrow depression. However similar compounds with less side effect and 
potent antileishmanial effect on intracellular amastigote in vitro screening could be further 
evaluated in in vivo rodent models for leishmaniasis. 
The developed mcherry-Ld and citrine-Ld parasite have been successfully implemented in 
the in vitro screening methods promastigotes and intracellular amastigotes. Both developed 
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parasites have bright fluorescence which enables to real-time monitoring of the parasite in complex 
in vivo settings. Leishmania parasites reside in visceral organs (e.g., liver, spleen) during a disease 
state. Every time animal has to secrecy to access the parasite load in liver or spleen at any time 
point for wild-type of leishmania parasite. So large number of animals has to sacrifice for a small 
in vivo study. In vivo studies with non-human primate are more problematic due to less availability 
of such type of animals. Even several IACUC does not allow such type of studies those involve 
the sacrifice of a large number of animals. Here, these transgenic parasites can be helpful in in vivo 
studies. Parasite load can be monitor directly with the help of in vivo imaging systems. Previously 
one attempt was made to develop in vivo screening method for VL using transgenic infrared 
fluorescent L. infantum parasite (Calvo-Alvarez et al., 2015). Still, the animals have to shave to 
reduce the background signal due to the fur. The developed mcherry-Ld and citrine-Ld with bright 
fluorescence can be implemented for in vivo rodent based antileishmanial screening method. 
Furthermore, these transgenic parasites have the potential for other applications that include 
understanding the parasite biology and host-parasite interactions with the help of real-time cell 
fluorescent imager systems. 
In this research project,  a new FCA method based on the LDS-751 stain that has utility in 
both in vivo and in vitro antimalarial screening has been developed. This novel method addresses 
the important challenges as pointed above. The methods based on flow cytometric analysis (FCA) 
of the malaria parasite have been developed for diagnosis and the parasitemia analysis. These 
methods can be applied to automation and high throughput parasitemia analysis (Woodrow et al., 
2015). However, application of FCA methods for routine clinical diagnosis of malaria has not been 
reported for automated screening (Grimberg, 2011). Recently, a miniaturized flow cytometer has 
been developed by Millipore company for the diagnosis of malaria. The work has been presented 
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in American Society of Tropical Medicine and Hygiene (ASTMH) in November 2016, at Atlant, 
GA, USA (Chromy, 2016). This miniaturized flow worked based on malaria antigen detection 
with the help of monoclonal antibody which may not be cost effective especially for the poor 
population of tropical areas. LDS-751 based FCA method can be further extended to the diagnosis 
of clinical samples, and a miniaturized flow cytometer can be developed that can be implanted for 
diagnostic purpose in malaria clinics in the tropical area.  
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